Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2017

The effects of the HIV-1 Tat protein and morphine on the structure
and function of the hippocampal CA1 subfield
William D. Marks
SUNY College at Buffalo

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Molecular and Cellular Neuroscience Commons, Pharmacology Commons, Systems
Neuroscience Commons, Toxicology Commons, and the Virology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/5168

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

The effects of the HIV-1 Tat protein and morphine on the structure and function of
the hippocampal CA1 subfield

A dissertation submitted in partial fulfillment of requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University

By
William D. Marks
Master of Arts, State University of New York College at Buffalo
Bachelor of Science, Franciscan University of Steubenville

Virginia Commonwealth University
Richmond, Virginia
December 2017

ii

Acknowledgements

A great deal of gratitude is owed to a great many people who have been
instrumental in this work and beyond. I would first like to thank my advisor, Dr. Kurt
Hauser for his insight, energy, and his patience along the way. His enthusiasm and
candor was most helpful, and, I feel, has given me valuable insight into life as a scientist
beyond the lab bench. I am likewise grateful to Dr. Pamela Knapp, whose keen eye for
experimental design and readiness to help made the setbacks I experienced (inevitable
in any project) more manageable than they would have been otherwise. I also would
like to thank Dr. Rory McQuiston and Dr. Thomas Reeves for their help, without which
none of the electrophysiological studies presented here would have been possible. Also
instrumental in getting this work done properly were Dr. Jason Paris, Dr. Virginia
McLane, Mr. Aaron Barbour, and Ms. Jean Moon.
Thanks are due also to the two men who inspired and encouraged me from a
very young age to pursue the natural sciences; my late grandfather, Mr. Arthur Marks,
who went out of his way to make sure I had every chance to be exposed to the wonders
of the natural world, and Dr. Norman Paolini Jr. who taught me to experiment with the
things around me (much to my parents chagrin), for example, by growing fungi in petri
dishes lightly coated with grape jelly (which I of course carried in my pockets for
warmth).
A great many thanks are due to my closest friends, Ms. Eileen Bartolozzi, Ms.
Maria Lang, Mr. Eric Smith, Dr. Michael Del Do, Mr. Zachary Curry, and Mr. Adam

iii

DePriest. Your friendship over these past few years has been a constant source of
inspiration, humor, and comfort.
To the members of the Hauser/Knapp collective past and present; I am incredibly
glad to have met you all. You have made the -myriad- frustrations of graduate education
more bearable. It’s hard to imagine a more vibrant and enjoyable workplace, and I am
seriously concerned that no place I go on from here will ever match y’all!
I would also like to thank the Catholic community of Richmond, especially the
parishes at the Cathedral of the Sacred Heart, St. Benedict’s and St. Mary’s, and all the
amazing people I’ve gotten to know through CatholicRVA. Finally, and most importantly,
I give my thanks to God, who sustains and strengthens me -Ad Majorem Dei Gloriam-.

iv

Table of Contents
Acknowledgements ..........................................................................................................ii
List of Figures ................................................................................................................. vii
List of Tables ...................................................................................................................ix
List of Abbreviations ........................................................................................................ x
Abstract ........................................................................................................................... 1
Chapter 1: Introduction .................................................................................................... 3
The human immunodeficiency virus ............................................................................. 3
HIV-1 structure and viral proteins ................................................................................. 4
HIV-1 Tat...................................................................................................................... 5
Transmission and Epidemiology of HIV Infection ......................................................... 7
AIDS............................................................................................................................. 7
Infection of the CNS ..................................................................................................... 9
The HIV Associated Neurocognitive Disorders .......................................................... 10
Neuronal pathology................................................................................................. 10
Astrocytic pathology and contribution to neuroAIDS ............................................... 13
Microglial and MDM pathology and contribution to neuroAIDS ............................... 17
Oligodendrocytic and myelin pathology .................................................................. 20
Global effects of HIV on the central nervous system .............................................. 21
The Hippocampus and HIV ........................................................................................ 24

v

Comorbidity of HIV infection and opioid abuse disorder ............................................ 28
The opiate receptors, morphine, and the hippocampus ............................................. 29
Morphine effects in the hippocampus ........................................................................ 32
Interactions between HIV and opiate use................................................................... 33
Hypotheses and Aims ................................................................................................ 36
Chapter 2: The effects of HIV Tat on CA1 interneuron microcircuitry and spatial memory
...................................................................................................................................... 38
Introduction ................................................................................................................ 38
Materials and methods ............................................................................................... 41
Results ....................................................................................................................... 47
Discussion.................................................................................................................. 51
Chapter 3: The effects of Tat and Morphine on the structure and function of CA1 ........ 73
Introduction ................................................................................................................ 73
Materials and Methods ............................................................................................... 75
Results ....................................................................................................................... 82
Discussion.................................................................................................................. 90
Chapter 4: General Discussion and future directions .................................................. 118
Future directions ...................................................................................................... 133
Concluding remarks ................................................................................................. 141
References .................................................................................................................. 146

vi

Vita .............................................................................................................................. 184

vii

List of Figures
Figure 2. 1: Barnes maze performance between Tat- and Tat+ mice .......................... 59
Figure 2. 2: Effects of Tat on novel object recognition task performance ...................... 61
Figure 2. 3: Tat effects on nNOS and NPY expressing CA1 interneurons .................... 62
Figure 2. 4: nNOS and NPY subcellular localization ..................................................... 64
Figure 2. 5: Effects of Tat on PV and SST expressing CA1 interneurons ..................... 65
Figure 2. 6: PV and SST subcellular localization ........................................................... 67
Figure 2. 7: Tat does not affect amount of PV or SST+ neurites in CA1 ....................... 69
Figure 2. 8: Interneurons affected by Tat are part of a memory microcircuit ................. 70

Figure 3. 1: Effects of Tat and morphine on Barnes maze performance in mice ........... 96
Figure 3. 2: Representative Barnes maze track traces.................................................. 98
Figure 3. 3: Visual representation of planned comparisons design for
electrophysiological analysis ......................................................................................... 99
Figure 3. 4: Firing frequency of CA1 pyramidal cells after exposure to Tat and/or
morphine-treated mice (in vivo) in which morphine is present during electrophysiological
recordings (ex vivo) ..................................................................................................... 100
Figure 3. 5: Membrane properties of CA1 pyramidal cells in Tat and/or morphine-treated
mice (in vivo) in which morphine is present during electrophysiological recordings (ex
vivo)............................................................................................................................. 101
Figure 3. 6: Firing frequency of CA1 pyramidal cells from Tat and/or morphine-treated
mice (in vivo) in which morphine is withheld during electrophysiological recordings (ex
vivo)............................................................................................................................. 103

viii

Figure 3. 7: Membrane properties of CA1 pyramidal cells from Tat and/or morphinetreated mice (in vivo) in which morphine is withheld during electrophysiological
recordings (ex vivo) ..................................................................................................... 105
Figure 3. 8: Examples of a 3D-reconstructed biocytin-filled CA1 pyramidal cells ........ 107
Figure 3. 9: Effects of Tat and morphine on the morphology of the portion of the
pyramidal cell dendrite within the stratum oriens (SO) ................................................ 108
Figure 3. 10: Effects of Tat and morphine on the morphology of the portion of the
pyramidal cell dendrite within the stratum radiatum (SR) ............................................ 110
Figure 3. 11: Effects of Tat and morphine on the morphology of the portion of the
pyramidal cell dendrite within the stratum lacunosum-moleculare (SL-M)................... 112
Figure 3. 12: Assessment of gephyrin puncta within the aspinous portion of pyramidal
cell basilar and apical dendrites .................................................................................. 114

Figure 4. 1: TdTomato x VIP expressing mice ............................................................ 143

ix

List of Tables
Table 1. 1 Selected listing of regional effects of HIV/HIV proteins within the CNS ........ 37

Table 2. 1: Raw exploration time and motor behavior among Tat- and Tat+ mice ........ 72

Table 3. 1: Membrane properties of CA1 pyramidal cells after exposure to Tat and
morphine ..................................................................................................................... 115
Table 3. 2: Membrane properties of CA1 pyramidal cells from Tat- and Tat+ animals in a
withdrawal like state .................................................................................................... 116
Table 3. 3 Correlations between morphological and electrophysiological findings ...... 117

Table 4. 1: Effects of Tat and morphine on hippocampal cytokine levels .................... 144
Table 4. 2: Protein extracted from hippocampal samples............................................ 145

x

List of Abbreviations
AIDS- autoimmune deficiency syndrome
AEG- astrocyte elevated gene
CA- cornu ammonis
CNS- central nervous system
CSF- cerebrospinal fluid
DG- dentate gyrus
DOR- delta opiate receptor
EC- entorhinal cortex
EPSP- excitatory post synaptic potential
GABA- Gama-aminobutyric acid
GP120- glycoprotein 120
GUD- genital ulcer disease
HAND- HIV associated neurocognitive disorders
HIV- Human immunodeficiency virus
HIVE- HIV encephalopathy
IHC- immunohistochemistry/immunohistochemical
IDU- intravenous drug user
IPSP- inhibitory postsynaptic potential
IS1- interneuron specific interneuron type 1
IS3- interneuron specific interneuron type 3
IV- intravenous
KOR- kappa opiate receptor

xi

LTP- long term potentiation
MOR- mu opiate receptor
MSM- Men who have sex with men
nNOS- neuronal nitric oxide synthase
NO- nitric oxide
NPY- neuropeptide Y
NR- nucleus reuniens
OLM- Oriens-lacunosum moleculare projecting cell
PFC- prefrontal cortex
P-TEFb- positive transcription elongation factor
PV- parvalbumin
ROS- reactive oxygen species
SIV- simian immunodeficiency virus
SL-M- Stratum lacunosum-moleculare
SO- stratum oriens
SP- stratum pyramidale
SR- stratum radiatum
SST- somatostatin
Syt2- synaptotagmin 2
Tat- transactivator of transcription
TAR- Transctivator response element
VIP- vasoactive intestinal peptide

Abstract
THE EFFECTS OF THE HIV-1 TAT PROTIEN AND MORPHINE ON THE
STRUCTURE AND FUNCTION OF THE HIPPOCAMPAL CA1 SUBFIELD
By William D Marks, MA, Ph.D.c.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2017.
Major Director: Kurt F. Hauser, Ph.D., Professor and Eminent Scholar,
Department of Pharmacology and Toxicology

HIV is capable of causing a set of neurological diseases collectively termed the
HIV Associated Neurocognitive Disorders (HAND). Worsening pathology is observed in
HIV+ individuals who use opioid drugs. Memory problems are often observed in HAND,
implicating HIV pathology in the hippocampus, and are also known to be exacerbated
by morphine use. HIV-1 Tat was demonstrated to reduce spatial memory performance
in multiple tasks, and individual subsets of CA1 interneurons were found to be
selectively vulnerable to the effects of Tat, notably nNOS+/NPY- interneurons of the
pyramidal layer and stratum radiatum, PV+ neurons of the pyramidal layer, and SST+
neurons of stratum oriens. Each of these interneuron subsets are hypothesized to form
part of a microcircuit involved in memory formation. Electrophysiological assessment of
hippocampal pyramidal neurons with Tat and morphine together revealed that Tat
caused a reduction in firing frequency, however, chronic morphine exposure did not
have any effect. When morphine was removed after chronic exposure, non-interacting
effects of Tat and morphine withholding on firing frequency were observed, suggesting
that a homeostatic rebalancing of CA1 excitation/inhibition balance takes place in

response to chronic morphine exposure independently of any Tat effects. Additionally,
differential morphological effects of Tat and morphine were observed in each of the
three major dendritic compartments, with SR being less affected, suggesting complex
circuit responses to these insults reflecting local change and potentially changes in
inputs from other brain regions. Behaviorally, Tat and morphine interactions occur in
spatial memory, with morphine potentially obviating Tat effects.
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Chapter 1: Introduction

The human immunodeficiency virus
The Human Immunodeficiency virus (HIV)-1 is a Lentivirus, within the larger
group of retroviruses, that was first isolated and identified as the cause of acquired
immunodeficiency syndrome (AIDS) in 1983 following the initial identification of the
disease in 1981 (Barre-Sinoussi et al, 1983; Gallo et al, 1983; Weiss, 1993; Sharp &
Hahn, 2011). A second species, HIV-2, was identified in 1986 (Clavel et al, 1986).
Although cases of AIDS and AIDS-related illnesses became common in the 1980s,
evidence of HIV infection can be seen as far back as 1959 (Weiss, 1993; Zhu et al,
1998; Worobey et al, 2008). The two major forms of the virus (HIV-1 and HIV-2) are
believed to have diverged relatively recently from the simian immunodeficiency virus
(SIV), with some studies suggesting the divergences occurred between 1880 and 1970
depending on the specific viral group (e.g. HIV-1 M or HIV-2 B), with 1940 being the
favored date for development of HIV-1 group M, the pandemic form of the virus. These
events are attributed to a number of interacting factors favorable to the transition and
initial spread of HIV, including low rates of circumcision, high rates of genital ulcer
disease (GUD), and unsafe injection practices (Chitnis et al, 2000; Marx et al, 2001;
Sharp et al, 2001; de Sousa et al, 2010; Sharp & Hahn, 2011). The transfer of SIV/HIV
to humans is believed to be due to a number of cross-species events, in which SIV
strains infecting various subgroups of apes were able to make the leap to humans, with
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the animal vector differing between the origin of HIV-1 and HIV-2 (Marx et al, 2001;
Sharp & Hahn, 2011).
HIV-1 and HIV- 2 are related, but distinct viruses, with disparate evolutionary
origin and differing virulence and transmission rates. Specifically, HIV-1 is more virulent,
and more transmissible than HIV-2. As a result, HIV-1 is the major cause of HIV
infection and AIDS worldwide, with HIV-2 infections being found only in West Africa
(Sharp et al, 2001; Reeves & Doms, 2002; Gilbert et al, 2003; Sharp & Hahn, 2011).
The rest of this work will focus on the details of HIV-1 and HIV-1 infections. HIV-1 can
be further divided into four distinct groups; M, N, O, and P. HIV-1 group M represents
the majority of HIV-1 infections worldwide, and is considered the pandemic form of the
virus. Groups N and O each make up less than 1% of total HIV-1 infections. HIV-1
group P is newly discovered, and has infected only a handful of individuals (Sharp &
Hahn, 2011). Group M can be further divided into 9 major groups, termed clades, (A, B,
C, D, F, G, H, J, and K) as well as a number of circulating recombinant forms (Taylor et
al, 2008; Sharp & Hahn, 2011).
HIV-1 structure and viral proteins
HIV has a single stranded RNA genome consisting of three main genomic
elements; gag, pol, and env. These regions produce a number of different proteins from
a relatively short genomic strand utilizing a combination of overlapping open reading
frames, differential splicing, and post-translational modifications. The structure of the
genomic RNA is also known to play a role in multiple facets of viral function, through
use of binding sites and superstructures (King, 1994; Paillart et al, 2002; Kuiken et al,
2010). The genomic RNA is packaged within the lipid membrane-covered capsid which
4

is comprised of several proteins (p24/CA-capsid, p17/MA-matrix, p7/NC-nucleocapsid,
and p6) which are cleavage products of p55, the product of the Gag gene. These
proteins form specific functions in the formation of the capsid structure, binding of the
genome, interaction with viral and host proteins as well as binding of the membrane
envelope, which the virus takes upon budding from its cellular host (King, 1994; Kuiken
et al, 2010). The product of the Env gene is broken down to gp41 and gp120, which
insert into the viral membrane and play a critical role in binding to and infecting cells
(Kuiken et al, 2010). The Pol gene product is the proenzyme for several components
necessary for viral integration and replication; Protease, Reverse Transcriptase, RNAse
H, and Integrase (King, 1994; Kuiken et al, 2010). The remaining proteins are encoded
by individual genes; Rev, Vif, Vpr, Vpu, Nef, Tev, and finally Tat, which is the main
focus of the work to be presented this document (Kuiken et al, 2010).
HIV-1 Tat
The HIV-1 transactivator of transcription (Tat) protein is critical for viral
replication. Tat will interact with host positive transcription elongation factor b (P-TEFb)
during the initiation of viral replication, and bind to the viral TAR genomic element.
Formation of this complex causes the phosphorylation and subsequent activation of
Abbreviation, and RNA Polymerase II, allowing for whole-genome transcription of the
virus to occur (Kim & Sharp, 2001; Sobhian et al, 2010; Debaisieux et al, 2012). Low
level production of Tat is achieved by reverse transcriptase production following
infection of a cell. This small initial amount of Tat allows for viral replication to occur
more rapidly (Kim & Sharp, 2001). The length of the Tat protein is variable depending
on specific viral strain, ranging from 80-103 residues (Walker & Burton, 2008;
5

Debaisieux et al, 2012). There are several highly conserved residues and domains
within the various Tat protein sequences. Notable domains include a Zn 2+ binding
domain, a highly basic domain, and the N-terminal domain which is strongly acidic
(Bayer et al, 1995; Debaisieux et al, 2012). Internal interactions within the Tat protein
are fluid, and influenced by a number of extrinsic factors, and as such the secondary
structure of the Tat protein is highly variable, with the basic domain usually being
available for binding interactions. Binding via the basic domain stabilizes the Tat protein,
and Tat binding interactions tend to be very tight (Zhang et al, 2000; Pantano et al,
2002; Pantano et al, 2004; Rayne et al, 2010; Debaisieux et al, 2012).In addition to its
role in binding, the basic domain of the Tat protein serves as a targeting sequence
which facilitates passage through plasma membranes. Tat can also be actively secreted
via vesicular transport, meaning that cellular lysis is not necessary to release Tat into
the extracellular space. (Frankel & Pabo, 1988; Green & Loewenstein, 1988; Rayne et
al, 2010; Debaisieux et al, 2012). Additionally, truncated Tat fragments can pass
through the membrane to interact with intracellular components (Soulas et al, 2009).
The flexibility in structure and lack of spatial restriction give Tat the ability to interact with
a wide variety of molecules outside of the Transactivation response (TAR) element,
including various cell surface receptors, conferring on Tat the ability to induce a number
of pathological states associated with AIDS and NeuroAIDS even in the absence of
active viral replication. The unique properties of Tat make it highly pathogenic, as well
as a candidate for re-engineering to deliver targeted therapeutics to otherwise difficultto-reach targets (Bayer et al, 1995; Nath et al, 1996; Debaisieux et al, 2012; CohenAvrahami et al, 2014).
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Transmission and Epidemiology of HIV Infection
HIV is spread by blood and sexual fluids, specifically, seminal, vaginal, and rectal
fluids. Early on in the AIDS crisis, several high-risk groups emerged; men who have sex
with men (MSMs), those receiving blood transfusions, and intravenous (IV) drug users.
Sexual transmission, however, is not limited to MSMs. Any sexual contact involving
sexual fluids coming in contact with a mucous membrane can transmit HIV (van der
Graaf & Diepersloot, 1986; CDC, 2016). Several other conditions of infection were also
noted; healthcare workers may become infected due to needlestick events, and HIV can
be transmitted mother-to-child in several ways; perinatally due to bodily fluid contact
events during the birthing process, and rarely across the placenta or by breastmilk (van
der Graaf & Diepersloot, 1986). Casual contact does not spread HIV, and while viral
particles have been found in other bodily fluids, transmission is uncommon unless blood
is present in the fluids, and fluid-to-blood contact occurs (van der Graaf & Diepersloot,
1986; CDC, 1987; CDC, 2016). Cerebrospinal fluid (CSF) can contain measurable
levels of HIV viral particles, however, the likelihood of actual transmission by CSF
contact is low outside of occupational exposure (CDC, 1987; Bell et al, 1998; Nath,
2015). Recent estimates by the World Health Organization (WHO) suggest 36.7 million
people worldwide are living with HIV infection, with 18.2 million HIV+ individuals on
antiretroviral therapy (WHO, 2016).
AIDS
The disease caused by HIV infection is called Autoimmune Deficiency Syndrome
(AIDS). When sufficient contact between the blood or sexual fluids of the infected
individual and the new host occurs, the virus will infect the CD4+ T cells and CD4/CD8+
7

macrophages of the peripheral immune system via interactions with CCR5 or CXCR4,
depending on viral tropism (Berger et al, 1998; Coakley et al, 2005; Zhou & Saksena,
2013). Shortly after infection, an initial drop in CD4+ cells will occur as the immune
system is attacked by the virus. Symptoms during this phase appear similar to a flu-like
viral infection; fever, lethargy, etc., although the overt symptoms of viral infection may
not present in all patients (WHO, 2017). This phase soon resolves as the immune
system produces antibodies to the virus and suppresses the infection, restoring the
CD4+ cell count to near pre-infection levels. At this point, the patient enters a relatively
symptom free period of latency (Shah et al, 2010; Elliot et al, 2012). The latency period
of the HIV virus lasts an average of 8 years, and since the viral genome is integrated
into the host genome, the virus continues to be actively replicated within infected cells
(Harris & Bolus, 2008; Elliot et al, 2012; CDC, 2017). Over this 8 year period, the
patients CD4+ cell count will steadily decline. A patient’s status changes from being HIV
positive to having AIDS when their CD4+ cell count drops below 200 (Crum-Cianflone et
al, 2009), with the number of CD4+ cells remaining being negatively correlated with
post-AIDS seroconversion survival (Jacobson et al, 1993). At this point, the patients’
immune system is compromised, and they become susceptible to a wide variety of
opportunistic infections that healthy individuals are generally able to handle, and
infections that are typically mild can become terminal (Gilmore et al, 1983). In addition,
the immune response to naturally occurring aberrations in cell growth is also affected.
As such, many patients develop a specific type of tumor known as Kaposi’s sarcoma
(Gilmore et al, 1983; Bohlius et al, 2014). There are also neurological complications to
HIV infection. Early on in the initial HIV epidemic period, the neurological effects,
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although sometimes quite severe, were less of a concern, as patients who contracted
HIV and developed AIDS died rapidly from various infections. However, as the lifespan
of HIV patients was extended by the use of antiretroviral therapies and the
immunological disease became more manageable, the treatment and study of the
neurological disease became more practical (Gelman et al, 2013).
Infection of the CNS
HIV enters into the brain and establishes a reservoir quickly after infection
(Masliah et al, 2000). The infection of the CNS is thought to occur via the “Trojan horse
model”, in which infected CD8+ monocytes cross over the blood brain barrier, allowing
the virus access to an area where it would typically be unable to cross on its own
(Peluso et al, 1985; Haase, 1986; Meltzer et al, 1990; Zhou & Saksena, 2013). While
the evidence most strongly supports the Trojan horse model, other less likely alternative
methods for viral entry have been proposed (Harouse et al, 1989; Kaul et al, 2001; Zhou
et al, 2008; Zhou & Saksena, 2013). Alternative theories include transcytosis, in which
viral particles in the blood are taken up into vacuoles by endothelial cells, and then
released into the brain (Kaul et al, 2001; Liu et al, 2002; Bobardt et al, 2004), and
primary infection of the choroid plexus which then spreads to the rest of the CNS via the
cerebrospinal fluid, or CSF (Harouse et al, 1989; Chen et al, 2000). Regardless of the
viral entry mechanism, once introduced, HIV will infect microglia, the resident immune
cells of the brain, as well as astrocytes. Neurons, however, are not infected by HIV
(Soulas et al, 2009).
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The HIV Associated Neurocognitive Disorders
Soon after the discovery of AIDS, it was realized that severe neurological
impairments could accompany the disease (Snider et al, 1983; Levy et al). Presently,
there are three broad classifications of HIV-associated neurocognitive disorders
(HAND); asymptomatic neurocognitive impairment (ANI), Mild neurocognitive disorder
(MND), and HIV associated dementia (HAD), in order of increasing severity (Antinori et
al, 2007; McArthur et al, 2010), with some of the most severe cases exhibiting HIV
encephalopathy (HIVE) (Everall et al, 2009). Greater understanding leading to treatment
of HAND, especially the more severe varieties, is crucial, as it is not prevented entirely
by combined antiretroviral therapy (cART) (Sacktor et al, 2002; Tozzi et al, 2005). In
fact, as longevity of AIDS patients is increasing, the number of AIDS patients living with
HAND is increasing, although there are declines in the prevalence of HAD as well as
HIVE (McArthur, 2004; Ellis et al, 2007; Everall et al, 2009; Heaton et al, 2011).
Neuroinflammation is considered to be the main cause for development of HAND (Glass
et al, 1995; Persidsky & Gendelman, 2003; Everall et al, 2009; Levine et al, 2016). The
presentation of HAND differs among patients, but tends to involve some common
symptomatology, which include deficits in various types of memory, learning and
attention, verbal function, mood disorders, generalized processing speed deficits, motor
dysfunction, and difficulties in processing visual information or performing spatial
manipulations (Antinori et al, 2007; Dawes et al, 2008; Levine et al, 2016). The severity
of HAND sometimes progressives to the point of inability to care for oneself or function
in society (Antinori et al, 2007).
Neuronal pathology
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Excitotoxicity is one of the main neuronal pathologies caused by HIV infection,
and also commonly presents in other neurodegenerative diseases, seizure disorders,
and traumatic brain injuries (Haughey et al, 2001; Avignone et al, 2005; Mattson et al,
2005; Li et al, 2008; Mehta et al, 2013). Excitotoxicity occurs when a neuron becomes
overactivated by glutamate signaling, which can be due to excessive glutamate release,
lack of glutamate clearance, or improper inhibitory feedback. Excitotoxicity is not a
single process, but rather an umbrella term used to describe the general effects which
can be driven by many pathological states, and have subtle differences in cellular and
systems presentation. (Bouilleret et al, 2000; Mehta et al, 2013). While excitotoxic
damage does not appear to be immediately deadly in neurons in vivo, a long-term
buildup of damage over time can lead to a loss of function and eventually death by the
activation of caspases, but not wholesale sudden necrosis. This sustained cumulative
damage is believed to explain why neurological symptoms take so long to appear after
the onset of AIDS (Coleman et al, 2004). An example of this can be seen in the loss of
dendritic spines in hippocampal neurons of transgenic mice with an active Tat
transgene without evidence of decreased neuronal number, or significant increase in
evidence of cell death (Fitting et al, 2013). Interestingly, some components of Tatinduced excitotoxic injury appear to be reversible (Kim et al, 2008). The HIV proteins
Tat and gp120 can induce excitotoxity (Haughey & Mattson, 2002). Tat binding to the
LRP receptor on neurons, which is associated with the NMDA receptor, causes an
abnormal association of PSD-95 and nNOS to the NMDA/LRP complex. Interestingly,
this can lead to apoptotic events in neurons that lack NMDA receptors as well as due to
increased nitric oxide (NO) production (Eugenin et al, 2007; King et al, 2010). This
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complex plays a role in the phosphorylation of several sites on the NMDA receptor
subunit 2A through the activation of Src kinase, the most important being Y1325.
Gp120 can also potentiate excitotoxicity; exposure potentiates calcium signaling
of NMDA receptors, with a greater effect driven by interactions with subunit 2B (King et
al, 2010; Krogh et al, 2014; Zhou et al, 2016). Tat can also directly bind the receptor
itself and act as an agonist, causing further toxicity (Li et al, 2008). The calcium
dysregulation that comes with excitotoxic injury will also cause mitochondrial
dysfunction, which may explain the shortening and loss of complexity seen in neurites
after HIV infection or exposure to HIV proteins (Iskander et al, 2004). Additionally, Tat
can act directly as a COX inhibitor, but only after it permeabilizes the mitochondrial
membrane, which will further contribute to mitochondrial failure. (Iskander et al, 2004;
Lecoeur et al, 2012). The HIV viral proteins Vpr and Tat may also have an effect on
neurons by altering miRNA expression. A study by Mukerjee et al (2011) showed that
Vpr is taken up by cultured neurons, leading to disturbances in calcium levels,
increased oxidative stress, synaptic dysfunction and damage to the mitochondria. The
group found an increase in miRNAs against several critical mRNAs, a number of which
(CACNB1, STIM1, IRIBT) are involved in calcium control within neurons. Others are
involved in synaptic plasticity (SIRT-1), general cellular processes and maintenance
(CREB) and maintaining structural integrity of processes (NEFM). Most of these mRNAs
were decreased compared to control in neurons exposed to Vpr. In Tat-treated cells, the
group found upregulation of miRNAs against many of the same mRNAs that are
targeted in the case of Vpr exposure. The data on miRNAs are presently contested,
however, due to questions of reproducibility (Chang et al, 2011; Mukerjee et al, 2011;
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Witwer, 2014). In addition to the direct effects of HIV on neurons there are also
bystander effects that cause neuronal injury which can be due to the direct effect of HIV
proteins on glia, the natural immune response, or other pathological processes
(González-Scarano & Martín-García, 2005; Fitting et al, 2010b; Ton & Xiong, 2013;
Zhou & Saksena, 2013). Some of these effects will be discussed in the subsequent
sections, which deal with HIV effects on glial cells.
Astrocytic pathology and contribution to neuroAIDS
Astrocytes perform a number of key roles in the brain including trophic support,
clearance of the synaptic cleft, and formation of the blood brain barrier. It is not
surprising that once these cells are infected, they play a significant role in the
progression of neurological disease. The onset of astrocytosis occurs rapidly once HIV
has entered the brain (An et al, 1999), and can be induced by direct infection of
astrocytes, or by independent extracellular action of viral proteins. This condition leads
to the production of pro-inflammatory cytokines and other neurotoxic factors (Ton &
Xiong, 2013; Zhou & Saksena, 2013).
There are many cytokines known to be released by astrocytes in HIV infection,
for example IL-1β, IL-6, IL-8 and TNF-α.A significant portion of these secreted products
are also produced by microglia (González-Scarano & Martín-García, 2005; Ton &
Xiong, 2013). To go into detail for each one of them would require its own review and so
this section will cover some of the more current research on astrocyte cytokine
production and effects in response to HIV infection and other general insults. The basic
profile of astrocyte cytokine production in the absence of an insult was recently profiled
in cultured human cells. The basic expression profile includes G-CSF, GM-CSF, GROα,
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IL-6, IL-8, MCP-1, MIF, and Serpin E1. The cultured astrocytes were then subjected to
insult via IL-1β and TNF-α. These cytokines caused expression of six other cytokines by
activation of an NF-κB pathway; IL-1β, TNF-α, RANTES, MIP-1α, IP-10, and IL-1ra,
along with other factors traditionally involved in cell adhesion, chemotaxis, and
immunity. Additionally, the basally-expressed cytokines G-CSF, GM-CSF, GROα, and
IL-6 were increased relative to their control levels while MCP-1 and MIF were
decreased. The authors believe that there are still more astrocyte derived cytokines
involved in neuroinflammation than what they found in their study (Choi et al, 2014). It is
important to note that the basal production of cytokines by astrocytes in different brain
regions will vary. In a 2010 study by Fitting et al, cultured astrocytes taken from mouse
cortex, cerebellum and spinal cord were probed for basal levels of cytokine production,
and then challenged with combinations of Tat, gp120, and with morphine (Fitting et al,
2010b). This study noted several more cytokines produced by resting astrocytes than
the previously-discussed study; KC, eotaxin, IL-9, MIP-1α, MIP-1β, and IFN-γ, although
this may be a species difference (Fitting et al, 2010b; Choi et al, 2014). Basal cortical
production of most cytokines was much lower than that observed in cerebellum or spinal
cord. The secretory response of activated astrocytes to HIV proteins independent of
morphine also varies by region and specific HIV protein. Only IL-1β production was
independent of brain region. Exposure to Tat elevated most cytokine production in all
assayed brain regions, but the cerebellar astrocytes had a much weaker response than
astrocytes of the cortex or spinal cord. In contrast gp120 did not significantly affect
cytokine release despite causing an increase in intracellular calcium levels (Fitting et al,
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2010b). CXCL8/IL-8 is also found to be upregulated in astrocytes following HIV infection
(Mamik & Ghorpade, 2012).
Aside from direct damage to neurons, HIV proteins along with cytokines can
cause astroglia to produce other toxic compounds. For example, gp-120 induced
production of arachidonic acid (Samikkannu et al, 2011). The oncogene AEG (astrocyte
elevated gene)-1 has been found to play a role in cytokine cascades that lead to
neuronal injury. It is found to be upregulated in astrocytes which are exposed to Tat and
complete HIV-1 virions, along with pro-inflammatory cytokines commonly observed in
neuroAIDS TNF-α, and IL-1β. Not only do these insults increase expression of AEG-I,
they cause it to translocate from the cytoplasm to the nucleus where it interacts with NFκB, leading to the downregulation of EAAT2, a glutamate transporter, and upregulated
YY1, which acts to repress EAAT2. Constitutive overexpression of AEG-1 causes the
same effects, but the process is exacerbated when IL-1β is introduced, presumably
because it precipitates nuclear translocation. Altogether, this novel pathway which
culminates in decreased glutamate clearance highlights one of the ways in which
released cytokines can cause indirect excitotoxic injury to neurons (Vartak-Sharma et
al, 2014).
Disruption of the blood brain barrier is also a contributing factor in the
progression of HAND. Astrocytic cytokines play a role in facilitating the passage of
infected immune cells across the BBB. In addition to having direct neurotoxic effects,
the increased expression of CXCL10 in HIV has been shown to have a chemotactic
effect on peripheral blood mononuclear cells (Mehla et al, 2012). CX3CL1/fractalkine
has been shown, with leukotrienes, to facilitate contact of HIV infected monocytes and
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brain macrophages and transfer of infection. This process itself does not induce
disruption of the blood brain barrier (Bertin et al, 2014). Additionally, IL-6 has also been
shown to act as a chemoattractant to circulating lymphocytes (Almolda et al, 2014).
This may be an important process for establishing the reservoir in the brain after initial
infection and exacerbating inflammatory damage as the creation of a more permissive
barrier due to decreases seen in expression of tight junction proteins, increased matrix
metallopeptidase-9 activity in brain endothelial cells, and endothelial cell apoptosis is
coupled with the increased attraction of immune cells from the blood stream (Andras et
al, 2003; Kim et al, 2003; Xu et al, 2012; Zhou & Saksena, 2013; Rao et al, 2014;
Leibrand et al, 2017; Patel et al, 2017).
Finally, the overall health of the astrocytes can contribute to neuronal pathology,
as astrocytes play a key role in supporting neuronal health. Astrocytes form the first line
of defense against aberrant ROS production in the brain (Desagher et al, 1996;
Masanetz & Lehmann, 2011; Ferrucci et al, 2013). Exposure of astrocytes to HIV-1 VPR
causes an increase in oxidative stress along with increased cytokine production. VPR
also causes decreases in ATP and glutathione levels, which would normally help to
alleviate oxidative stress. It was also found that there was a decrease in GAPDH
expression and therefore decreased glycolytic activity after VPR exposure, resulting in
neuronal apoptosis. Astrocytes normally secrete glutathione which is taken up by
neurons. Neurons exposed to conditioned medium taken from VPR-treated astrocytes
showed increased apoptosis compared to neurons exposed to control astrocyte
conditioned medium. This is likely due to the neurons’ inability to reduce oxidative stress
due to the lack of secreted glutathione (Desagher et al, 1996; Ferrucci et al, 2013). The
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HIV-1 protein Nef, which is expressed in infected astrocytes also decreases fitness.
Under normal circumstances, immune cells put out reactive oxygen species in addition
to inflammatory cytokines, and astrocytes play a strong role in protecting neurons from
damage due to ROS production acting as a buffer and providing glutathione. Astrocytes
transfected with Nef and exposed to a medium containing 10 μM hydrogen peroxide
were much more likely to die in a four hour incubation than astrocytes not transfected.
This effect may be due to the loss of glutathione production (Desagher et al, 1996;
Masanetz & Lehmann, 2011; Ferrucci et al, 2013).
Microglial and MDM pathology and contribution to neuroAIDS
Microglia and monocyte-derived macrophages (MDMs) also contribute to the
progression of neuroAIDS. Microglia are the resident immune cells of the brain, and are
known to produce cytokines, ROS, and other soluble factors against potential insults.
Many of the pro-inflammatory cytokines that are produced by astrocytes are also
produced by microglia and MDMs, with microglia representing the main source of proinflammatory cytokines (Rock et al, 2004; Ghorpade et al, 2005; González-Scarano &
Martín-García, 2005; Almolda et al, 2014; Rao et al, 2014). Microglia respond rapidly to
HIV infection. Infection of cultured microglia with HIV causes the production of pro-IL-1β
and other inflammatory products as early as four hours after exposure to the virus
(Walsh et al, 2014). It is important to note that the production of inflammatory molecules
is only one of the reasons that the increased attraction of immune cells across the BBB
and activation of microglia play such a significant role in the progression of neuroAIDS
pathology (Andras et al, 2003; Kim et al, 2003; González-Scarano & Martín-García,
2005; Xu et al, 2012; Almolda et al, 2014; Rao et al, 2014). It is also important to note
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that in HIV patients receiving antiretroviral therapy, microglia remain activated and
continue to produce inflammatory molecules. This phenomenon correlates with mild
neurocognitive decline in otherwise asymptomatic patients (Garvey et al, 2014).
Much like astrocytes, microglia also have different characteristics and responses
depending on where in the brain they are located. In a comparison of microglia collected
from a patient with HAD against seronegative patients, tissue samples were collected
from multiple brain regions (cortex, basal ganglia, striatum, cerebellum, brain stem, and
hippocampus). Microglia in all the regions observed were activated in the HIV patient,
and increased microglial numbers were seen in the cortical white matter, basal ganglia,
cerebellum and brain stem. In all areas, immunohistochemical (IHC) tissue analysis
showed that there were microglia (identified by CD68 and vimentin IHC reactivity)
positive for HIV-1 p24, indicating infection, although the number of cells varied region to
region and correlated with presence of microglial nodules and immune activation.
Microglia also formed multinucleated giant cells post-infection. Comparison of the
amount of viable glial cells showed no significant differences. In all brain regions
surveyed, microglia in the HIV+ patient showed less production of TNF-α both basally
and induced, indicating a decreased immune reaction rather than a die-off of microglia
(Ghorpade et al, 2005). In addition to a decreased immune response, increases in
production of IL-8 (CXCL8) by astrocytes and microglia can contribute to increasing viral
genome integration rates and replication rates within infected microglia and
macrophages. The replication rates increase with longer exposure to the factors
involved and infection of new cells, leading to a downward spiral effect (Huang et al,
2011; Mamik & Ghorpade, 2012; Mamik & Ghorpade, 2014).
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These cells also play a role in exacerbating neuronal excitotoxicity. Microglia
infected by HIV produce an increased amount of glutamate due to an increased
expression of microglial glutaminase in culture. This effect is also found in patients
suffering from HAD (Huang et al, 2011). Additionally, the production of TNF-α and IL-1β
by microglia and MDMs causes upregulation of glutaminase in human neuronal cultures
(Ye et al, 2013). Other microglial/monocyte produced compounds can strengthen the
effect. For example, activated microglia and monocytes produce quinolinic acid, a
metabolite of tryptophan that acts as an NMDA agonist at the glutamate binding site.
This agonism has been shown to enhance excitotoxicity. The production of quinolinic
acid is more robust in MDMs (Kerr et al, 1998; Guillemin et al, 2005). Another MDM
secreted factor that promotes excitotoxicity is Platelet activating factor (PAF), which can
also be secreted by astrocytes (Gelbard et al, 1994).
Microglia can also play a more direct role in neural damage than simply secreting
toxic factors. In mice injected intracranially with Tat, microscopy on tissue slices
indicated that activated microglia produce filopodia, and form contacts with dendritic
spines, presynaptic terminals, and extend into excitatory and inhibitory synaptic clefts,
which may disrupt the synapses in a process called synaptic stripping. The filopodia
had phagosomes which contained parts of the synaptic structures, and the surrounding
area showed evidence of proteolytic degradation, indicating that microglia may be
actively breaking down synapses in response to HIV proteins (Tremblay et al, 2013).
This could be a potential mechanism contributing to the loss of dendritic spines
observed in neurons when combined with the problem of failing metabolic support which
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leads to loss of dendritic length and arborization (Iskander et al, 2004; Vander Jagt et al,
2008; Tremblay et al, 2013).
Oligodendrocytic and myelin pathology
While oligodendrocytes are not believed to be infected by HIV (Zhou & Saksena,
2013), they do have receptors for many of the inflammatory cytokines released by
astrocytes, MDMs, and microglia, making them susceptible to damage by the
pathological processes that occur in neuroAIDS (González-Scarano & Martín-García,
2005). In individuals infected with HIV, a condition called vacuolar myelopathy (VM) can
arise in white matter. A post-mortem assessment of AIDS patients revealed that in white
matter tracts of the spinal cord, there was significant vacuolation, demyelination, and
increased presence of macrophages, and there was no correlation with astrocyte
activation (Gyorkey et al, 1987; Tran et al, 1995). In some regions of the brain, but not
all, myelin thickness around axons has been observed to decrease, as has the volume
of the anterior corpus callosum from loss of both nerve fibers and myelin
(Wohlschlaeger et al, 2009). There is a significant reduction in oligodendrocyte process
length observed in an in vivo Tat injection model, and losses in oligodendrocyte
membrane area in the HIV-1 Tat transgenic mouse model (Hauser et al, 2009; Zou et
al, 2015). Additionally, oligodendrocytes exposed to Tat alone show an upregulation in
caspase production, but no increase in apoptosis rate (Hauser et al, 2009). This is likely
related to increases in Ca2+ influx into the oligodendrocytes mediated the interaction of
Tat with the AMPA and NMDA receptors (Zou et al, 2015).
MRI often shows “white matter pallor”, which might indicate demyelination or an
area of edema, perhaps due to increased leak through the blood brain barrier in HIV
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patients. In a 2001 study using MRI diffusion tensor imaging, an MRI method for white
matter, microstructural abnormalities were seen in early stage HIV positive patients in
the frontal cortex and the internal capsule, however newer data suggest other
disturbances can occur in any CNS white matter tract (Pomara et al, 2001; Xuan et al,
2013). The altered myelination may lead to decreased conduction velocity along white
matter tracts as is the case in the HIV infected peripheral nervous system (Kokotis et al,
2007), and such changes would undoubtedly contribute to aspects of HAND.
One of the pathological conditions that arises in oligodendrocytes/white matter is
the production of self-antibodies against myelin proteins as seen in multiple sclerosis
(Maimone et al, 2009; Lackner et al, 2010). In a comparison of HIV patients, MS
patients, and control subjects, myelin basic protein antibodies were found in the CSF of
HIV patients at higher levels than MS patients while none were found in control
subjects. Patients who had both HIV and MS had equivalent antibody levels to MS free
HIV patients (Maimone et al, 2009). Antibodies against myelin oligodendrocyte
glycoprotein (MOG) were found in the CSF of AIDS patients, but not of patients
suffering from other neurological conditions. Furthermore, the antibodies of HAND
patients were more specific than those in asymptomatic patients. Additionally the
antibodies against MOG were found before and after effective antiretroviral therapy
(Lackner et al, 2010).
Global effects of HIV on the central nervous system
Throughout the brain, there appears to be a decrease in volume across multiple
regions. This atrophy is observed in adults and in children, and correlates with
decreases in CD4+ cell count and cognitive decline, but not with duration of infection
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(Johann-Liang et al, 1998; Thompson et al, 2006; Chiang et al, 2007; Andronikou et al,
2014). Concurrent with brain atrophy is an expansion of ventricular volume by an
average of 2.18 times the observed volume in control patients as detected by MRI. The
expansion is not uniformly distributed within the ventricles, with the occipital and frontal
horns expanding more than the temporal horn (Thompson et al, 2006). These effects
are persistent even with effective ART, as is the progression of neurocognitive
impairment (Gongvatana et al, 2013; Hua et al, 2013). Elevated quinolinic acid in the
CSF is linked to the atrophy observed in the brain, specifically in those regions that are
susceptible to excitotoxic injury (Heyes et al, 2001). Histologically, it has been observed
that in patients with HAD, the spatial distribution of astrocytes changes as the disease
progresses. Astrocytes cluster near interneurons, and away from large pyramidal cells,
with the level of clustering correlating to the severity of the disease. The clustering was
determined by identifying specific cell types in slices and measuring the closeness to
the interneurons by applying concentric rings of a known distance and observing the
number of cells present within these rings (Roberts et al, 2013). Additionally, there is
deposition of amyloid-β plaques as in Alzheimer’s disease, with higher levels of
amyloid-β in cases of HIVE, and a correlation between amyloid-β deposition and age.
While amyloid-β deposition is not necessarily causative of HAND symptoms, it can
serve as a marker of disruption in protein clearance (Esiri et al, 1998; Achim et al, 2009;
Soontornniyomkij et al, 2012).
While there are global changes, a wide variety of pathologies are observed in
most brain subregions, giving rise to the various behavioral facets of NeuroAIDS (Table
1) (Nath, 2015). These differences in pathology are due to numerous factors both
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anatomical and cellular which influence the nature of HIV-host interactions. A variety of
genes, with the most notable being MAP2 and syanaptophysin (SYP), have been
identified as being correlated with HAND severity and increased HIV RNA levels across
multiple brain regions (Masliah et al, 1997; Moore et al, 2006; Levine et al, 2016). Due
to the complex interplay between genes in individuals, the response to HIV-induced
neuroinflammation may vary from patient to patient, in part explaining the differential
presentation of HAND in individual cases (Lojek & Bornstein, 2005; Dawes et al, 2008;
Fazeli et al, 2014; Levine et al, 2016). Anatomically, the relative closeness of a structure
to the ventricles is suspected to be a factor, as viral particles, produced toxins like
quinolinic acid, and pro-inflammatory factors are found to be elevated in the CSF (Kerr
et al, 1998; Petito et al, 1999; Heyes et al, 2001; Thompson et al, 2006; Tate et al,
2011; Ances et al, 2012; Andronikou et al, 2014; Choi et al, 2014). At the cellular level,
HIV Tat has been shown to have disparate effects on the astrocytes of different regions
(Fitting et al, 2010b). There have been observations of regional heterogeneity in
astrocytic and microglial subpopulations genetically and functionally (Hochstim et al,
2008; Chaboub & Deneen, 2012; Martin et al, 2015; Covelo & Araque, 2016; Grabert et
al, 2016). This is in addition to the wide array of neuronal phenotypes found in the
structures of the CNS (Klausberger & Somogyi, 2008; Bikoff et al, 2016), So it should
come as no surprise that the great variety in CNS cell subtypes within discrete brain
regions would create unique responses to HIV infection and its sequelae (Fitting et al,
2010b; Nath, 2015).
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The Hippocampus and HIV
The region of interest in the studies to be discussed is the hippocampus. This
structure can be found in each hemisphere of the brain, and is folded up beneath the
edge of the cortex. While the neocortex has six layers, the hippocampus has 3-4
depending on the subfield of interest. The hippocampal formation is defined as the
hippocampus proper (the Dentate gyrus and cornu ammonis regions) and several
associated structures, usually referring to the subiculum, entorhinal cortex, and fimbria
of the hippocampus. The two main regions of the hippocampus proper can be further
divided into anatomically and functionally distinct domains. The dentate gyrus can be
divided by layers, the principal cell layer, or granule cell layer forms a chevron-like
structure opening onto the end of cornu ammonis (CA). The layer within the chevron is
called the hilus. This layer contains axonal projections to the CA. On the outer edge of
the dentate gyrus is the molecular layer, which borders the interior edge of the
CA/subiculum border. The CA structure is divided into three main regions, CA3, CA2,
and CA1 (Ranson, 1932; Amaral & Lavenex, 2007). The CA3 region can be divided into
4 layers; in order from the outside border with the alveus; the SO, stratum pyramidale or
pyramidal layer, stratum lucidum, and the stratum lacunosum-moleculare (SL-M). The
stratum lucidum is unique to CA3. Outside of this difference, the layered structure of
CA2 and CA1 is very similar to CA3. The overall flow of information in the hippocampus
follows a defined path from the entorhinal cortex to the dentate gyrus via axons known
as the perforant path. The dentate gyrus projections to CA3 are termed the mossy
fibers, and the projections from CA3 to CA1/2 are referred to as the Schaffer collaterals.
CA1 pyramidal neurons primarily project to the entorhinal cortex, completing the
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processing loop through the hippocampus. In addition to this main loop, several backand-co-projections occur, allowing for more complex processing(Amaral & Lavenex,
2007). Most notably, some perforant path axons also project directly to CA3 and CA1
(Deng et al, 2010). Within the hippocampal subfields, a wide variety of cell types interact
to build defined regional microcircuits that allow for complex processing of information to
occur (Amaral & Lavenex, 2007; Klausberger & Somogyi, 2008; Deng et al, 2010;
Muller & Remy, 2014). Originally thought to simply be a high-order olfactory processing
center (Ranson, 1932),this region of the brain is responsible for a number of functions,
including spatial and social memory (Okuyama et al, 2016), as well as having some
involvement in emotional processes.
The hippocampus has been shown to be vulnerable to the effects of HIV and HIV
protiens. Learning, memory and spatial awareness, which are among the deficits
observed in neuroAIDS, are mediated in part by the hippocampus (Castelo et al, 2006).
A 2013 study by Fitting et al showed that in Tat transgenic mice, a loss of dendritic
spines and inhibitory synaptic proteins within pyramidal layer of the CA1, indicating the
loss of a specific subset of GABAergic interneurons, correlated with reduced
hippocampal LTP and a reduction of both spatial learning and contextual fear
conditioning. Another study also showed increased evidence of autophagy in
hippocampal astrocytes (Vander Jagt et al, 2008). Similarly, Vpr also causes memory
impairment. Vpr transfected astrocytes injected into the hippocampus of rats caused a
decrease in long-term memory formation and an increase of neurons undergoing
chromatolysis in CA1 and CA3 (Torres & Noel, 2014). These memory deficits exist in
human patients as well. In a study consisting of only women, three different measures
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of memory were found to be impaired; verbal episodic memory, visual memory, and
working memory both in short and long term. Neuroimaging of the hippocampi in these
subjects showed a lesser response during the encoding process, and a heightened
response when attempting to recall after a delay in stimulus presentation (Maki et al,
2009). An earlier study also showed that regions of the hippocampus exhibit a reduced
response during encoding, but increased activity was observed in the frontal and
parietal cortices (Castelo et al, 2006). Hippocampal tissue is also susceptible to the
accelerated aging processes associated with HIV infection and experiences a decrease
in volume (Ances et al, 2012; Pfefferbaum et al, 2014), It likewise sees increased
deposition of α-synuclein and β-amyloid (Kallianpur et al, 2012). In addition to its
contribution to memory, dysfunction in the hippocampus also contributes to the
depressive disorders seen in HIV patients resulting from the activation of indoleamine
2,3 dioxygenase (IDO) via p38 MAPK in response to inflammatory cytokine secretion
(Fu et al, 2011).
The excitotoxic effects of HIV proteins are evident in the hippocampus.
Synaptosome preparations of hippocampal neurons from Tat transgenic mice
demonstrate an increased K+ evoked glutamate release but no change in GABA
release (Zucchini et al, 2013), suggesting that Tat effects on GABAergic transmission
within the hippocampus involve more than simply altered release mechanisms (Marks et
al, 2016). In culture, hippocampal neurons have been demonstrated to lose synaptic
terminals as a result of Tat-induced excitotoxicity, as indicated by a decrease in
synaptophysin levels (Shin & Thayer, 2013). In addition to this, the remaining synaptic
terminals are also affected. Neurons treated with Tat are more likely to generate
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inhibitory synapses than excitatory synapses (Hargus & Thayer, 2013). These effects
on synaptic integrity and formation are also based on excitotoxicity, and mediated by
the binding of Tat to LRP, and formation of the LRP-PSD95-NMDA-nNOS complex
rather than the apoptotic processes of excitotoxicity (Eugenin et al, 2007; King et al,
2010; Hargus & Thayer; Shin & Thayer, 2013). This may appear to conflict with the
results from Fitting et al (2013) which show a decrease in inhibitory synaptic formation
in CA1, however with the wide variety of hippocampal neuronal types, it is likely that
there is a differential effect on a specific subset in that specific region (Klausberger &
Somogyi, 2008; Fitting et al, 2013). This effect can be seen in an earlier study on the
differential neuronal toxicity of Tat and gp120 in the hippocampus by Fitting et al. in
2008 (Fitting et al, 2008). Tat or gp120 were injected bilaterally into the hippocampi of
newborn rats to assess long term toxicity. Neuron numbers were found to be decreased
by Tat in CA 2/3, dentate gyrus, and subiculum, while gp120 only reduced neuron
number in CA2/3, suggesting differential sensitivity of neuron subsets in those regions.
Differential effects were also noted in glia, with astrocyte number being increased in the
dentate gyrus and subiculum by Tat, and oligodendrocyte numbers being increased
only in the dentate gyrus (Fitting et al, 2008). In addition, the hippocampus has been
shown to have a reduced capacity to respond to oxidative stress in an HIV-transgenic
rat model via the 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid; ABTS) assay
(Pang et al, 2013).
The hippocampus is different from other regions, in that research indicates
that it has a greater likelihood of recovery following injury resulting in loss of neurons.
The hippocampus is one of the few regions in which neurogenesis continues into
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adulthood. This neurogenesis is inhibited by HIV (Lee et al, 2011; Avraham et al, 2015),
however, in a gp120 transgenic model, treating with an SSRI can rescue adult
neurogenesis (Lee et al, 2011). In animals with a deletion of the gene encoding FAAH,
the enzyme responsible for breakdown of endocannabinoids, neurogenesis in adult
mice was not affected by gp120 (Avraham et al, 2015), raising hope for potential
development of treatments. In fact, the damage caused to the hippocampus might not
be irreversible. Within CA1, the chromatolysis induced by HIV proteins does not
necessarily lead to neuronal death (Torres & Noel, 2014). The cellular deficits observed
in CA1 do not appear to include loss of neuronal cells, but simply their impairment
(Fitting et al, 2008; Fitting et al, 2013; Zucchini et al, 2013) . A 2008 paper by Kim et
al.(Kim et al, 2008) also showed that in hippocampal cultures, synaptic loss via
excitotoxicity is due to the LRP-PSD95-NMDA-nNOS complex rather than the apoptotic
events of excitotoxicity (Eugenin et al, 2007; Kim et al, 2008; King et al, 2010; Hargus &
Thayer, 2013; Shin & Thayer, 2013). It additionally showed that the process is
reversible by treatment with receptor associated protein (RAP), which is an LRP
blocker, after Tat treatment, while NMDA antagonists did not reverse the effect after Tat
administration. The authors of this paper suggest that this reversible loss of synaptic
structures is a compensatory mechanism meant to mitigate the effects of the excitotoxic
state (Kim et al, 2008).
Comorbidity of HIV infection and opioid abuse disorder
A growing problem worldwide is the coincidence of HIV infection with opioid
abuse disorder (Bruce & Altice, 2007). HIV infection can occur through the sharing of
needles between injection drug users (IDUs), resulting in the transfer of small amounts
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of blood between individuals and allowing the chance of HIV infection (van der Graaf &
Diepersloot, 1986). The sharing of needles between users is a significant contributor to
infections in individuals not engaging in risky sexual contact (Friedland, 1985; van der
Graaf & Diepersloot, 1986; NIDA, 2017), and there is a significant overlap in the
populations of individuals that are IDUs and those that engage in risky sexual behaviors
(Bruce & Altice, 2007). Between 40 and 45% of IDUs are also HIV positive (Francis,
2003), and while opiates are not the only drugs injected intravenously, they do make up
a large proportion of total injection drug use (Bruce & Altice, 2007). Even in the absence
of injection drug use and the risk of increased infection, there is still a risk posed by the
abuse of prescription opioids, which may or may not be prescribed to an HIV infected
individual. Around 8% of HIV-Infected patients may be on long term, physicianprescribed courses of opiates. In an analysis of individuals whose tissue had been
donated to a national brain tissue bank, over half of the HIV positive patients that were
prescribed opiates were determined to exhibit improper use, however the lack of
longitudinal data on these individuals leaves this value open to interpretation (RobinsonPapp et al, 2012; Silverberg et al, 2012).
The opiate receptors, morphine, and the hippocampus
There are three main classes of opiate receptor; mu (MOR), kappa (KOR), delta
(DOR), with a fourth, the nociceptin opioid receptor (NOP), having close sequence
homology, but little functional overlap with the other three. All of these receptors are Gprotein coupled receptors that respond to a group of peptide neurotransmitters
collectively known as the endogenous opioids, including enkephalins and endorphins
(Butour et al, 1997; Gutstein & Akil, 2006; Bodnar, 2012). The three main receptors
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have distinct functions and ligand affinities, with differential cell signaling cascades and
behavioral outcomes associated with the activation of each receptor (Gutstein & Akil,
2006; Bodnar, 2012; Beckman, 2014). Activation of the opioid receptor system in
general is associated with analgesia, however, other effects beyond analgesia occur
(Gutstein & Akil, 2006; Lutz & Kieffer, 2013; Stein, 2016). Activation of the MOR causes
the activation of reward pathways, and underlies the abuse liability of many opiate
drugs. At the same time, MOR activation can cause depressive effects (Lutz & Kieffer,
2013; Stein, 2016). DOR acts in many ways as a mirror to MOR activity, with its
activation effecting reward pathways, however, its role is modulatory and does not
independently establish reward/dependence processes. As a result, many DOR
agonists do not have the same abuse liability as MOR agonists. DOR activation also
has been shown to have a mood elevating effect, and to be neuroprotective against
excitotoxic damage (Gutstein & Akil, 2006; Kawalec et al, 2011; Lutz & Kieffer, 2013).
Activation of the KOR runs counter to MOR/DOR activity, having dysphoric properties
and having an anti-reward effect. KOR is involved in, and potentiated by stress
processes (Lutz & Kieffer, 2013). Morphine, the prototypical opiate drug, and a drug of
abuse, has the strongest affinity for the MOR, with off-target interactions at both the
DOR and KOR (Gutstein & Akil, 2006; Hauser et al, 2012; Lutz & Kieffer, 2013;
Beckman, 2014). In addition to the neurological effects of morphine, activation of the
opioid receptors in immune cells has been shown to modulate inflammatory processes,
and therefore can affect neuroinflammation (Stein et al, 2003; Gutstein & Akil, 2006).
As is common with most drugs of abuse, chronic use of opioid drugs leads
toward development of tolerance and dependence. Anytime a drug is used over time in
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a receptor system, the natural function of the system is supplanted by over- or underactivation, hence giving the desired effect. Sometimes, these systems will either adjust
to the new levels of receptor activation by increasing or decreasing the available
receptors or ligands in an attempt to return to a homeostatic baseline, resulting in more
and more need for (dependence on) the drug, as the amount of drug or neurotransmitter
needed to obtain the desired effect increases (tolerance). Morphine has been shown to
cause tolerance and dependence in patients with chronic or repeated use (Gutstein &
Akil, 2006). Interestingly, tolerance to the various effects of morphine develop at
differential rates, with tolerance to analgesia developing rapidly, but tolerance to motor
effects having a more complex progression depending on dosage regimen rates (Vasko
& Domino, 1978; Ling et al, 1989). This effect may be tied to differential development of
tolerance by the different receptor groups (MOR vs DOR/KOR) or MOR subtypes (Ling
et al, 1989; Angelopoulos et al, 1995). The development of tolerance has been
attributed to reductions in the available receptor at the cell surface, reduced availability
of the endogenous opioid peptides, or a shift in agonist efficacy (Wimpey et al, 1989).
While multiple mechanisms exist, the one described here is of particular interest due to
the strong potential for overlap with HIV-induced excitotoxicity (King et al, 2010). In
healthy neurons, the activation of the MOR by morphine activates Akt/PKB, which in
turn activates nNOS. nNOS signaling leads to activation of PKC, which activates Src,
resulting in phosphorylation of the NMDA NR2A subunit at Y1325, and increased
calcium influx. This calcium influx triggers a feedback mechanism to reduce Akt and
nNOS activity to reduce phosphorylation of NR2A. This process also leads to
phosphorylation of MOR over time, resulting in receptor internalization and the
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development of morphine tolerance (Wimpey et al, 1989; Sanchez-Blazquez et al,
2010). The inhibition of NOS has been demonstrated to reduce the development of
tolerance due to MOR activation, but not KOR (Kolesnikov et al, 1993; Lue et al, 1999).
The specific agonist studied is important, as some drugs but not others precipitate
receptor internalization despite having similar activity at the receptor, making it an
important consideration in drug replacement therapies used to treat opioid dependence
(Kolesnikov et al, 1993; Fitting et al, 2015b) and in experimental paradigms.

Morphine effects in the hippocampus
Morphine is known to be neurotoxic on its own in cases of chronic and repeated
exposure (Hauser et al, 2012; Liu et al, 2013; Razavi et al, 2014), and is especially
detrimental to development of hippocampal neurons in pre- and postnatal development
(Traudt et al, 2012; Bajic et al, 2013; Ghafari & Golalipour, 2014). Morphine’s effects on
behavioral processes linked to the hippocampus are largely on development of
conditioned place preference in relation to morphine cues, and are also involved in
modulation of contextual fear conditioning (Razavi et al, 2014; Tan et al, 2015), but can
also cause deleterious effects on spatial memory performance (Kitanaka et al, 2015).
This is linked to the effects of morphine on synaptic plasticity within the hippocampus
(Heidari et al, 2013; Portugal et al, 2014; Sadegh & Fathollahi, 2014; Tan et al, 2015),
and notable alterations to the normal pattern of activity in the ability of the endogenous
opioid system to modulate inputs and outputs (Wimpey et al, 1989; Harrison et al, 2002;
Erbs et al, 2016). Morphine has demonstrated effects on hippocampal glutamatergic
and GABAergic neurotransmission that may interact synergistically to enhance
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excitotoxicity. Levels of glutamate were found to be increased after morphine
sensitization, but decreased prior to the establishment of sensitization, and GABA levels
were found to be initially decreased in the sensitization process, but then later become
elevated following repeated exposure to morphine (Bodzon-Kulakowska et al, 2010;
Farahmandfar et al, 2011a; Farahmandfar et al, 2011b; Zucchini et al, 2013). The
increase of glutamate levels does not necessarily relate to the amount of glutamate
synthetase, but rather to its biochemical activity, which is an important point to keep in
mind when considering the levels of expression of other enzymes (Bodzon-Kulakowska
et al, 2010). Even with the increase in glutamatergic activity, and the tendency toward
excitotoxic states with long term opiate exposure in the hippocampus, altering the levels
of activation between the three receptor groups can offset the damaging effects of
morphine (Kawalec et al, 2011; Fitting et al, 2015b). The effects of morphine in the
hippocampus are largely discussed in terms of broad outputs. However, from a
modulatory standpoint it is important to recognize that the endogenous opioid system in
the hippocampus is largely involved with regulation of the Inhibitory interneuron
network, with differential expression of opioid receptors occurring on different subsets of
interneurons, and notable overlap between signaling modalities found in CA1 (eg
somatostatin) and opioid receptor activity (Hatzoglou et al, 1995; Drake & Milner, 2002;
Pfeiffer et al, 2002; Rácz & Halasy, 2002; McQuiston, 2008; Jorand et al, 2016).
Interactions between HIV and opiate use
The effects of HIV on brain function and immunosuppression in both the
periphery and CNS can be exacerbated by the use of opiates (Bell et al, 1998; Anthony
et al, 2008; Byrd et al, 2012; Hauser et al, 2012; Meyer et al, 2013; Edelman et al,
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2017). Increased severity of cognitive deficits has been linked to interaction of HIV and
drug abuse (Bell et al, 1998), and HIV encephalitis has been found more frequently in
drug-abusing patients infected with HIV than in HIV-infected non-abusers (Byrd et al,
2012). This is linked with increased inflammatory markers (Meyer et al, 2013), and
coincides with increases in the viral load both in AIDS patients and in infected animal
models (Anthony et al, 2008; Byrd et al, 2012; Hauser et al, 2012; McLane et al, 2014).
The interaction between HIV and opiates can increase the severity of neuroAIDS, with
increases in markers of disease severity such as multinucleated giant cells and HIV-1
p2-positive microglia (Anthony et al, 2008; Hauser et al, 2012). In addition to increased
severity, HIV will emerge from latency earlier in opiate-abusing individuals (Anthony et
al, 2008; Hauser et al, 2012). In the HIV-1 Tat transgenic mouse model (Bruce-Keller et
al, 2008), morphine has been demonstrated to exacerbate excitotoxic effects in cultured
neurons from the striatum and from the enteric nervous system (Hauser et al, 2012;
Fitting et al, 2014). The development of neuronal excitotoxicity after Tat exposure is
likely due to multiple interactive pathways with multiple points of convergence. For
example, exposure to Tat results in phosphorylation of site Y1325 on the NR2A subunit
of NMDA (King et al, 2010). This site is also a target of phosphorylation in the cascade
triggered by activation of the µ-opioid receptor (MOR) (Sanchez-Blazquez et al, 2010;
Garzon et al, 2011). The influx of Ca2+ through open NMDA channels into the dendrites
of neurons after combined HIV-1 Tat and morphine exposure contributes to excitotoxic
injury (Fitting et al, 2014). The activation of GSK3β is another point of convergence for
HIV pathology and opiate pathology. Inhibition of GSK3β can block both HIV-induced
neurotoxicity in cultured cells as well as the synergistic effects of morphine exposure
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(Masvekar et al, 2015). There is some evidence, however, that the use of opiates does
not always result in a synergistic worsening of HIV induced neurotoxicity, and can in fact
be mildly neuroprotective. When buprenorphine, a common replacement therapy used
to treat opiate addiction is used instead of morphine at high doses in neuronal culture,
interactive neurotoxicity occurs. In contrast, at low doses, a mild neuroprotective effect
is noted (Fitting et al, 2015b). This could be due to multiple factors. Tat has been
shown to alter expression of the mu opiate receptor and certain endogenous opioids in
the striatum and hippocampus while leaving kappa- and delta-opioid receptor
expression unchanged. Similarly, MOR association with downstream signaling
components has been demonstrated to be altered by morphine in the striatum and
amygdala (Fitting et al, 2010a; Hahn et al, 2016). The activity of buprenorphine at these
other receptors is likely to have played a role in the mild neuroprotection observed
(Ammon-Treiber et al, 2007; Fitting et al, 2010a; Fitting et al, 2015b). In fact, there is
some evidence suggesting that under the right circumstances, even morphine itself can
be mildly neuroprotective due to its off-target effects if the dosage and receptor type
spread within a region is right, despite its normal pro-apoptotic effects (Ammon-Treiber
et al, 2007; Kawalec et al, 2011; Razavi et al, 2014). The extent to which this is true is
likely to vary by brain region just as vulnerability to HIV pathologic processes vary, and
to be affected by the degree to which different drugs affect internalization of the different
opioid receptors (Ammon-Treiber et al, 2007; Fitting et al, 2010b; Gelman et al, 2012;
Nath, 2015; Hahn et al, 2016). Additionally, HIV-1 Tat has been shown to increase the
level of tolerance mice develop to chronic morphine exposure, while decreasing the
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physical symptoms of withdrawal, perhaps through a series of compensatory
mechanisms (Fitting et al, 2012; Fitting et al, 2016; Hahn et al, 2016).
Hypotheses and Aims
Although a number of studies have focused on the comorbidity of HIV-1 infection
and opiates in the brain, few of these studies have assessed these comorbid
interactions within the hippocampus. Moreover, while the response of the hippocampus
to opioid drugs is fairly well defined from a functional standpoint (Valentino &
Dingledine, 1982; Bao et al, 2007; Saboory et al, 2007; McQuiston, 2008), the functional
response to Tat in the hippocampus is not as well characterized, with few studies
examining the functional effects of the protein within the area (Carey et al, 2012; Fitting
et al, 2013; Kesby et al, 2016). At present, no studies focus specifically on the functional
circuit outcomes of HIV-1 Tat and morphine interactions within the hippocampus. The
studies laid out here are aimed at first addressing in greater detail the effects of Tat on
the hippocampal formation. This facilitated a more robust comparison between its
effects and the effects of morphine during the later phases of these studies, which are
aimed at understanding the potential interactions between Tat and morphine on
hippocampal structure and function.
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CNS Region

Striatum

SN

Frontal Cortex

Hippocampus

Corpus callosum

Amygdala
Cingulate gyrus

Cerebellum

Retina

Optic nerve

Effect
Atrophy (Johann-Liang et al, 1998; Chiang et al, 2007; Andronikou et al, 2014)
Calcification in juveniles (Andronikou et al, 2014)
Decreased expression of DAT, VMAT2 (Midde et al, 2012; Theodore et al, 2012)
MAO expression altered (Acharjee et al, 2014; Meulendyke et al, 2014)
Decreased synaptogenesis (Gelman et al, 2012; Yuferov et al, 2013)
Decreased dopamine levels (Kumar et al, 2011)
Decreased dopamine levels (Kumar et al, 2011)
Selective loss of dopaminergic/TH+ neurons (Agrawal et al, 2010)
Regional atrophy (Thompson et al, 2005; Chiang et al, 2007; Hua et al, 2013)
Accelerated aging (Khanlou et al, 2009; Pfefferbaum et al, 2014)
Loss of synchronous firing in frontal eye field (Wilson et al, 2013)
Increased ROS sensitivity (Zhang et al, 2012; Pang et al, 2013)
Increased glutamate neurotransmission (Zucchini et al, 2013)
Decreased GABA neurotransmission (Zucchini et al, 2013)
Loss of dendritic spines (Fitting et al, 2013)
Increased chromatolysis (Torres & Noel, 2014)
Decreased activity during encoding tasks (Maki et al, 2009)
Increased glutamate neurotransmission (Zucchini et al, 2013)
Increased ROS sensitivity (Pang et al, 2013)
Impaired adult neurogenesis (Lee et al, 2011; Avraham et al, 2015)
Regional atrophy (Johann-Liang et al, 1998; Thompson et al, 2006; Chiang et al, 2007; Tate et
al, 2011; Ances et al, 2012; Hua et al, 2013; Andronikou et al, 2014)
White matter pallor and volumetric disturbances (Gongvatana et al, 2009; Pfefferbaum et al,
2009; Muller-Oehring et al, 2010; Tate et al, 2011; Zou et al, 2015)
Axonal damage (Gongvatana et al, 2009; Pfefferbaum et al, 2009; Muller-Oehring et al, 2010;
Tate et al, 2011; Zou et al, 2015)
Variable volumetric disturbance (Ances et al, 2012)
Atrophy (Heyes et al, 2001)
Decreased synaptogenesis (Yuferov et al, 2013)
Beta oscillations diminished (Becker et al, 2013)
Regional atrophy (Abe et al, 1996)
Increased neuronal glutamate toxicity (Savio & Levi, 1993)
Increased pH (Patton et al, 2001)
Decreased neuronal kinase activity (Everall & Barnes, 1999)
Activation of Müller glia (Krishnan & Chatterjee, 2014)
Decreased neural and glial cell viability (Chatterjee et al, 2011; Krishnan & Chatterjee, 2014)
Decreased thickness of RNFL (Plummer et al, 2001; Cheng et al, 2011)
Abnormal pattern evoked firing patterns (Iragui et al, 1996)
Demyelination/vacuolar myelopathy (Sadun et al, 1995)
Axonal degeneration (Sadun et al, 1995)
Abnormalities in Visually evoked potentials (Iragui et al, 1996; Mwanza et al, 2004; Mahadevan
et al, 2006)

Table 1. 1 Selected listing of regional effects of HIV/HIV proteins within the CNS
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Chapter 2: The effects of HIV Tat on CA1 interneuron microcircuitry and spatial
memory
Parts of this chapter appear in the Journal of Neurovirology, and are reproduced with
permission of Springer (License #4205710527260):
J. Neurovirol. HIV-1 Tat causes cognitive deficits and selective loss of parvalbumin,
somatostatin, and neuronal nitric oxide synthase expressing hippocampal CA1 interneuron
subpopulations 22(6). 2016, 747-762, Marks WD, Paris JJ, Schier CJ, Denton MD, Fitting S,
McQuiston AR, Knapp PE, Hauser KF. © Journal of NeuroVirology, Inc. 2016, with
permission of Springer.
PMID: 27178324
Clarification of contributions: Novel object recognition testing was performed by Dr.
Jason Paris

Introduction
Following the discovery of human immunodeficiency virus type 1 (HIV-1) and
acquired immunodeficiency syndrome (AIDS), a profile of progressive neurological
symptoms came to be associated with HIV-1 infection (Snider et al, 1983; Levy et al,
1985), now collectively referred to as HIV-associated neurocognitive disorders (HAND)
(Antinori et al, 2007; McArthur et al, 2010). Although there is variation among patients,
common symptoms include deficits in attention, learning, memory, and impaired motor
function. The neurocognitive aspects of HAND can be severe enough to interfere with
independent living (Antinori et al, 2007). Notably, combined antiretroviral therapy
(cART) does not fully ameliorate these symptoms (Sacktor et al, 2002; McArthur, 2004;
Tozzi et al, 2005; Ellis et al, 2007).
HIV may contribute to the progressive neurocognitive impairment in combination
antiretroviral therapy (cART)-controlled patients through the continued production of
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neurotoxic HIV-1 proteins from cellular reservoirs within the central nervous system
(CNS) (Johnson et al, 2013). Shortly after infection, HIV-1 can enter the brain and
establish central reservoirs (Lane et al, 1996; An et al, 1999), infecting microglia or
astrocytes, but not neurons (He et al, 1997; Brack-Werner, 1999; Kramer-Hammerle et
al, 2005; Churchill et al, 2009; Li et al, 2011). Uninfected cells can be damaged by viral
proteins, as well as by the host neuroinflammatory response to virions and free viral
proteins (Nath et al, 1996; Kruman et al, 1998; Nath et al, 1999; Aksenov et al, 2001;
Soulas et al, 2009; Zhou & Saksena, 2013; Nath & Steiner, 2014). Among these
neurotoxic factors, the HIV-1 transactivator of transcription (Tat) protein is critical for
HIV replication (Zhou & Saksena, 2013; Nath & Steiner, 2014) and can be secreted by
infected cells (Ensoli et al, 1990; Thomas et al, 1994; Rayne et al, 2010; Debaisieux et
al, 2012) even in the presence of cART (Johnson et al, 2013). Furthermore, Tat can
bind to a large number of extracellular receptors due to its highly basic domain
(Philippon et al, 1994; Zhou & Saksena, 2013), penetrate and traverse the plasma
membrane, and interact with a number of intracellular factors (Debaisieux et al, 2012).
Despite regional differences in CNS vulnerability to HIV-1 (Nath, 2015), few
studies have examined why some brain regions and neuronal types are preferentially
susceptible to the virus. A number of behavioral deficits, including attenuation of spatial
learning and memory, which are common features of HAND, can be recapitulated by
Tat exposure and may be attributed to cellular and functional deficits in the
hippocampus (Li et al, 2004; Fitting et al, 2006; Fitting et al, 2013). Long-term
potentiation (LTP) is lost when Tat is injected intrahippocampally or expressed
endogenously (Behnisch et al, 2004; Li et al, 2004; Fitting et al, 2013). Despite the
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pronounced loss of LTP and deficits in behavior, CA1 pyramidal cells showed only a
modest decrease in the density of apical dendritic spines, but no loss in dendrite length
or synaptic integrity at the ultrastructural level, and no alterations in the level of proteins
involved in excitatory glutamatergic pre- and post-synaptic function (Li et al, 2004;
Fitting et al, 2013). By contrast, there were selective alterations in proteins involved in
inhibitory γ-aminobutyric acid-ergic (GABAergic) synaptic function, including a
significant decline in synaptotagmin 2 (Syt2) expression (only within SR) and marked
increases in the expression of gephyrin throughout CA1 (Fitting et al, 2013). These
findings concur with human gene array data which show a high degree of correlation
between the expression of genes associated with inhibitory GABAergic synaptic
transmission, including GAD1 and GABAR1, and the severity of HAND, but showed less
robust correlations with genes associated with glutamatergic neurotransmission
(Gelman et al, 2012).
GABAergic interneurons are a diverse population of specialized cells responsible
for much of the processing that occurs in the hippocampus. With estimates of at least
21 distinct interneuron subtypes in CA1, there are numerous potential targets for the
development of hippocampal pathology (McBain & Fisahn, 2001; Klausberger &
Somogyi, 2008; Lovett-Barron & Losonczy, 2014). While numerous studies have
examined the effects of HIV-1 on glutamatergic transmission in the hippocampus, few
studies have assessed whether GABAergic synapses are altered. Pathology within
specific GABAergic interneuron subpopulations, and the hippocampal interneuron
network as a whole, has been demonstrated in a number of neurological disorders
(Korotkova et al, 2010; Toth et al, 2010; Hazra et al, 2013; Levenga et al, 2013), some
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of which produce behavioral deficits similar to those observed in experimental models of
neuro-acquired immunodeficiency syndrome (neuroAIDS) (Carey et al, 2012; Fitting et
al, 2013). In HIV models, reductions in the number of hippocampal neurons expressing
parvalbumin (PV) in CA3 and somatostatin (SST) in CA1 have been observed (Masliah
et al, 1992; Fox et al, 1997); however, since multiple neuron types in CA1 and CA3
express these markers, the identities of the affected interneuron subtypes remain
unclear.
Based on the collective findings above, we hypothesized that specific interneuron
subpopulation(s) might be preferentially vulnerable to HIV-1 Tat and that deficits in one
or more interneuron subtypes following Tat exposure would coincide with impaired
cognitive performance on hippocampus-dependent behavioral tasks. Our data show
that HIV-1 Tat exposure was accompanied by memory impairment in mice and resulted
in a selective decrease in the proportion of nNOS positive (nNOS+), neuropeptide Y
negative (NPY−) neurons in both the stratum pyramidale and SR, as well as decreases
in somatostatin-positive (SST+) neurons in the SO and parvalbumin positive (PV+)
neurons in the stratum pyramidale.

Materials and methods
Animals and treatments
Male mice were used exclusively throughout these studies. Inducible, glial
fibrillary acidic protein-driven transgenic Tat mice (aged 60–80 days) were used to
identify the effects of HIV-1 Tat1–86 on hippocampal interneuron subpopulations and
associated behavior (Bruce-Keller et al, 2008). In order to induce Tat expression, mice
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expressing the tat and rtTA transgenes (Tat+) were fed doxycycline-containing chow
(DOX; 6 mg/g, Harlan, Indianapolis, IN) for 12–14 days depending on the experiment.
Control mice lacking the tat transgene, but expressing the rtTA gene (Tat−), were given
the same DOX treatment. Animal procedures were approved by the Virginia
Commonwealth University Institutional Animal Care and Use Committee and are in
accordance with Association for Assessment and Accreditation of Laboratory Animal
Care guidelines.

Barnes maze
Tat− (n = 13) and Tat+ (n = 8) mice were assessed for spatial learning and motor
function in a Barnes maze test (Barnes, 1979). Mice consumed DOX chow for 7–8 days
prior to 1 day of prehabituation, followed by 4 days of testing and 1 day of probe trials.
For prehabituation, mice were placed in the escape hole (positioned in a randomly
assigned location) for 2 min, then were placed in the brightly lit center of a Barnes maze
(91 cm diameter, 90 cm height, with 20 holes each 5 cm diameter; Stoelting Co., Wood
Dale, IL), and guided to the assigned escape hole where they remained for 2 min, then
were placed under a glass cylinder next to the escape hole, and allowed up to 3 min to
volitionally enter (mice that did not enter the hole were guided in and remained for 2
min). On testing days (four trials per day over 4 days), mice were placed in the brightly
lit center of the Barnes maze and were allowed up to 3 min to enter the escape hole.
Mice that did not enter the hole were gently guided to the hole and allowed to remain for
2 min. Shorter latencies to find the escape hole, a greater proportion of time spent in the
correct quadrant of the maze, and fewer errors were considered indices of greater
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learning (Camara et al, 2013). On day 5, a reversal probe trial was conducted wherein
the maze was turned 180° such that the correct goal box was on the opposite end of the
Barnes maze table, and the proportion of time spent in the new target quadrant, latency
to find the new escape hole, and number of errors made were assessed. Distances and
velocities traveled were used as an index of motor behavior.

Novel object recognition
Tat− (n = 14) and Tat+ (n = 14) mice were assessed for neurocognitive function
in a novel object recognition test (Ennaceur & Delacour, 1988; Dere et al, 2007) after 14
days on DOX. Briefly, mice were habituated to a testing room, placed in an open field
(35 × 40× 40 cm; Stoelting Co., Wood Dale, IL), and allowed to explore two identical
round objects (plastic toys in the shape of kiwis, oranges, potatoes, or tomatoes; each
～6 × 3 cm) for a 10-min training trial. After a 4-h inter-trial interval, one of the previously
explored objects was replaced with a novel cone-shaped object of similar size (a plastic
toy in the shape of a half ear of corn or a half-pickle), which mice were allowed to
explore for a 10-min retention trial. Across subjects, replacement of the familiar object
on the left vs. right side of the apparatus was counterbalanced to control for potential
side-preferences. For each trial, the time spent investigating the object in the novel
position, as a function of the entire time spent investigating, was calculated: [(novel
object time − familiar object time)/(novel object time + familiar object time)]. To assess
motor behavior, the overall distance traveled, as well as the time and frequency spent
rearing were recorded.
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Vision testing
Tat− (n =6) and Tat+ (n=6) mice were assessed for visual function based on prior
methods
(Wersinger et al, 2002) prior to DOX exposure, and at 7 and 14 days following DOX
exposure. In brief, mice were suspended approximately 12 in. above a vertical ringstand and were gently lowered with the ring-stand approximately 2 in. from the left or
right visual field (close enough to allow visual, but not whisker, contact with the ringstand). The left and right visual fields were assessed consecutively for each mouse.
Visual responding was considered positive when mice reached with the forepaws for the
rod when presented to both the left and right side (a response to only one visual field
would have been considered a negative response). Two observers rated visual
responses.

Immunohistochemistry
Brains were fixed in 4 % paraformaldehyde using transcardial perfusion,
removed, halved, and embedded in Tissue-Tek O.C.T. compound (Sakura Finetek,
Torrance, CA). Hemisected brains were sectioned in the sagittal plain at a thickness of
16 μm for analysis of interneuron populations or in the coronal plane at a thickness of
40 μm to determine the reference volume using stereology. A Leica CM1850 cryostat
was used to cut the sections (Leica Biosystems, Buffalo Grove, IL). Sections were
mounted on slides and then stored at −80 °C until use. Tissue sections for interneuron
analyses were blocked, then incubated with individual primary antibodies (anti-PV,
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Synaptic Systems, Cat. No. 195 004, guinea pig polyclonal, 1:1200; anti-nNOS, Abcam,
ab1376, goat polyclonal, 1:5000; anti-NPY, Abcam,
ab30914, rabbit polyclonal, 1:100; anti-SST, Santa Cruz Biotechnology, sc-13099,
rabbit polyclonal, 1:50; anti-NeuN, Chemicon, MAB377, mouse monoclonal, 1:500) for
18 h at 4 °C, and rinsed in phosphate-buffered saline (PBS). Solutions containing
appropriate, fluorescently labeled secondary antibodies (goat anti-guinea pig IgG-Cy3,
Abcam ab6965-100, 1:500; Abcam ab102370, 1:500; donkey anti-goat IgG-Alexa
Fluor® 488, Invitrogen, A11055, 1:500; goat anti-rabbit IgG-Alexa Fluor® 647,
Invitrogen A21244, 1:500; donkey anti-mouse IgG-Alexa Fluor® 594, Invitrogen,
A21203, 1:500; goat antimouse IgG-488 Oregon green, Molecular Probes, 0-6380,
1:500) were placed onto tissue sections for 2 h at room temperature. Slices were then
rinsed 3 × 10 min in PBS. All tissue sections were incubated in PBS/Hoechst solution
(0.5 μg/ml, Invitrogen, H3570) for 5–10 min, repeatedly rinsed in PBS, and mounted in
ProLong Gold Antifade reagent (Invitrogen, P36930).

Reference volume analysis
Hoechst-stained 40-μm serial sections were sampled through the entire
hippocampus. From a random starting position, sections at evenly spaced intervals
were sampled to obtain an unbiased stereological assessment of hippocampal volume
(Gundersen et al, 1988). In short, sections from halved brains were taken from Tat− (n =
6) and Tat+ (n = 5) mice and imaged using a Zeiss Axio-Observer Z1 microscope, MRm
digital camera, and a 10× objective (Zeiss, Oberkochen, Germany). Montages of the
entire left hemisphere of the brain (5 × 6) were obtained utilizing a motorized stage
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encoder (Zeiss) and a computerized tile reconstruction method (Zeiss, Axio-Vision
software). Hippocampal volume was then estimated by overlaying a standardized grid
over the image of the brain and performing a point count analysis (Gundersen et al,
1988; Mouton, 2002).

Imaging
Hippocampi were imaged using a Zeiss LSM 700 microscope at 20×
magnification (Zeiss, Oberkochen, Germany). Neurons, as noted by the presence of
NeuN immunoreactivity within the nucleus, were counted in SO, stratum pyramidale,
SR, and SL-M of CA1. Immunoreactivity for each protein was noted independently, and
the markings were overlaid to confirm co-expression of proteins without bias. From 4 to
10 sections (typically 7 to 8) were analyzed and averaged per animal, and 6 mice per
experimental group were used for all experiments. All cell count data are presented as a
percent of the total NeuN+ population in each layer. To examine the potential effects of
the Tat transgene on the neuritic processes, densitometric analysis of PV+ dendrites
and SST + axons was performed using ImageJ (NIH, Bethesda, MD). In addition,
dendritic varicosities of PV+ interneurons were quantified on the five most pronounced
dendrite segments from each image within SR from 2 to 3 sections per animal.
Dendrites not reaching at least 50 μm in length or discontinuous dendrites were not
analyzed.

Statistical analyses
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Behavioral endpoints were recorded and digitally encoded by an ANY-maze
animal tracking system (Stoelting Co., Wood Dale, IL) and assessed via repeatedmeasures analyses of variance (ANOVA) with novel object recognition trial (training trial
or retention trial) or Barnes maze testing day (days 1–5) and mouse genotype (Tat− or
Tat+) as the respective within-, and between-, subjects factors. Tukey’s honestly
significant difference post hoc tests were used to assess group differences following
main effects. Interactions were delineated via simple main effects and main effect
contrasts with alpha corrected for multiple comparisons. Immunohistochemical
endpoints were assessed with one-tailed Student’s t tests. Effects were considered
significant when p<0.05.

Results
HIV-1 Tat expression impairs mnemonic performance
Inducing HIV-1 Tat expression in the CNS of mice significantly impaired spatial
learning in the Barnes maze test. Compared to Tat− controls, Tat+ mice demonstrated
significantly longer latencies to find the escape hole [F(1,76)=9.39, p<0.05] and spent a
significantly lower proportion of time [F(1,76)=8.17, p<0.05] in the correct quadrant of
the Barnes maze (Fig. 1). Irrespective of genotype, all mice took significantly longer to
find the escape hole following a 180° swap of the escape location on the probe trial day
[F(4,76)=3.42, p<0.05] compared to any previous day’s performance (p = 0.0001–0.01;
Fig. 1). No differences were observed in the number of errors made or the distance
traveled between Tat− and Tat+ mice (Fig. 1); however, a difference in velocity was
observed between Tat− and Tat+ mice [F(1,76)=5.35, p<0.05] with a significant
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reduction observed in the reversal probe trial [F(4,76)=8.45, p<0.05], compared to day 1
performance (p < 0.0001). All mice demonstrated significantly decreased maze
exploration (indicated by distance traveled) [F(4,76)=12.86, p<0.05] and made fewer
errors [F(4, 76) = 11.37, p < 0.05] compared to day 1 (p = 0.0001–0.02; Fig. 1).
Similarly, HIV-1 Tat expression significantly impaired cognitive performance in a
novel object recognition task [F(1, 26) = 5.67, p < 0.05]. Compared to performance in
the training trial, Tat− control mice spent a significantly greater proportion of time with a
novel object in the retention trial (p = 0.0007; Fig. 2) indicating intact mnemonic
performance. However, Tat+ mice demonstrated impaired object recognition during the
retention phase (Fig. 2), spending significantly less time investigating the novel object
compared to Tat− controls (p = 0.04). No significant differences were observed between
Tat− or Tat+ mice on the total amount of time spent investigating objects nor on any
motor measure investigated (Table 1).
Given that a visual component is present in the Barnes maze and novel object
recognition tasks, vision was assessed in a separate group of mice. All Tat− and Tat+
mice responded positively to a stimulus presented to the left and right fields of vision
prior to DOX exposure and at 7 and 14 days following DOX exposure.

Hippocampal volume is unchanged following Tat exposure
Point count analysis of hippocampal volume revealed no difference between Tat−
(16.71 ± 0.39 mm3) and Tat+ (17.62 ± 0.47 mm3) mice. Additionally, the volume of the
CA1 subfield was unchanged between Tat− (9.97 ± 0.19 mm3) and Tat+ (10.74 ± 0.69
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mm3) mice indicating that there was no difference in the volume of the hippocampus or
in hippocampal area CA1 following 12–14 days of Tat induction.

HIV-1 Tat expression is associated with reductions in specific CA1 nNOS-expressing
interneuron subpopulations
We investigated Tat effects on a subset of nNOS+/NPY+ cells known as ivy cells.
These cells are found primarily in the stratum pyramidale as well as the SR of CA1
(Fuentealba et al, 2008). To assess the vulnerability of nNOS+/NPY+ cells to HIV-1 Tat,
hippocampal sections were immunolabeled for nNOS, NPY, and NeuN (Figs. 3 and 4).
The distribution of nNOS and NPY immunoreactivity within CA1 was consistent with
previous research (Morris, 1989; Jinno et al, 1999; Fuentealba et al, 2008). Significant
reductions in the percentage of nNOS-expressing cells were observed in the stratum
pyramidale [t(8) = 2.25, p < 0.05] and SR [t(8) = 2.43, p < 0.05] of Tat+ mice compared
to Tat− mice (Fig. 3). Importantly, the reduction in nNOS+ interneurons was specifically
restricted to the subpopulation of interneurons that did not possess NPY antigenicity in
both the stratum pyramidale [t(8) = 2.36, p < 0.05] and SR [t(8) = 1.92, p < 0.05] after
Tat exposure, indicating ivy cells were not selectively vulnerable. No significant
differences were observed for NPY+ interneurons lacking nNOS in any layer of CA1.
Tat induction did not significantly alter the percentage of NPY+ interneurons or
interneurons coexpressing nNOS and NPY in any layer of the hippocampus (Fig. 3).

The proportion of SST+ and PV+ neurons is reduced by HIV-1 Tat expression
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To assess the vulnerability of PV+ and SST+ interneurons, hippocampal sections
were immunolabeled for PV, SST, and NeuN (Figs. 5 and 6). PV immunoreactivity was
nearly exclusive to stratum pyramidale and SO, consistent with previous research
(Kosaka et al, 1987). Observations of SST immunoreactivity in SO, stratum pyramidale,
and SR also agree with previous findings (Oliva et al, 2000); however, SST+ neurons
occurring in the SR were not quantified as part of this study (Fig. 5). The percentage of
PV+ neurons were significantly diminished in the stratum pyramidale of Tat+ mice
compared to Tat− mice [t(10) = 1.839, p < 0.05]. While no significant effect of Tat was
observed in PV+/SST− interneurons, there was a trend toward significance in
PV+/SST+ interneurons in the stratum pyramidale [t(10) = 1.711, p = 0.059]. No effect
of Tat was observed in PV+ interneuron groups in the SO. In contrast, the proportion of
SST+ interneurons was reduced in the SO [t(10) = 2.664, p < 0.05], but not in the
stratum pyramidale of Tat+ mice. While there were no significant differences in SO to
suggest that subpopulations of SST+ neurons were reduced in the layer, there was a
trend toward significant decreases in the proportion of PV−/SST+ [t(10) = 1.673, p =
0.063]. These data indicate subregion-specific declines in interneuron populations,
supporting the idea of selective vulnerability among hippocampal neuron
subpopulations.

PV+ and SST+ processes in CA1 appear unaffected by Tat
ImageJ analysis of PV expression in the SR and SST expression in the SL-M
showed no differences in fiber density between Tat+ and Tat− mice. There were also no
differences in dendritic varicosity number or size in PV+ neurons (Fig. 7).
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Discussion
Given the great diversity in function, morphology, and localization of hippocampal
interneurons, the highly localized reduction of Syt2+ fibers described by Fitting et al
(Fitting et al, 2013) suggests selective vulnerability of distinct subpopulations of
interneurons to HIV-1 Tat. We thus hypothesized that a subpopulation of hippocampal
interneurons would be selectively vulnerable to HIV-1 Tat and used an
immunohistochemical/morphological approach to identify neurodegenerative changes in
cells within defined regions of CA1. We found that Tat+ animals exhibited aberrant
learning behavior in both the Barnes maze and novel object recognition tests. Tat
expression reduced the population of nNOS+/NPY− interneurons in both the SR and
stratum pyramidale, SST+ cells in the SO, and PV + cells in the stratum pyramidale.
nNOS+/NPY+ or nNOS−/NPY+ neurons remained unchanged.
The pathology of specific interneuron subpopulations, and the hippocampal
interneuron network as a whole, have been demonstrated in a number of neurological
disorders (Korotkova et al, 2010; Toth et al, 2010; Antonucci et al, 2012; Fitting et al,
2013; Levenga et al, 2013), some of which produce behavioral deficits in learning
similar to the findings of Fitting et al (Fitting et al, 2013). Due to neuronal heterogeneity
in the hippocampus (Bouilleret et al, 2000; Moga et al, 2002; Avignone et al, 2005),
differential responses to Tat-induced excitotoxicity and neuroinflammation may be
expected. In a kainate-induced model of excitotoxicity, a loss of GAT-1, a GABA
reuptake protein, was greater in the stratum pyramidale than in the SO and the SR,
suggesting regional variability in selective vulnerability of hippocampal interneurons
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(Bouilleret et al, 2000). In HIV models, reductions in the number of cells expressing PV
in CA3, and SST in CA1 were observed, although identification of the affected subtypes
was incomplete (Masliah et al, 1992; Fox et al, 1997). The results of the present study
indicate that there is at least one subtype of nNOS+ interneuron within CA1 that is
selectively vulnerable to HIV-1 Tat. nNOS+ interneurons appear in all layers of the
hippocampus, a majority of which are subpopulations of neurogliaform cells (NGFCs;
nNOS+/NPY−) (Jinno et al, 1999; Tricoire et al, 2010). In addition to NGFCs, there are
ivy (nNOS+/NPY+) and interneuron-specific interneuron type III (IS3; nNOS+/NPY−)
cells. Ivy cells exist primarily in the stratum pyramidale, as well as the SR (Fuentealba
et al, 2008; Lapray et al, 2012). nNOS+/NPY− cells have been found in the stratum
pyramidale (IS3s) and SR (NGFCs) (Acsady et al, 1996a; Acsady et al, 1996b; Porter et
al, 1998; Jinno et al, 1999; Jinno & Kosaka, 2002; Jinno & Kosaka, 2004; Tricoire et al,
2010; Armstrong et al, 2012; Somogyi et al, 2012).
Our findings suggest that the ivy cells (i.e., nNOS+/NPY+ neurons residing in the
stratum pyramidale) are not vulnerable to HIV-1 Tat as previously hypothesized
(Fuentealba et al, 2008). Rather, a significant decline was observed in the number of
nNOS+/NPY− interneurons in both the stratum pyramidale and SR. In the stratum
pyramidale, these vulnerable neurons are thought to be IS3s (given the lack of NPY).
Additionally, these neurons are positive for vasoactive intestinal polypeptide (VIP), and
calretinin (CR) (Acsady et al, 1996a; Acsady et al, 1996b; Porter et al, 1998; Jinno et al,
1999; Jinno & Kosaka, 2002; Tricoire et al, 2010) and the expression of nNOS
differentiates them as IS3s versus an IS1 subtype (Tricoire et al, 2010). Functionally,
IS3s support feedback inhibition within CA1 (Gulyas et al, 1996; Chamberland et al,
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2010; Chamberland & Topolnik, 2012; Tyan et al, 2014). Of particular interest, the
selective vulnerability of multiple subsets of CR + cells in the hippocampus may occur in
a temporal-lobe epilepsy model, a good predictor of neuronal vulnerability to
excitotoxicity. Those cells that remain exhibit pathologic dendritic varicosities and a loss
of dendritic complexity and synapses, as a result of excitotoxic injury (Toth et al, 2010;
Toth & Magloczky, 2014). Patients with epilepsy can have fewer nNOS+ interneurons
within CA1 (Leite et al, 2002).
The population of nNOS+/NPY− cells affected by Tat in SR likely consists of
multiple nNOS+ interneuron subtypes, including IS3s (Acsady et al, 1996a; Acsady et
al, 1996b; Porter et al, 1998; Jinno et al, 1999; Jinno & Kosaka, 2002; Tricoire et al,
2010) and NGFCs (Tricoire et al, 2010; Armstrong et al, 2012; Somogyi et al, 2012;
Tricoire & Vitalis, 2012). Since IS3s represent a small proportion of nNOS+ cells in the
SR, it is probable that NGFCs constitute a majority of nNOS+/NPY− cells lost (Jinno et
al, 1999; Jinno & Kosaka, 2002; Tricoire et al, 2010; Armstrong et al, 2012). The
presence or absence of CR, which is expressed in IS3s, but not NGFCs, might be used
to further differentiate these interneuron subtypes in the future (Jinno & Kosaka, 2002;
Armstrong et al, 2012; Somogyi et al, 2012). Considering the lack of cell death in the
hippocampus observed at early time points following Tat induction (Fitting et al, 2013),
we speculate that the affected interneuron subtypes are downregulating nNOS in
response to excitotoxic injury in order to restore homeostasis (Hu et al, 2008; Di et al,
2012).
nNOS is required for the normal functioning of the hippocampal interneuron
network and maintenance of related behavioral endpoints. In complete nNOS knockout
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mice, there is an attenuation of contextual fear conditioning and spatial memory
formation similar to what is observed in Tat transgenic mice (Kirchner et al, 2004;
Weitzdoerfer et al, 2004; Kelley et al, 2009; Fitting et al, 2013). While nNOS is important
for normal hippocampal function (Kirchner et al, 2004; Zanelli et al, 2009), research
indicates that nNOS-induced neuronal damage occurs in pathological states (Cui et al,
2007; Eugenin et al, 2007; Steinert et al, 2010; Wang et al, 2010; Drury et al, 2014; Hsu
et al, 2014; Wu et al, 2014b). The role of nNOS in excitotoxicity, including HIV-1 Tat
excitotoxicity, is reportedly linked to its activation of PSD-95 and NMDA receptor
complexes (Christopherson et al, 1999; Eugenin et al, 2007; Fan et al, 2010; King et al,
2010; Steinert et al, 2010). Exposure to excitotoxic levels of glutamate causes temporal
dysregulation of nNOS activation-inactivation processes (Rameau et al, 2007). Thus,
Tat-induced increases in the activation of nNOS may enhance NMDA receptor
phosphorylation, the recruitment of additional AMPA receptors, and the generation of
peroxynitrite resulting in greater susceptibility to excitotoxic damage in nNOSexpressing interneurons (Yu et al, 1997; Grima et al, 2001; Rameau et al, 2007;
Hossain et al, 2012). Lastly, we speculate that the proposed compensatory
downregulation of nNOS may be absent or may be less prevalent in nNOS+/NPY+
neurons due to the neuroprotective effects of NPY, which can regulate neuronal
excitability via paracrine/ autocrine signaling (Xapelli et al, 2006; Smialowska et al,
2009).
The present findings stand in contrast to prior studies that did not demonstrate a
loss of PV+ interneurons in CA1 of HIV-infected patients or rodent models (Masliah et
al, 1992; Guo et al, 2012). Herein, we differentiate the percentages of CA1 PV
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expressing cells by CA1 layer and by SST co-expression, allowing for delineation of
CA1 cell types (PV+ interneurons including bistratified and oriens-lacunosummoleculare (O-LM) cells) (Kosaka et al, 1987; Masliah et al, 1992; Buhl et al, 1994;
Freund & Buzsáki, 1998; Jinno & Kosaka, 2000; Jinno & Kosaka, 2002; Klausberger et
al, 2004; Klausberger & Somogyi, 2008; Muller & Remy, 2014; Yamada & Jinno, 2015).
Bistratified cells were discerned from O-LM interneurons via the relative intensity of PV
(high in bistratified) and SST (minimal in bistratified) immunoreactivity. In contrast, OLMs exert an opposing PV/SST profile, with a subset of O-LMs being entirely PV−
(Chittajallu et al, 2013; Muller & Remy, 2014). Our data show a modest effect of Tat on
the total PV+ population of the stratum pyramidale; however, this was not restricted to a
particular PV+ cell type. Although we believe Tat may be selectively affecting bistratified
cells based on a trend toward reduced PV+/SST+ interneuron numbers, additional
information is needed for confirmation. Interestingly, while the loss of PV+ cells in CA1
is not reported in patients with neuroAIDS, many of the PV+ interneurons were
reportedly unhealthy with damaged neurites being the chief descriptor (Masliah et al,
1992). Despite limitations in generalizing findings from Tat transgenic mice to HIVinfected individuals, the collective findings suggest PV+ interneuron subsets are
selectively vulnerable to HIV—perhaps through synaptodendritic injury and pruning.
Reductions in SST gene expression in the brains of HIV patients are linked to the
development of depression (Everall et al, 2006). Fox et al. (Fox et al, 1997) showed a
reduction in SST+ interneurons in HIV patients, but did not differentiate between the
layers of CA1. We observed a strong net reduction of SST+ interneurons in the SO, but
not in the stratum pyramidale. The SR was not quantified due to the relative rarity of
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SST+ cells in this region. Interestingly, there was a trend toward reductions in
SST+/PV− interneurons in the SO following Tat induction. The loss of SST has been
shown to have profound effects on LTP within CA1, with differential effects in the apical
and basilar dendrites of pyramidal cells based on receptor subtypes and response to
specific oscillation patterns (Fan & Fu, 2014). Considering the decline in SST+ neurons
observed in this study and previous findings of reduced SST expression in HIV patients
(Everall et al, 2006), it will be important to examine whether region-specific SST losses
contribute to impairments in LTP and related behavior following Tat-exposure (Behnisch
et al, 2004; Fitting et al, 2013). In support of this notion, ablating SST+ interneurons,
focal to distal apical dendrites of pyramidal cells in SL-M (likely O-LMs), causes a loss
of cue-based fear learning, while removal of PV+ neurons, focal to basal dendrites and
proximal portions of apical dendrites in the SR, does not result in loss of fear learning.
(Leão et al, 2012; Lovett-Barron et al, 2014; Lovett-Barron & Losonczy, 2014; Muller &
Remy, 2014)} While it is not possible to say with certainty which SST+ population is
affected in the present study, the net loss in SST in the SO is most likely due to O-LM
cell vulnerability.
We and others have found that HIV-1 Tat can impair learning and memory, and
the present study begins to advance our understanding of the limbic neuronal types that
may underlie such effects. In the present study, Tat+ mice exhibited deficient
performance on two hippocampally dependent tasks, the Barnes maze and novel object
recognition tests, compared to their Tat− counterparts. Consistent with these results,
stereotaxic injections of Tat directly to dorsal hippocampus have recently been
demonstrated to increase the latency to find a hidden platform in a Morris water maze
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and to impair novel object recognition among Sprague-Dawley rats (Harricharan et al,
2015). Similar intracerebroventricular injections of Tat impaired radial arm maze
performance concurrent with disrupted LTP in the hippocampus of C57BL/6J mice (Li et
al, 2004). Additionally, similar impairment of Barnes maze performance and object
recognition has been observed in a separate GFAP driven Tat-inducible mouse model
(Carey et al, 2012). Considering that behavioral deficits similar to those seen in
neuroAIDS can be traced back to the dysfunction of one or more of the interneuron
types discussed here, it is reasonable to assume that imbalance in this complex circuit
may contribute to the attenuation of spatial memory observed in HAND (Masliah et al,
1992; Buhl et al, 1994; Acsady et al, 1996a; Fox et al, 1997; Sik et al, 1997; Ali et al,
1998; Kirchner et al, 2004; Klausberger et al, 2004; Weitzdoerfer et al, 2004; Carey et
al, 2012; Leão et al, 2012; Fitting et al, 2013; Lovett-Barron et al, 2014; Muller & Remy,
2014; Sun et al, 2014; Tyan et al, 2014).
Hippocampal interneurons interact as part of a functional network and it is clear
that the removal of even one cell type from the network can have drastic effects on
information processing, pyramidal cell excitation, and consequent behavioral outcomes
(Moga et al, 2002; Dugladze et al, 2007; Goldin et al, 2007; Toth et al, 2010; Peng et al,
2013; Long et al, 2014; Lovett-Barron et al, 2014; Lovett-Barron & Losonczy, 2014; Toth
& Magloczky, 2014; Orban-Kis et al, 2015). Importantly, the susceptible nNOS+/NPY−
interneurons of the stratum pyramidale and the SR, PV+ cells of the stratum pyramidale,
and SST+ interneurons of the SO form a microcircuit known to be involved in a complex
feedback loop/input gating mechanism that regulates network synchronization within
CA1 (Fig. 8) (Buhl et al, 1994; Acsady et al, 1996a; Sik et al, 1997; Ali et al, 1998;
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Klausberger et al, 2004; Chamberland et al, 2010; Chamberland & Topolnik, 2012; Leão
et al, 2012; Muller & Remy, 2014; Sun et al, 2014; Tyan et al, 2014; Milstein et al,
2015). Herein, we propose this microcircuit to be selectively vulnerable to HIV-1 Tat.
Given clinical observations that implicate HAND- and psychostimulant-related
neurocognitive deficits to be associated with interneuron losses in other brain regions
(Chana et al, 2006), the present findings suggest that a proportionally small,
interconnected ensemble of hippocampal CA1 interneurons may contribute to key
functional and neurobehavioral deficits observed in HAND.
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Figure 2. 1: Barnes maze performance between Tat- and Tat+ mice
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Representative traces of the movements of Tat− (a–c) and Tat+„ (d–f) mice
exploring a Barnes maze on testing days 1 (a, d) and 4 (b, e), as well as the reversal
probe trial [escape hole reversed 180° (c, f)]. Escape hole is noted as the black circle in
each figure. Tat+ mice (n = 8) demonstrate significantly longer latencies to find the
escape hole (g) and (h) spend a significantly lower proportion of time in the correct
quadrant of the Barnes maze test, indicating impaired learning compared to Tat− control
mice (n = 13). Neither the number of errors made (i) nor the distance traveled (j) differs
between Tat− and Tat+ mice, but decreases among all animals from day 1
performance. Tat+ mice have a reduced velocity compared to Tat− mice, and all mice
show reduced velocity in the reversal probe trail compared to day 1 performance (j,
inset). The asterisk indicates a main effect for Tat− and Tat+ mice to significantly differ.
The dagger sign indicates performance significantly differs from day 1 performance. The
double dagger sign indicates reversal probe trial performance significantly differs from
all other testing days, except day 1 (main effects, repeated measures ANOVA, p < 0.05)
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Figure 2. 2: Effects of Tat on novel object recognition task performance

Tat+ mice (n = 14) spend a significantly lower proportion of time investigating a
novel (vs. familiar) object in a novel object recognition test, indicating impaired cognitive
performance compared to Tat− control mice (n = 14). The asterisk indicates a significant
difference from the respective training trial exploration. The dagger sign indicates a
significant difference between Tat− and Tat+ mice in the retention trial (interaction,
repeated measures ANOVA, p < 0.05)
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Figure 2. 3: Tat effects on nNOS and NPY expressing CA1 interneurons
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Effects of HIV-1 Tat induction on neuronal nitric oxide synthase (nNOS) and
neuropeptide Y (NPY) immunoreactive interneuron subpopulations in hippocampal area
CA1. a–e Immunoreactivity for nNOS (c, c′), NPY (d, d′), and the neuronal marker,
NeuN (b, b′), was co-localized in sections from Tat+ and Tat− mice counterstained
using Hoechst dye (a, a′). e, e′ NeuN (blue), nNOS (green), and NPY (red) merged. f–j
The percentage of labeled neurons in hippocampal area CA1 by layer and marker. The
proportion of nNOS+ neurons in stratum pyramidale (Pyramidal) and stratum radiatum
(Radiatium) is significantly decreased in Tat+ compared to Tat− mice (*p < 0.05, one
tailed t test) (f), while the percentage of NPY+ neurons or neurons co-expressing nNOS
and NPY in any layer is unaffected by Tat (g, h). The percentage of cells expressing
nNOS in the absence of NPY is significantly reduced in stratum pyramidale and in
stratum radiatum (*p < 0.05, one tailed t test) (i), while the proportion of NPY cells that
lack nNOS was unaffected by Tat (j). Stratum oriens (Oriens), stratum lacunosummoleculare (L–M). Scale bar = 200 μm
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Figure 2. 4: nNOS and NPY subcellular localization

Subcellular localization of neuronal nitric oxide synthase (nNOS) and
neuropeptide Y (NPY) immunoreactivity in interneurons in hippocampal area CA1 of
Tat+ and Tat− mice. a–d Immunoreactivity for nNOS (green), NPY (red), and the
neuronal marker, NeuN (blue), was co-localized in sections from Tat+ and Tat− mice
counterstained using Hoechst dye (nuclei). a, c nNOS+/NPY− interneurons located in
stratum pyramidale (sp). b, d nNOS+ and NPY+ interneurons of stratum pyramidale.
Stratum oriens (so), stratum radiatum (sr). Scale bar = 10 μm
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Figure 2. 5: Effects of Tat on PV and SST expressing CA1 interneurons
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Effects of HIV-1 Tat induction on parvalbumin (PV) and somatostatin (SST)
immunoreactivity in interneurons within hippocampal area CA1. a–d Low-magnification
images of PV, SST, and NeuN immunoreactivity in sections from Tat+ and Tat− mice
additionally counterstained with Hoechst dye. a–e Hippocampal sections from Tat+ and
Tat–mice treated with DOX, probed with Hoechst (a, a′), NeuN (b, b′), PV (c, c′), and
SST (d, d′). e, e′ NeuN (blue), PV (green), and SST (red) merged. f–j The percentage of
labeled neurons in hippocampal area CA1 by layer and marker. A decrease in the
percent of PV+ neurons is seen in stratum pyramidale (Pyramidal) (f), and a decrease in
the percent of SST+ neurons is observed in stratum oriens (Oriens) (g). No significant
decrease is observed for neurons expressing both PV and SST or for neurons that
express either marker in the absence of the other (h–j). The asterisk denotes a
significant reduction from Tat− control population percentage (one tailed t test, p <
0.05). Scale bar = 200 μm

66

Figure 2. 6: PV and SST subcellular localization
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Subcellular localization of parvalbumin (PV) and somatostatin (SST)
immunoreactivity in interneurons in hippocampal area CA1 of Tat+ and Tat− mice. a–d
High-magnification images of PV (red), SST (green), and NeuN (blue) immunoreactivity
in sections from Tat+ and Tat− mice additionally counterstained with Hoechst dye (a–f).
a, d PV+/SST− interneurons located in stratum oriens (so). b, e PV+ and SST+
interneurons of the stratum oriens. c, f PV+ neurons of stratum pyramidale (sp). Stratum
radiatum (sr). Scale bar = 10 μm
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Figure 2. 7: Tat does not affect amount of PV or SST+ neurites in CA1

No evidence of changes to parvalbumin-immunoreactive (PV+) dendrites or
somatostatin immunoreactive (SST+) axons is observed following Tat induction. a PV+
neurons and neurites in Tat− mice. No differences in the density of PV+ fibers or
increases in the number of dendritic varicosities was seen in the stratum radiatum (sr).
Scale bar = 20 μm. b Tat− SST+ axons in stratum lacunosum-moleculare (sl-m). No
difference in fiber density of SST+ axons in the SL-M was observed. Stratum oriens
(so), stratum pyramidale (sp), dentate gyrus (dg). Scale bar = 50 μm
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Figure 2. 8: Interneurons affected by Tat are part of a memory microcircuit

The interneurons affected by Tat form a microcircuit within the CA1 area of the
hippocampus. CA1 pyramidal cells receive inputs from both hippocampal area CA3 and
the entorhinal cortex. Oriens-lacunosum-moleculare (O-LM) cells gate inputs from the
entorhinal cortex onto pyramidal cell distal apical dendrites. CA3 inputs are disinhibited
by bistratified cells and Shaffer collateral-associated interneurons in the stratum
radiatum (Sik et al, 1997; Klausberger et al, 2004; Leão et al, 2012). O-LMs receive
excitatory inputs from CA1 pyramidal cells and the septum, and inhibitory innervation
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from interneuron-specific interneuron type 3 (IS3) cells (Acsady et al, 1996a; Muller &
Remy, 2014; Sun et al, 2014; Tyan et al, 2014). Bistratified cells receive excitatory input
from Shaffer collaterals, CA1 pyramidal cells, and the septum (Ali et al, 1998;
Klausberger et al, 2004; Muller & Remy, 2014) and innervate pyramidal cells (Buhl et al,
1994; Sik et al, 1997; Klausberger et al, 2004). In addition to being inhibited by O-LMs,
bistratified cells receive GABAergic inputs from the neuronal nitric oxide
(nNOS)+/neuropeptide Y (NPY)− IS3s (Leão et al, 2012; Tyan et al, 2014). IS3s
innervate O-LMs preferentially, as well as bistratified cells, in the stratum oriens (Acsady
et al, 1996a; Tyan et al, 2014). Disruption of this circuit by Tat may disrupt the gating of
inputs from CA3 and the entorhinal cortex and therefore produce aberrant pyramidal cell
outputs, which could account for the behavioral phenotype observed following Tat
exposure (Sik et al, 1997; Klausberger et al, 2004; Leão et al, 2012). CA1 pyramidal cell
(yellow), bistratified cell (Bis, orange), O-LM (red), IS3 (light blue), Shaffer collateral
input from CA3 (green), perforant path input from the entorhinal cortex (EC, purple).
Glutamatergic synapses are noted with a plus (+) and GABAergic synapses are noted
with a minus (−).
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Familiar Object Exploration (s)
Novel Object Exploration (s)
Total Distance Traveled (m)
Frequency of Rearing
Total Time Rearing (s)

Tat− n= 14
12 ± 2
24 ± 3
13 ± 1
51 ± 8
43 ± 7

Tat+ n= 14
15 ± 2
20 ± 3
11 ± 1
44 ± 8
35 ± 6

Table 2. 1: Raw exploration time and motor behavior among Tat- and Tat+ mice
Raw exploration time and motor behavior among Tat− and Tat+ mice (n =
14/group) that were assessed in a novel object recognition task (mean ± SEM). No
significant differences were observed between Tat− and Tat+ mice.
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Chapter 3: The effects of Tat and Morphine on the structure and function of CA1
Parts of this chapter will be submitted for publication in the Journal of Neuroscience

Clarification of contributions: Dr. Virginia McLane, Aaron Barbour, and Jean Moon
assisted with morphological analyses

Introduction
Infection of the CNS by the human immunodeficiency virus (HIV) results in a
series of neurological impairments collectively termed the HIV associated
neurocognitive disorders (HAND). The neurological effects of HIV have also been
shown to be exacerbated by using opiates (Hauser et al, 2012). Diminished spatial
memory, frequently associated with hippocampal dysfunction, is a hallmark of HAND
and aggravated by opiate abuse (Maki et al, 2009; Keutmann et al, 2017). Despite this,
the mechanisms underlying the pathological effects of HIV and morphine alone or in
combination within the hippocampus are incompletely understood.
Both Tat (Kesby et al, 2016; Marks et al, 2016), and morphine (Zhu et al, 2011;
Kitanaka et al, 2015) have been demonstrated to impair spatial memory in mice.
Previous work identified HIV-1 Tat-induced reductions of long term potentiation (LTP) in
CA1, which coincides with deficits spatial memory formation in HIV transgenic mice
(Fitting et al, 2013). However, reductions in LTP were accompanied by only modest
reductions in the density of dendritic spines in CAI pyramidal cells and no change in the
levels of excitatory synaptic proteins. In contrast, Tat markedly reduced expression of
synaptotagmin 2, while triggering presumably compensatory increases in gephyrin
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postsynaptically, reflecting a disruption in inhibitory GABAergic transmission within CA1.
Further investigation of the GABAergic cells within CA1 revealed that several distinct
subgroups of GABAergic interneurons were preferentially vulnerable to Tat, while others
were unaffected (Fitting et al, 2013; Marks et al, 2016). Many of the interneurons
affected by Tat are known to be part of a microcircuit within CA1 that is involved in
feedback regulation and input gating of pyramidal cells (Buhl et al, 1994; Sik et al, 1997;
Klausberger et al, 2004; Leão et al, 2012; Muller & Remy, 2014; Tyan et al, 2014; Marks
et al, 2016), making it likely that Tat will cause notable effects on the physiological
activity of these targets as a consequence of disruptions in the supporting microcircuitry,
even beyond any direct Tat effects on pyramidal cells themselves. Morphine generally
decreases neuronal excitability (Liao et al, 2005; McQuiston, 2008; Xu et al, 2013;
Fitting et al, 2015a; Fitting et al, 2016). However, because morphine disinhibits
GABAergic interneuron inputs onto pyramidal cells, this may exacerbate Tat-induced
excitotoxicity in pyramidal cells. This is all dependent on neuron type and opiate
receptor distribution (Drake & Milner, 2002; Liao et al, 2005; McQuiston, 2007;
McQuiston, 2008; Xu et al, 2013). Interestingly, Tat and morphine can exert effects in
pathways which have converging processes (Sanchez-Blazquez et al, 2010; Garzon et
al, 2011). Tat can also cause morphine to have differential effects on sodium channel
activity in cultured neurons. Depending on morphine concentration, combined Tat and
morphine can profoundly disrupt physiologic processes (Fitting et al, 2015a).
With observed deficits in the GABAergic network of the hippocampus,
accompanied by only slight morphological disturbances in the pyramidal cells, we
hypothesized that the functional output of CA1 might be disrupted by HIV-1 Tat. We
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also set out to examine whether the observation of reduced synaptotagmin 2 in SR
results in loss of synaptic contacts on pyramidal cells. Additionally, the evidence that
morphine exacerbates HIV effects in human patients as well as our Tat transgenic
mouse model led us to hypothesize that the deleterious effects of Tat would be
exacerbated by the presence of morphine, especially in the morphologic domain,
considering the very modest effects previously observed. To test these hypotheses, we
used whole cell patch clamp to examine the firing frequency and other
electrophysiological properties of CA1 pyramidal cells, as they represent the focal point
of inhibitory and excitatory processed in the region before projecting out toward the
entorhinal cortex, and perform morphological analyses on the cells recorded from
afterward. Additionally, we sought to identify behavioral deficits in spatial memory
formation, closely associated with the hippocampus associated with the combined
effects of HIV-1 Tat and morphine exposure.
Materials and Methods
The use of mice in these studies was pre-approved by the Institutional Animal
Care and Use Committee at Virginia Commonwealth University and the experiments
were conducted in accordance with ethical guidelines defined by the National Institutes
of Health (NIH Publication No. 85-23).
Subjects and housing
Male mice between 8 and 12 weeks of age with or without the presence the HIV1 tat transgene (HIV-1 T Tat1-86) under the control of a doxycycline activated Tet-on
expression system driven by glial fibrillary acidic protein (GFAP) were used in these
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studies (Bruce-Keller et al, 2008). Doxycycline (Dox) was administered in a specially
formulated diet (Dox Diet #2018, 6 g/kg, Harlan Laboratories, Madison, WI) to the mice
for 10-11 days. On the last day, animals were sacrificed for electrophysiological
experiments or tissue harvesting. All mice were housed 4-5/cage and maintained in a
temperature- and humidity-controlled room on a 12:12 h light/dark cycle (lights off at
18:00 h) with food and water available ad-libitum. On day 5 following Dox
administration, animals had a morphine pellet (25 mg morphine sulfate, NIH) or placebo
pellet implanted in beneath the skin in the subscapular region.
Tissue preparation for electrophysiological experiments
Following 10-11 days of Dox exposure, adult male mice were transcardially perfused
with sucrose cutting media (in mM; 3 KCl, 4.12 MgSO4, 1.2 NaH2PO4, 206 sucrose, 25
NaHCO3, 25 glucose) chilled to around 1-3°C and bubbled with a 5% CO2 balanced
oxygen mix. Brains were extracted and halved along the sagittal sulcus, then cut
horizontally in 350 µm sections from the ventral surface using a Leica VT1200 S
vibratome (Leica Biosystems, Buffalo Grove, IL). Slices were cut in oxygenated sucrose
cutting media held at 1-3°C by an external cooling apparatus (Huber, Offenburg,
Germany). Following the cutting procedure, slices were transferred onto a nylon mesh
submerged in oxygenated extracellular recording solution (in mM; 3 KCl, 1.2 CaCl2, 1.2
MgSO4, 1.2 NaH2PO4, 125 NaCl, 25 NaHCO3, 25 glucose) maintained at 36.5°C for 30
minutes. The beaker was then returned to room temperature and the slices allowed to
rest for 30 minutes prior to recording. In some cases, both the cutting solution and
extracellular solution were supplemented with 500nM morphine sulfate.
Electrophysiological recording
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Slices were continuously perfused with extracellular recording solution warmed to
30-34°C with an external heating apparatus (Warner instruments, TC-344B, Hamden,
CT). The CA1 subfield of the hippocampus was visualized using a 4x magnification
objective on a Zeiss Axio Examiner A1 microscope (Zeiss, Oberkochen, Germany).
Magnification was switched to a 63x fluid-immersion objective to identify putative
pyramidal neurons in the CA1 pyramidal layer. Pipettes for whole cell patch clamp were
pulled (Narishige PC-10 pipette puller; Narishige, Tokyo, Japan) from borosilicate glass
pipettes (WPI #1B1505-4) to a resistance of 2-6 MΩ. Pipettes were filled with an
intracellular solution containing (in mM) 135 KMeSO4, 10 HEPES, 2 MgATP, 0.1
MgGTP, 8 NaCl, 0.1 BAPTAK4, Biocytin 0.2% (pH 7.25). Membrane potentials were
recorded using a MultiClamp 700B amplifier (Molecular Devices, Sunnyvale, CA),
processed using a Digidata 1550A digitizer, and analyzed using Clampex 10.4 software
(Molecular Devices, Sunnyvale, CA) a Windows-based computer. Membrane potentials
were observed in response to step-wise, 25 pA current increases from −100 pA to 400
pA.
Histology: Upon termination of whole cell patch clamp configuration, slices containing
biocytin-filled cells were moved into a 24-well plate and fixed with 4% paraformaldehyde
in 1x phosphate buffered saline (PBS) for 4-7 days at 4°C. Following fixation, slices
were rinsed in PBS 6 times for 10 min each on a rocking platform at 4°C. Slices were
permeabilized for 30 min in a solution of 50% ethanol in 1x PBS, containing 0.02%
Triton X100, then transferred into a similar solution containing 70% ethanol for 30 min,
and returned to 50% ethanol for 30 min. Slices were rinsed as described earlier, and
then blocked in PBS containing 2% chicken serum, 0.02% bovine serum albumin, and
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0.02% Triton X100 for 30 min. Primary antibodies against gephyrin (goat polyclonal,
1:1000, Santa Cruz, Sc-6411), and synaptotagmin 2 (Syt2; Rabbit polyclonal, 1:1000,
Synaptic Systems, Goettingen, Germany; Cat. No. 105 123) were applied, and slices
were incubated for 48 h on a rocking platform at 4°C. The slices were rinsed as before,
and incubated in secondary antibodies (donkey anti-goat IgG-Alexa Fluor® 488 1:500,
Invitrogen A-1055; goat anti-rabbit IgG-Alexa Fluor® 647 1:500, Invitrogen A-21244), as
well as an Alexa Fluor® 594 Conjugated streptavidin probe (1:100, Invitrogen, S-32356)
for 48 h, and then rinsed in PBS. Slices were incubated in Hoechst (0.5 μg/ml in PBS,
Invitrogen, H3570) for 10 min, rinsed in PBS, and mounted on slides using ProLong
Gold Antifade reagent (Invitrogen, P36930).
Imaging and morphological analysis:
Z-stack imaging of neurons was performed using a Zeiss LSM 700 (0.55 NA) at 20x
(Plan-Apochromat 20x/0.8 NA, M27) and 63x (Plan-Apochromat 63x/1.40 NA Oil
immersion DIC, M27) magnification (Zeiss, Oberkochen, Germany). Hoechst was
visualized using a 405 nm laser with an SP 490 nm Filter, Alexa 488 using a 488 nm
laser and a BP 490-555nm filter, and Alexa 594 using a 555nm laser with a BP 505-600
nm filter. Z-Stack data was reconstructed into a 3-D image using Imaris Bitplane 7.6.4
(Zurich, Switzerland). Primary dendrites were determined as dendrites that protrude
from the cell body and dendritic order increased with every branching point. Dendritic
spine analysis was performed with Imaris Bitplane 7.6.4 and regions selected for
analysis were 20-30 µm in length and were selected at a 5-10 µm distance from the
previous branch point and at least 5 µm from the next branch point. Dendritic spine
densities are reported as the average number of spines per 10 µm length of dendrite.
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Spine morphology was analyzed using uncompressed Z-stacks. Spines were counted
along 20-30 µm long dendrite segments laying parallel to the plane of view. Three
categories of spine morphology were quantified: thin, stubby, and mushroom (Harris et
al, 1992; Ochs et al, 2015). Each spine type was counted and expressed as a
percentage of total spines. Analysis of the co-localization of inhibitory puncta within
neurite segments was performed using the co-localization module of Imaris Bitplane
[version 9.0]. Briefly, background signal was filtered out of from the 488 channel
(gephyrin), and the signal from the 594 channel (streptavidin tagged pyramidal cells)
was used as a mask to create a co-localization channel for gephyrin puncta occurring
within spaces occupied by filled pyramidal cells. The number of puncta within a
measured length of approximately 10 µm along the identified neurite segment was then
counted. Data is expressed as number of gephyrin puncta per micrometer. Analysis of
inhibitory contacts took place on the aspinous portions of the apical and basilar
dendrites immediately adjacent to the cell body, as well as the spiny portions at the
distal ends of dendrites terminating in SL-M, as these dendritic compartments are have
the highest percentage of inhibitory contacts in the average CA1 pyramidal cell (Megıa
́ s
et al, 2001).
Barnes maze
Tat− and Tat+ mice were implanted with either morphine (n = 15 Tat−, 15 Tat+)
or placebo pellets (n = 17 Tat−, 18 Tat+) and assessed for spatial learning and motor
function using a Barnes maze test (Barnes, 1979). Mice consumed DOX chow for 6
days prior to 1 day of prehabituation (1 day following subscapular pellet implantation),
followed by 4 days of testing. In the prehabituation phase, mice were placed in a
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randomly positioned escape hole for 2 min, then were placed in the brightly lit center of
the Barnes maze (91 cm diameter, 90 cm height, with 20 holes each 5 cm diameter;
Stoelting Co., Wood Dale, IL). Mice were the guided to the same assigned escape hole
where they remained for 2 min. Finally, the mice then were placed under a glass
cylinder next to the escape hole, and allowed up to 3 min to volitionally enter (mice that
did not enter the hole were guided in and remained for 2 min). On testing days (two
trials per day over 4 days), mice were placed in the brightly lit center of the Barnes
maze and were allowed up to 3 min to enter the escape hole. Mice that did not enter the
hole were gently guided to the hole and allowed to remain for 2 min. Shorter latencies to
find the escape hole, a greater proportion of time spent in the correct quadrant of the
maze, and fewer errors were considered indices of greater learning (Camara et al,
2013). On the final day, following the completion of training trials, a reversal probe trial
was conducted in which the maze was rotated 180° from its original position such that
the correct goal box was on the opposite end of the Barnes maze table. The proportion
of time spent in the new target quadrant, latency to find the new escape hole, and
number of errors made were assessed. Distances and velocities traveled were used as
an index of motor behavior. Behavioral data were recorded and digitally encoded using
the ANY-maze animal tracking system (Stoelting Co., Wood Dale, IL).
Vision testing
All mice were tested for visual function following conclusion of the Barnes maze
test (Wersinger et al, 2002; Marks et al, 2016). Briefly, mice were suspended
approximately 12 in. above a vertical ring-stand and were lowered with the ring-stand
approximately 2 in. from the left or right visual field (close enough to allow visual, but not
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whisker, contact with the ring-stand). The left and right visual fields were assessed for
each mouse, with the starting side selected randomly. Visual responding was
considered positive when mice reached with the forepaws for the rod when presented to
both the left and right side. A response to only one visual field is considered a negative
response. One male animal (Tat+/morphine) failed vision testing and was excluded from
analysis.
Statistical analysis
Behavioral data were assessed via repeated-measures analyses of
variance (ANOVA) with Barnes maze testing trial (days 1–4 and reversal probe) as the
within subjects factor, and both mouse genotype (Tat− or Tat+) and drug treatment
(morphine or placebo) as the between subjects factors. Fishers PLSD post hoc tests
were used to assess group differences following main effects. Interactions were
delineated via simple main effects and main effect contrasts with alpha corrected for
multiple comparisons. All electrophysiological data was collected and analyzed using a
planned comparisons paradigm. Tat− and Tat+ animals treated with placebo pellets
were compared against Tat− and Tat+ animals treated with morphine pellets and
maintained in morphine containing solutions. As a separate comparison, Tat− and Tat+
animals treated with morphine pellets and maintained in morphine-containing solutions
were compared against Tat− and Tat+ animals treated with morphine pellets and
maintained in morphine-free solutions. Firing frequency was analyzed using a repeated
measures ANOVA with current step as the within-subjects factor, and Tat genotype and
drug treatment combination as the between-subjects factors. Intrinsic firing properties
were performed with a standard two-way ANOVA. In all cases, the threshold for
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significance was considered p < 0.05, and post-Hoc testing was performed using
Fisher’s PLSD except where the requirements of planned comparisons testing
necessitated more stringent application of Bonferroni corrections for multiple
comparisons.
Results
Barnes maze
A main drug effect was noted in latency to escape [F (1,61) = 15.708, p < 0.05],
with morphine treated animals taking longer to escape in all trials than placebo treated
animals, regardless of genotype [p = 0.0002] (Fig. 3.1A). A significant interaction was
observed for the factors of time, genotype, and drug in a repeated measures ANOVA [F
(1,61) = 2.704, p < 0.05] for the percentage of time animals spent in the correct
quadrant. Tat−, placebo-treated animals outperformed Tat+, placebo-treated animals
after four days of training trials. Morphine-treated animals were unaffected by genotype
status (p = 0.0402), obviating the Tat effect (Fig 3.1B, 3.2) While no significant effects
were noted in the number of errors made between groups, an overall effect of time was
observed, in which all groups made fewer errors as testing progressed [F (1,59) =
20.749, p < 0.05] from day 1 to day 4, and increased with the reversal trial [p = 0.0001 –
0.0034] (Fig 3.1C). Similarly, the distance traveled (Fig 3.1D) was not significantly
different between groups, but changed across all groups over time [F (1,61) = 22.036, p
< 0.05], with decreasing distance from days 1 to four, and an increase in the reversal
trial [p = 0.0001 – 0.0296]. While no significant interactions were noted in the average
velocity of the animals, independent main effects of drug [F(1,61) = 5.366, p < 0.05] and
time [F(1,61) = 4.116, p < 0.05] are present (Fig 3.1E). Placebo treated animals move at
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higher velocity across all trials [p = 0.0239], and all groups move at a lower velocity on
Day 4 compared to day 1, with a return to baseline velocity in the reversal trial [p =
0.0142 – 0.002].
Electrophysiological analysis of Tat and drug effects on CA1 pyramidal cells
In order to assess the effects of Tat and morphine on physiological function of
CA1 pyramidal cells as the functional output of CA1, a planned comparisons testing
paradigm was designed to test the differences between six sets of conditions: Groups
A and B consisted of Tat− and Tat+ placebo-treated animals (n = 13 cells from 3
animals, and 11-12 cells from 3 animals respectively). Groups C and B consisted of
Tat− and Tat+ morphine-treated mice in which the ex vivo slices were maintained in 500
nM morphine-containing physiological solutions during recordings and referred to as
‘morphine maintained’ (n = 19 cells from 4 animals, and 13 cells from 4 animals,
respectively) and were compared to groups A and B. Groups E and F consisted of Tat−
and Tat+ morphine-treated mice in which morphine was withheld from the ex vivo slices
that were maintained in physiological solutions lacking morphine during recordings and
referred to as ‘morphine withheld’ (n = 29 cells from 8 animals, and 22 cells from 7
animals). Groups A and B were independently compared to groups C and D (‘morphine
maintained’) or to groups E and F (‘morphine withheld’; Fig 3.3), but C and D and E and
F were not directly compared to one another.
In the comparison between Tat− and Tat+ placebo-treated animals vs. Tat− and
Tat+ morphine maintained animals, several effects were observed. Assessments of
firing frequency showed a significant interaction between current step and Tat genotype
[F(1,52) = 3.037, p < 0.05]; however, no other interactions occurred (Fig 3.4A-D). One83

way ANOVA revealed that between the 50 pA and 150 pA current steps, pyramidal cells
from Tat+ mice fired at a lower frequency than those from Tat− mice [p = 0.0024 0.0461] (Fig. 3.4C). Intrinsic membrane properties were assessed by two-way ANOVA.
An interaction between Tat and morphine exposure was observed in the resting
membrane potential of the CA1 pyramidal cells [F(1,53) = 7.341, p < 0.05]. Pairwise
comparisons using the Bonferroni correction for multiple comparisons (significance
threshold set at p < 0.0083) revealed that only placebo-treated Tat− and Tat+ mice
differed (Fig. 3.5A), with Tat+ placebo-treated animals having significantly more
depolarized resting membrane potentials [p = 0.0057]. In addition, a main effect of
morphine was observed on the firing threshold of CA1 pyramidal cells [F(1,53) = 15.812,
p < 0.05], with morphine-treated cells firing at a more hyperpolarized potential than
placebo-treated mice [p = 0.0001] (Fig 3.5C). No significant effects were noted for
rheobase, however, Tat treatment caused a trend toward increased rheobase compared
to controls [F(1,53) = 3.367, p = 0.0622] (fig 3.5B). Notably, no significant differences
were seen between any groups in the values of input resistance or capacitance (Table
3.3).
To assess the effects of withholding morphine in our model, we compared the
physiological response of CA1 pyramidal cells in Tat− and Tat+ placebo treated animals
with those of Tat− and Tat+ morphine treated animals, in which physiological recordings
took place in solutions lacking morphine, so as to induce a withdrawal-like state in the
tissue slices. Assessment of firing frequency revealed two interactions, one between Tat
and current step [F(1,71) = 3.465, p < 0.05], and another between drug treatment and
current step [F(1,71) = 6.425, p < 0.05]. Tat and morphine treatment did not show any
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interactions (Fig 3.6A-D). To independently test the effects the Tat induction and
morphine on the firing rates pyramidal cells exposed to increasing amounts of current,
the Bonferroni corrected significance threshold was set at p < 0.025. Collapsing across
genotype and ignoring the effects of morphine, Tat exposure altered the firing rate of
pyramidal cells depending on the amount of the stimulating current. Tat+ pyramidal
cells fired at a lower frequency than Tat− neurons [p = 0.0013 – 0.0208] (Fig 3.6C) at 25
pA to 200 pA, but firing rates did not differ at other current levels. Collapsing across
drug treatment, without considering the effects of genotype, showed that when
morphine was withheld from slices from morphine-treated mice, pyramidal cells fired at
a significantly lower frequency than those in placebo-treated mice when stimulated with
275 pA to 375 pA [p = 0.0069 – 0.0204] (Fig 3.6D). Intrinsic membrane properties were
again compared by using two-way ANOVA. An interaction between Tat and drug
treatment was observed in the resting membrane potential [F(1,72) = 37.989, p < 0.05].
Pairwise comparisons using the Bonferroni correction for multiple comparisons
(significance at p < 0.0083) revealed that only the resting membrane potential of Tat−
and placebo-and Tat+ and placebo-treated mice differed (Fig 3.7A), with Tat+ placebotreated animals having significantly more depolarized resting membrane potentials [p =
0.0031]. Additionally, a Tat effect was noted in the observed rheobase [F(1,72) = 7.704,
p < 0.05], where Tat positive cells required more current to reach threshold [p = 0.0039]
(Fig 3.7B). No significant effects were observed on the firing threshold CA1 pyramidal
cells (Fig 3.7D). As in the previous comparison, neither the resistance nor capacitance
was affected by Tat and/or morphine, suggesting that the effects of Tat and morphine
on CA1 pyramidal cells are indirect (e.g., through alterations in presynaptic inputs
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originating from interneurons, circuits outside CA1, and/or glial activity), rather than
direct/intrinsic effects of Tat and/or morphine on the pyramidal cells themselves (Table
3.4).
Morphological analyses
The morphological effects of Tat on CA1 pyramidal cells have previously been
analyzed as whole cells or larger segments without consideration to the sublaminar
divisions within CA1 (Fitting et al, 2013), which may result in subtler effects of Tat being
missed, as distinct structural and functional differences exist between, and within, the
dendritic compartments occupying different CA1 sublamina (Megıa
́ s et al, 2001). To
better assess the regional variations within CA1 dendritic structure, analyses of
morphology were broken down by sublamina (Figs 3.8, 3.9A, 3.10A, 3.11A). The cells
and dendrite segments used for morphological analysis were all used in the
electrophysiological analysis of Tat and morphine (n for all groups = 10-12; figs 3.8,
3.9B, 3.10B, 3.11B).
The effects of Tat and morphine on the density of dendritic spines differed in
each layer of hippocampal area CA1. In the SO, there was a main effect of morphine on
spine density [F(1,41) = 8.402, p < 0.05], where cells from morphine treated animals
had fewer spines per 10 µM segment [p = 0.0069] (Fig 3.9C). No effects on spine
density were observed in SR (Fig 3.10C); however, a significant effect of Tat was
observed in SL-M [F(1,38) = 5.015, p < 0.05], with Tat+ cells having a higher spine
density than Tat- cells [p = 0.0252] (Fig 3.11C). A trend toward an interaction between
Tat and morphine was also observed in SL-M [F(1,38) = 3.465, p = 0.0704]. With this in
mind, the effects of morphine were examined further in pyramidal cells in Tat− and Tat+
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mice separately. Significant effects were observed in Tat- cells [F(1,20) = 7.075, p <
0.05], but not Tat+ cells. Morphine-treated pyramidal cells in Tat− mice had fewer SL-M
spines than in placebo-treated mice [p = 0.0150]. With the lack of change in pyramidal
cells in the Tat+ mice by comparison considered with the trend toward interaction, it is
likely that the main effect of Tat on SL-M spine density is actually driven by a reducing
effect of morphine that is present only in Tat- cells.
As with regional spine density, the effects of Tat and morphine on the
morphologic types of spines present on dendrites varied by sublamina. Significant
interactions between Tat and morphine were observed in the SO (Fig 3.9D) for the
percentage of mushroom spines [F(1,40) = 6.932, p < 0.05] and stubby spines [F(1,40)
= 8.764, p < 0.05], and SL-M (Fig 3.11D) for the percent of mushroom spines [F(1,35) =
6.140, p < 0.05]. SO mushroom spines were found to be reduced in Tat+ morphinetreated animals compared to Tat− placebo-treated animals [p = 0.0028], and Tat−
morphine-treated animals [p < 0.0001]. Tat+ placebo-treated animals had more
mushroom-type spines than Tat− morphine-treated animals [p = 0.0034], but only
showed a trend toward increase from Tat− placebo-treated animals [p = 0.0865].
Additionally, Tat+ morphine-treated animals trended toward decreased mushroom
spines in comparison to Tat− morphine-treated animals [p = 0.0563]. Stubby spines in
the SO were reduced in Tat+ placebo-treated mice [p = 0.0115], as well as both Tat−
and Tat+ morphine-treated mice [p = 0.0001 – 0.0062]. SL-M mushroom spines were
reduced in Tat+ morphine-treated animals compared to all other groups [p = 0.0005 –
0.0112]. In addition to interactive effects, main effects of morphine were observed on
the mushroom-type spines of SR (Fig 3.10D) [F(1,43) = 7.027, p < 0.05], with morphine-
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treated animals having fewer mushroom-type spines than placebo-treated animals [p =
0.0107], and on the stubby-type spines of SLM [F(1,35) = 5.867, p < 0.05], with
morphine-treated animals having more stubby-type spines than placebo-treated animals
[p = 0.0129]. Finally, a main of Tat was seen on the percentage of thin/filopodial type
spines in SR [F(1,43) = 5.043, p < 0.05], with an increase seen in Tat+ animals
compared to Tat− animals [p = 0.0274]
Differing levels of dendritic damage were observed in SO, SR, and SL-M. Tat
and morphine had an interactive effect on the percent of SO dendrites with varicosities
[F(1,43) = 5.125, p < 0.05] (Fig 3.9E). This interaction was driven by all Tat+ groups and
morphine-treated groups being higher than the Tat− and placebo-treated controls [p =
<0.0001-0.0004]. In the SR, there were independent Tat [F(1,43) = 13.571, p < 0.05]
and morphine effects [F(1,43) = 13.100, p < 0.05] on the percentage of dendrites
exhibiting varicosities (Fig 3.10E), and a trend toward an interaction between them
[F(1,43) = 3.093, p = 0.0857]. Pyramidal cells in Tat+ mice had more dendrites with
varicosities than those in Tat− mice [p = 0.0006], and morphine-exposed pyramidal cells
had more dendrites with varicosities than those in placebo-treated mice [p = 0.0005]. In
addition to damage in the terminal dendrites, some degenerative effects were evident
on the main axis dendritic shaft (Fig 3.10F). The nonparametric Kruskal-Wallis test was
used because, unlike pyramidal cells in Tat+ mice, Tat− placebo-treated animals
displayed no varicosities along the main axis of their dendrites. Because of the lack of
variance in the Tat− placebo-treated animals compared to other groups, the ANOVA is
an improper test. A significant effect was observed between the four group medians (H’
= 16.993, p < 0.05]. Mann-Whitney testing (with significance threshold set at p < 0.0083)
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revealed that Tat+ and placebo-treated animals and Tat+ or Tat– mice receiving
morphine had more dendritic varicosities than control neurons [p < 0.0001-0.0025].
Additionally in SL-M, a significant effect of morphine was observed in the percentage of
terminal dendrites with varicosities [F(1,38) = 11.142, p < 0.05], with morphine-exposed
cells having more dendrites with varicosities than in placebo-treated mice [p = 0.0019]
(Fig 3.11E).
Assessment of the number of inhibitory postsynaptic puncta within pyramidal
cells was performed to further explore the loss of Syt2 expression and increase of
gephyrin previously observed in the hippocampus (Fitting et al, 2013). The number of
puncta was quantified along the aspinous portions of the basilar and apical dendrites as
they emerged from the soma, as this is the region known to have the highest
percentage of inhibitory contacts onto pyramidal cells (Megıa
́ s et al, 2001). The results
show no significant interactions between or main effects of either Tat or morphine on
the number of inhibitory puncta within the basilar [p = 0.3145-0.7208] or apical [p =
0.1287-0.5430] dendritic shafts in the perisomatic region (Fig 3.12).
Correlational analysis
A number of correlations were observed between morphological outcomes, and
electrophysiological outcomes. Several noteworthy correlations between the
morphological features in discrete dendritic compartments and electrophysiological
function were observed, and are presented with statistical results in Table 3.3. Negative
correlations between the density of spines in SR and the firing frequency of pyramidal
cells between 50 and 300 pA were observed. SR spine density also positively correlated
with rheobase. The percentage of mushroom spines in SO was seen to positively
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correlate with firing threshold, and negatively with firing frequency at the 100, 125, and
150 pA current steps. The percentage of mushroom spines in SL-M positively correlated
with resting membrane potential, and the percentage of thin spines in SL-M positively
correlated with firing frequency between the 275-300 pA and 350-400 pA current steps.
Measures of dendritic damage did not correlate with electrophysiological function.
Discussion
In a variety of cell types, Tat is known to cause neuronal excitotoxicity (Yu et al, 1997;
Mattson et al, 2005; Eugenin et al, 2007; Soulas et al, 2009; King et al, 2010). While
Hippocampal pyramidal cells have been shown to be vulnerable to excitotoxic injury
induced by excessive NMDA agonism (Avignone et al, 2005), the present study, and
previous studies of CA1 pyramidal cell function and morphology, suggest that direct
effects on CA1 pyramidal cells by Tat are minimal (Fitting et al, 2013) and that there is
an effect on local circuitry that impinges on CA1 pyramidal cells (Marks et al, 2016).
Indeed, there are more routes to excitotoxic injury than simple excess activation of
NMDA receptors (Bouilleret et al, 2000; Avignone et al, 2005). The excitotoxic effects of
Tat seem to mimic the syndrome caused in the kainite-induced injury model used to
examine temporal lobe epilepsy rather than exposure to NMDA, as the effects appear to
be more pronounced in subsets of CA1 interneurons rather than in CA1 pyramidal cells
(Bouilleret et al, 2000; Avignone et al, 2005; Marks et al, 2016). This variation in
excitotoxic disease could be due to interactions with multiple signaling pathways beyond
NMDA receptor activation (Cossart et al, 2001; Oliva et al, 2002; Avignone et al, 2005),
which is not surprising in the case of Tat considering how many interactions it can have
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with intra- and extracellular targets (Eugenin et al, 2007; King et al, 2010; Debaisieux et
al, 2012).
Physiologically, a Tat effect is seen in the analyses of Tat vs. morphine, and Tat
vs. pyramidal cells in which morphine was withheld, in which firing frequency is
significantly reduced al low current stimulation intensities. If direct excitotoxic activity of
Tat on CA1 pyramidal cells was sufficiently great, or occurring in isolation, it could be
expected that there would be an increase in their firing frequency, rather than a
decrease, as has been shown in pyramidal cells isolated from upstream circuitry and
exposed to excitotoxic insult (Avignone et al, 2005). Moreover, in the present study, the
decrease in firing frequency was accompanied by an increase in the amount of current
for pyramidal cells in Tat+ mice needed to reach their firing threshold. Although the firing
frequency of pyramidal cells from Tat+ animals is decreased, the resting membrane
potential of these cells is significantly elevated. This finding suggests that while Tatexposed pyramidal cells may tend to be hyperexcitable, Tat may sufficiently
overactivate the surrounding presynaptic inhibitory inputs to negate any intrinsic
excitatory effects of Tat on the pyramidal cells themselves.
Disparate effects occurred when comparing the active presence of morphine
against the effects of prolonged exposure followed by removal of morphine on CA1
pyramidal cells. Most interestingly, the only measure on which Tat and a morphine
paradigm interacted was the resting membrane potential, and in each case, the
difference is largely driven by the difference between the Tat− and Tat+ placebo-treated
population, with morphine exposure appearing to obviate the effect, as we observe in
both the Barnes maze results, and in the cytokine data. When morphine is present
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during recordings of animals previously exposed to morphine, there is no observed
morphine effect on firing, and it appears again that the presence of morphine obviates
the Tat effect. There is, however, a reduction in the firing threshold of morphine-treated
cells. By contrast, however, when tissues from morphine-treated animals are tested in
solutions lacking morphine the firing frequency of withdrawn CA1 pyramidal cells is
lower at high current stimulations (275-375 pA), but there is no effect of withholding
morphine on the firing threshold.
HIV-1 Tat has been shown to cause changes in dendritic spines throughout the brain,
indicating aberrations in normal patterns of plasticity. Reductions of spine density have
been observed in the cortex, striatum, and hippocampus (Fitting et al, 2013; Raybuck et
al, 2017; Schier et al, 2017), and alterations in the type of dendritic spines present on
dendrites in the striatum have been observed (Schier et al, 2017). Decreased long term
potentiation has also been seen in the hippocampus independently with Tat and
morphine exposure (Bao et al, 2007; Fitting et al, 2013). Additionally, HIV-1 Tat and
morphine exposure have an interactive negative effect on spine density in the striatum
(Fitting et al, 2010a). The present study shows morphine-driven reductions in the spine
density of dendrites in SO that do not interact with Tat, and differential morphine effects
in the SL-M on Tat− and Tat+ pyramidal cells, with no change in the SR. In comparison,
an eleven percent reduction in CA1 pyramidal cell spines was described by Fitting et al
(2013) and attributed to Tat alone, differences in the methodology and quantification are
present in this study which may give a more nuanced view by looking at discrete
dendritic compartments rather than the cell as a whole. The analysis of dendritic spine
loss is complemented by observations of regional shifts in spine types, which reflect
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region specific shifts in plasticity. The excitatory systems, however, do not act alone.
Our data show no differences in the amount of gephyrin puncta within dendrites near
the soma (fig 3.12), which could suggest that the previously-found increase in gephyrin
expression is related to inhibitory contacts onto other interneurons (Fitting et al, 2013;
Marks et al, 2016). In any case, it is likely that in each of the CA1 lamina, a subtle
balancing between excitatory and inhibitory processes is occurring independently of the
other layers. The changes observed in spine number and morphology, as well as
measures of dendritic damage were more pronounced in SO and SL-M, while SR
remained comparatively stable, indicating systems interacting within SR may be more
stable or better able to adapt. Dendritic damage observed in this study did not appear in
previous work (Fitting et al, 2013), which may indicate that added insults, such as the
manipulations under the hours-long sectioning, patching recording, and immersion
fixation processes employed here might expose underlying pathology that is not readily
visible given the relatively acute exposure to Tat in the prior experiments.
Results from previous studies have shown that Tat attenuates spatial memory as
assessed by the Barnes maze task. This includes an increased latency to escape, a
decreased time in the correct quadrant, and altered search strategies, as well
decreased performance in working memory and phase dependent alterations in reversal
learning (Kesby et al, 2016; Marks et al, 2016). The attenuation of spatial memory by
Tat is still evident, with Tat+ placebo-treated animals performing significantly worse than
Tat- placebo-treated animals according to post-hoc testing. Morphine treatment
appeared to obviate the negative effects of Tat, with morphine treated mice performing
at levels between the Tat- and Tat+ placebo-treated animals, regardless of genotype.
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Interestingly, there is only an observed effect of morphine on latency to escape, with
morphine-treated animals taking longer to escape than placebo-treated counterparts
regardless of genotype. While both Tat and morphine independently can impair spatial
memory function (Zhu et al, 2011; Kitanaka et al, 2015 ; Kesby et al, 2016; Marks et al,
2016), the present study shows no interaction between these factors, and even points
toward a morphine-based attenuation of the deleterious effects of Tat. Morphine has
been shown to have both stimulating and depressive effects on motor behavior
depending on dose, with higher doses generating a biphasic response in which activity
first decreases, then increases before returning to baseline. Tolerance to the depressive
effects, however, develops more rapidly than the stimulant effects with chronic high
dose administration. (Vasko & Domino, 1978; Ling et al, 1989; Le Marec et al, 2011)
raising the possibility of motor confound in the present study. Other studies, however,
have suggested that the effect of morphine on spatial memory is not attributable to
locomotor effects (Kitanaka et al, 2015). This is likely considering that there is an
observed effect of morphine on the overall velocity of travel (but not distance travelled),
and could be a consequence of the drug delivery method used in the present studies.
Additionally, it is possible that post-surgical inflammation, which can be expected from
any surgical procedure, may affect behavioral function (Chen et al, 2008; Vizcaychipi et
al, 2014). Also of note is that the testing protocol employed here used 2 fewer training
trials than in Marks et al (2016) to eliminate the problem of overtraining the animals, as
in the previous study we observed that after four days of training trials, a number of the
animals became habituated to the aversive stimulus used to drive the task and stopped
performing. It is possible that the risk of overtraining was outweighed by the
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confounding effects of morphine, and that the present study would have benefited from
more training trials. Further studies should be directed towards examining the
behavioral outcomes of Tat and morphine interactions
The results of this study suggest that despite the general observation that
morphine exposure exacerbates Tat toxicity in the brain (Hauser et al, 2012), the
hippocampus as a discrete region may not be as susceptible to this phenomenon. This
might be related to the Tat induced reduction of MOR expression, which could result in
a subtle shift between the deleterious effects of chronic MOR activation, and the counter
effects of DOR or KOR activation (Fitting et al, 2010a; Fitting et al, 2015b).
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Figure 3. 1: Effects of Tat and morphine on Barnes maze performance in mice

Barnes maze performance of Tat+ animals compared to Tat− animals,
with either placebo or morphine pellets implanted. (A) Animals given morphine took
longer to escape than mice given placebo pellets, regardless of genotype (p = 0.00002).
(B) A significant interaction was observed between Tat and morphine in the percent of
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time spent in the correct quadrant (p < 0.05), with placebo-treated Tat− mice performing
better than placebo-treated Tat+ animals (p = 0.0402). Mice treated with morphine
performed at an intermediate level regardless of genotype. No significant differences in
the number of errors made (C), or the distance traveled (D), were observed between
groups; however, these measures decreased from Day 1 to day 4, returning to Day 1
levels during the reversal probe (p = .00001-0.0209). The velocity differed across all
days between mice given placebo pellets and morphine pellets (E), with morphine
pellet-treated mice moving more slowly than placebo-treated animals (p = 0.01420.002).
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Figure 3. 2: Representative Barnes maze track traces

Representative track plots of the movements of male mice taken during 3 min (180 Sec)
performance of the Barnes Maze spatial memory test. Track plots represented show the
performance of Tat− and Tat+ mice, with either a morphine- or placebo-pellet implanted
subcutaneously in the subscapular region.
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Figure 3. 3: Visual representation of planned comparisons design for
electrophysiological analysis

Visual representation of the planned comparisons design described in the
methods section to assess the physiological activity of morphine naive Tat− and Tat+
CA1 pyramidal, and cells exposed to morphine in a morphine maintained state, and a
morphine deprived state independently. Briefly, six separate groups of mice were
generated contemporaneously for electrophysiological recordings. Intended
comparisons were between pyramidal cells from Tat− and Tat+ placebo treated mice,
and recorded in unsupplemented physiological solutions (A, B) and Tat− and Tat+ mice
treated with morphine, and recorded in physiological solutions supplemented with
morphine (C, D). The second intended comparison was between groups A, and B as in
the first comparison, and Groups E and F (Tat− and Tat+ mice treated with morphine,
but recorded in unsupplemented physiological solutions).
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Figure 3. 4: Firing frequency of CA1 pyramidal cells after exposure to Tat and/or
morphine-treated mice (in vivo) in which morphine is present during
electrophysiological recordings (ex vivo)

Analysis of the firing frequency of CA1 pyramidal cells from Tat– or Tat+ mice
treated with either a placebo or morphine. Slices from morphine-treated animals were
recorded in artificial CSF containing 500 nM morphine to continue to expose the
hippocampal slices to morphine ex vivo. Patched cells were stimulated with escalating
current pulses 500 ms in duration starting at −100 pA and escalating to 400 pA in 25 pA
steps. Representative traces (A) for each group are depicted at the 100 and 350 pA
current steps. An interaction between Tat genotype and the amount of current applied
was observed in the repeated measures ANOVA (p < 0.05) (B). CA1 pyramidal cells
from Tat+ mice fired at a lower frequency than those of Tat− animals at between 50 and
150 pA (p = 0.0024 - 0.0461; C), but were unaffected by the sustained exposure to
morphine during recordings (D).
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Figure 3. 5: Membrane properties of CA1 pyramidal cells in Tat and/or morphinetreated mice (in vivo) in which morphine is present during electrophysiological
recordings (ex vivo)

Further analysis of the excitability of CA1 pyramidal cells from Tat– or Tat+ mice
treated with either a placebo- or morphine-pelleted implants for 5 days in vivo. Slices
derived from morphine-treated animals were isolated and recorded in physiological
solutions containing 500 nM morphine to maintain receptor occupancy and morphine
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effects on the tissue. A significant interaction between Tat and morphine was observed
for the resting membrane potential (VR) of CA1 pyramidal cells (A). Post hoc analysis
showed that the differences were driven by a significant increase in the resting
membrane potential of pyramidal cells from Tat+ and placebo-treated mice relative to
those from Tat− and placebo-treated mice (p = 0.0057). Morphine treatment appears to
obviate the effects of Tat. While no significant effects were noted in the rheobase, there
was a trend (p = 0.0619) for pyramidal cells from Tat+ animals to require a greater
amount of current (pA) to reach threshold for firing compared to cells from Tat− mice
(B). A main effect of drug observed on firing threshold. The threshold for firing (mV) is
significantly reduced in cells from morphine-treated animals (p = 0.0622; C).
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Figure 3. 6: Firing frequency of CA1 pyramidal cells from Tat and/or morphinetreated mice (in vivo) in which morphine is withheld during electrophysiological
recordings (ex vivo)

Analysis of the firing frequency of CA1 pyramidal cells from Tat– or Tat+ mice
treated with either a placebo or morphine. Slices from morphine-treated mice and
morphine naïve mice were recorded in physiological solutions which did not contain
morphine. Patched cells were stimulated with escalating current pulses 500 ms in
duration starting at −100 pA and escalating to 400 pA in 25 pA steps. Representative
traces (A) for each group are depicted at the 100 and 350 pA current steps. Interactions
between Tat and current step, and morphine withdrawal and current step were
observed in the repeated measures ANOVA (p < 0.05; B). Tat and morphine removal
did not interact at any level of the analysis. At stimulating currents between 25 and
2,000 pA, CA1 pyramidal cells in slices from Tat+ mice fired at a lower frequency than
those from Tat− mice (p = 0.0013-0.0208; C). Withholding morphine from pyramidal
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cells slices isolated from morphine-exposed mice resulted in significantly lower firing
rates at stimulating currents from 275 pA to 375 pA compared to morphine-naïve
pyramidal cells (p = 0.0069-0204; D).
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Figure 3. 7: Membrane properties of CA1 pyramidal cells from Tat and/or
morphine-treated mice (in vivo) in which morphine is withheld during
electrophysiological recordings (ex vivo)

Analysis of the firing frequency of CA1 pyramidal cells from Tat– or Tat+ mice treated
with either a placebo or morphine. Morphine-treated and morphine-naive mice in this
analysis were recorded in physiological solutions that did not contain morphine. A
significant interaction between Tat and morphine was again observed for the resting
membrane potential (VR) of CA1 pyramidal cells (A). Post hoc analysis showed that the
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differences resulted from a significant increase in the resting membrane potential in
pyramidal cells from Tat+ than Tat− mice treated with placebo pellets (p = 0.0031).
There was a significant effect of Tat on rheobase. Independent of morphine presence or
withholding, pyramidal cells in Tat+ mice required a greater amount of current (pA) to
reach the threshold potential for firing compared to Tat− mice (p = 0.0039; B), despite
the fact that the firing threshold (mV) of CA1 pyramidal cells was unaffected by Tat or
morphine exposure (C).
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Figure 3. 8: Examples of a 3D-reconstructed biocytin-filled CA1 pyramidal cells

Reconstructions of Z-stack images of biocytin-filled pyramidal cells within
hippocampal area CA1. Z-stack images were used for analysis of morphological
characteristics following exposure to Tat and morphine. Scale bars = 50 µM.
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Figure 3. 9: Effects of Tat and morphine on the morphology of the portion of the
pyramidal cell dendrite within the stratum oriens (SO)

Morphological effects of Tat and morphine on the portion of the CA1 pyramidal
cell dendrite within the stratum oriens (SO) (A). (B) Sample SO dendrites and 3D
reconstructions from each of the four experimental groups (C) An overall reduction in
spine density was attributed to the effects of morphine (p = 0.0069). (D) There were also
significant shifts in the morphologic types of spines present on SO dendrites. The
percentage of stubby spines was reduced in Tat+/placebo-treated animals when
compared to all other groups (p= 0.0001-0.0115). The percentage of mushroom spines
was reduced in Tat+/morphine-treated animals compared to both placebo-treated
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groups (p = 0.0034), and was trending toward being significantly lower that
Tat−/morphine-treated animals (p = 0.0563). There was evidence of an increase in
dendrites with varicosities in all groups compared to control animals (p = 0.0001-0.004;
E). Multiple symbols are used in this figure for a p < 0.05 due to the complexity of panel
D; (*) denotes a main effect of Tat, (†) denotes a main effect of morphine, (**) denotes a
difference between Tat−/placebo and Tat+/placebo, (***) represents a difference
between Tat−/placebo and Tat−/morphine, (††) represents significance between
Tat−/placebo and Tat+ morphine, the difference between Tat+/placebo and
Tat−/morphine is shown by (‡), Significance between Tat+/placebo and Tat+/morphine
is denoted with (§), and finally The differences between Tat−/morphine and
Tat+/morphine are denoted as (§§).
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Figure 3. 10: Effects of Tat and morphine on the morphology of the portion of the
pyramidal cell dendrite within the stratum radiatum (SR)

Morphological effects of Tat and morphine on the portion of the CA1 pyramidal
cell dendrite within the stratum radiatum (SR) (A). (B) Sample SR dendrites from each
of the four experimental groups. No differences were observed in spine density in SR
dendrites (C). (D) Tat and morphine caused shifts in the spine morphology on SR
dendrites. The percentage of thin type spines was increased by Tat (p = 0.0107), while
the percentage of mushroom-type spines was decreased by morphine (p = 0.0274).
There were non-interacting effects of Tat (p = 0.0006) and morphine (p = 0.0004) to
increase the amount of varicosity formation along peripheral SR dendrites (E).
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Additionally, significant increases in the number of varicosities along the main axis of
pyramidal cells were observed in all groups compared to controls (p = 0.0001-0.0025; F)
,. Parametric statistics were used except where noted in parenthesis. Multiple symbols
are used in this figure for to denote significance; (*) denotes a main effect of Tat, (†)
denotes a main effect of morphine, (**) denotes a difference between Tat−/placebo and
Tat+/placebo (Mann-Whitney U test), (***) represents a difference between
Tat−/placebo and Tat−/morphine (Mann-Whitney U test), (††) represents significance
between Tat−/placebo and Tat+/morphine (Mann-Whitney U test), the difference
between Tat+/placebo and Tat−/morphine is shown by (‡), Significance between
Tat+/placebo and Tat+/morphine is denoted with (§), and finally The differences
between Tat−/morphine and Tat+/morphine are denoted as (§§).
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Figure 3. 11: Effects of Tat and morphine on the morphology of the portion of the
pyramidal cell dendrite within the stratum lacunosum-moleculare (SL-M)

Morphological effects of Tat and morphine on the portion of CA1 pyramidal cell
dendrite within the stratum lacunosum-moleculare (SL-M) (A). (B) Sample SL-M
dendrites from each of the four experimental groups. Morphine caused a reduction of
dendritic spine density in pyramidal cells from Tat−, but not Tat+, mice. In fact, there
was a trend for Tat to reverse morphine-dependent reductions in dendritic spine density,
albeit not significant (p = 0.07), suggesting that the Tat and morphine may uniquely
interact to increase spine numbers on the SL-M (C). Spine morphology was observed to
change with Tat and morphine exposure (D). Morphine caused an increase in the
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percentage of stubby-type spines (p = 0.0129), and Tat+/morphine-treated animals had
fewer mushroom-type spines than all other groups (p = 0.0005-0.0112). Increases in
dendritic damage observed with the percentage of dendrites with varicosities increasing
in morphine-treated animals (p = 0.0019; E). Multiple symbols are used in this figure for
a p < 0.05; (*) denotes a main effect of Tat, (†) denotes a main effect of morphine, (**)
denotes a difference between Tat−/placebo and Tat+/placebo, (***) represents a
difference between Tat−/placebo and Tat−/morphine, (††) represents significance
between Tat−/placebo and Tat+/morphine, the difference between Tat+/placebo and
Tat−/morphine is shown by (‡), Significance between Tat+/placebo and Tat+/morphine
is denoted with (§), and finally The differences between Tat−/morphine and
Tat+/morphine are denoted as (§§).
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Figure 3. 12: Assessment of gephyrin puncta within the aspinous portion of pyramidal cell basilar and
apical dendrites

Assessment of gephyrin puncta within the perisomatic dendrites of CA1
pyramidal cells. Biocytin filled pyramidal cells labeled with an Alexa 594-conjugated
streptavidin probe (red) and gephyrin puncta (green) were analyzed in Imaris Bitplane
9.0.0. (A, B, B’), and a third channel was created which contained only green voxels
which overlapped in the space occupied by red voxels (A’, C, C’). The number of colocalized puncta (B, C) was quantified in a region of interest of a defined length (B’, C’)
to generate a value reflecting the number of co-localized puncta per 10µM. No changes
in the number of gephyrin puncta were observed occurring on the aspinous portions of
the basilar (D) or apical (E) dendrites in the perisomatic region following Tat expression
or exposure to morphine.
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Capacitance
(pF)
Resistance
(MΩ)

Tat- Placebo
n = 13
29.42 ± 2.8

Tat+ Placebo
n = 12
32.59 ± 3.65

Tat- Morphine
n = 19
30.77 ± 2.8

Tat+ Morphine
n = 13
31.44 ± 2.72

19.858 ± 2.2

22.86 ± 3.06

23.81 ± 1.96

21.98 ± 2.06

Table 3. 1: Membrane properties of CA1 pyramidal cells after exposure to Tat and
morphine
Table 3.1 lists the Capacitance and resistance values for the comparison of Tat−
and Tat+ animals treated with placebo against those treated with morphine. No
significant changes were observed. All values are shown as mean ± SEM.
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Capacitance
(pF)
Resistance
(MΩ)

Tat- Placebo
n = 13

Tat+ Placebo
n = 12
32.59 ± 3.65

TatWithdrawn
n = 29
43.13 ± 7.66

Tat+
Withdrawn
n = 22
35.89 ± 3.5

29.42 ± 2.8
19.86 ± 2.2

22.86 ± 3.06

24.12 ± 1.54

22. ± 1.49

Table 3. 2: Membrane properties of CA1 pyramidal cells from Tat- and Tat+
animals in a withdrawal like state
Table 3.2 lists the Capacitance and resistance values for the comparison of Tat−
and Tat+ animals treated with placebo against those treated with morphine and then
forced into a withdrawal-like state. No significant changes were observed. All values are
shown as mean ± SEM.
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Morphological
Data
SO % Mushroom

SR spine density

SL-M % Mushroom
SL-M % Thin

Physiological
Correlation
Data
Threshold
.348
Frequency 100 pA
-0.311
Frequency 125 pA
-0.313
Frequency 150 pA
-0.331
Rheobase
0.422
Frequency 50 pA
-0.347
Frequency 75 pA
-0.433
Frequency 100 pA
-0.393
Frequency 125 pA
-0.403
Frequency 150 pA
-0.393
Frequency 175 pA
-0.407
Frequency 200 pA
-0.382
Frequency 225 pA
-0.371
Frequency 250 pA
-0.351
Frequency 275 pA
-0.337
Frequency 300 pA
-0.319
VR
.396
Frequency 275 pA
.344
Frequency 300 pA
.326
Frequency 350 pA
.352
Frequency 375 pA
.375
Frequency 400 pA
.406

N

Z

p

43
43
43
43
45
45
45
45
45
45
45
45
45
45
45
45
38
38
38
38
38
38

2.298
2.033
2.045
2.174
2.918
2.347
3.001
2.692
2.771
2.691
2.803
2.611
2.521
2.376
2.275
2.142
2.291
2.122
2.004
2.176
2.330
2.548

0.0216
0.0421
0.0408
0.0297
0.0035
0.0189
0.0027
0.0071
0.0056
0.0071
0.0051
0.0090
0.0117
0.0175
0.0229
0.0322
0.0219
0.0339
0.0451
0.0295
0.0189
0.0108

Table 3. 3 Correlations between morphological and electrophysiological findings
Table 3.3 presents a selection of relevant correlations between morphological
observations and electrophysiological data. The data presented here include samples
from 4 groups: Tat− and Tat+ placebo-treated animals, and Tat− and Tat+ morphinetreated animals that had been maintained in morphine containing physiological
solutions.
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Chapter 4: General Discussion and future directions
Clarification of contributions: Dr. Virginia McLane performed the Bioplex assay.

HIV infection and HIV-1 have been demonstrated as having profound effects on
the hippocampus. There is also a preponderance of evidence that shows concurrent
exposure to opiates exacerbates progression of HIV or HIV protein-related pathology
immunologically and neurologically (Hriso et al, 1991; Anthony et al, 2005; Bruce-Keller
et al, 2008; Fitting et al, 2010a; Byrd et al, 2011; Hauser et al, 2012; Xu & Fitting, 2016);
however, few of these studies have been performed specifically in the hippocampus,
and those that do tend to focus on biochemical or morphological effects rather than
hippocampal function (Guo et al, 2012; Hauser et al, 2012; McLane et al, 2014). The
collected aim of the studies discussed here is to determine the effects of HIV-1 Tat
and/or morphine on the circuitry of the hippocampus morphologically, and to assess the
disruptions

to

functional

outputs

of

the

hippocampus

behaviorally

and

electrophysiologically in order to understand the etiology, and ultimately inform the
development of treatment options, of the spatial memory deficits commonly seen in HIV
patients suffering from HAND (Antinori et al, 2007; Stark, 2007; Byrd et al, 2011;
Bilgrami & O'Keefe, 2014).
While multiple inputs and outputs play a critical role in hippocampal function, the
studies presented herein focus on the CA1 subfield as the final step in the hippocampal
tripartite circuit before passing information to other brain regions (Ranson, 1932; Amaral
& Lavenex, 2007; Stark, 2007). Particularly, the focus is on the CA1 pyramidal cells and
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the circuitry affecting pyramidal cell function is important since this is a major excitatory
output of the hippocampus. The pyramidal cells do not act alone, and are supported by
a diverse array of network interactions (Acsady et al, 1996b; Ali et al, 1998; Klausberger
et al, 2004; Klausberger & Somogyi, 2008; Kelley et al, 2009; Leão et al, 2012; Tyan et
al, 2014; Pelkey et al, 2017). Both Tat and chronic morphine exposure impair spatial
learning concomitantly where LTP is inhibited (McQuiston, 2008; Fitting et al, 2013;
Zhou et al, 2015). Prolonged exposure to Tat and/or morphine have both been shown to
impair LTP in CA1 with (Fitting et al, 2013; Heidari et al, 2013; Wen et al, 2014; Zhou et
al, 2015) and the acquisition of spatial memory, which is closely associated with LTP
(Carey et al, 2012; Kitanaka et al, 2015; Marks et al, 2016; Raybuck et al, 2017). The
action of morphine within the CA1 system varies depending upon the context in which
morphine is given, reflecting the adaptation of the hippocampus to chronic exposure to
morphine (McQuiston & Saggau, 2003; Zhu et al, 2011; Fakira et al, 2014; Portugal et
al, 2014; Kitanaka et al, 2015). Reductions in LTP caused by Tat and morphine
independently (Fitting et al, 2013; Wen et al, 2014; Zhou et al, 2015) likely result from a
shift in the functionality of the interneuron network and the disinhibition of discrete sets
of interneurons (Pelkey et al, 2017). Over time, compensatory processes may occur as
tolerance develops, or as Tat exposure continues, through alterations in the expression
of ion channels, opioid and/or other receptor types, or other signaling events (Hall et al,
1991; Fakira et al, 2014; Portugal et al, 2014; Sadegh & Fathollahi, 2014; Zhou et al,
2015). GABAergic interneurons in the hippocampus are comparatively more susceptible
to excitotoxic damage, one of the main hallmarks of HIV associated neurocognitive
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damage, than pyramidal cells (Avignone et al, 2005; Chandra et al, 2005; Hoskison et
al, 2007), and are often also a target for morphine (Drake & Milner, 2002).
The net effect of morphine in CA1 is to decrease GABA release, resulting in
increased pyramidal cell excitability under acute activation paradigms (McQuiston &
Saggau, 2003), mediated through primarily GABAA receptors, but also through GABAB
receptors (McQuiston & Saggau, 2003; McQuiston, 2007). It is important to note that the
exposure paradigm can have a significant effect on the outcome of experiments, with
acute, chronic, and withdrawal administration pattern effecting the results of
experiments (McQuiston & Saggau, 2003). In our experiments, morphine administration
via subscapular pellet implantation results in a continuous release of morphine over a 5day period, which is more than sufficient for development of tolerance in the
hippocampus. In hippocampal slice physiology preparations, tolerance has been
observed to develops within 2-6 hours of the initiation of morphine exposure (Lue et al,
1999). Tolerance will develop to different aspects of morphine’s effects (e.g. analgesic
first, locomotor second) at different rates (Vasko & Domino, 1978; Hall et al, 1991;
Bodnar, 2012), and the development of tolerance has been shown to proceed at
different rates for the different opioid receptors (Angelopoulos et al, 1995). The effects
of tolerance in the present studies may be more pronounced, but harder to discern than
in wild type mice; however, as Tat+ mice induced with doxycycline show increased
tolerance to the analgesic and locomotor effects of morphine, while paradoxically
exhibiting less pronounced withdrawal symptoms (Fitting et al, 2012; Fitting et al, 2016).
This may be related to Tat-induced changes in the expression or activity of MOR and its
cognate endogenous ligands (Fitting et al, 2010a; Hahn et al, 2016). The observations
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of acute increases in excitability mediated both through loss of GABAergic inhibition and
increase of extracellular glutamate levels (Wimpey et al, 1989; Farahmandfar et al,
2011a; Farahmandfar et al, 2011b) give way to a re-established homeostasis In the
pyramidal cells, as evidenced by the lack of difference between the firing rate of
morphine-treated cells and placebo-treated cells shown in chapter 3. Subsequent
removal of morphine likely releases the MOR expressing interneurons to re-inhibit the
disinhibited pyramidal cells, which have become acclimated to a new homeostasis with
lower inhibition. As a result, their excitability becomes reduced (Fig 3.3B). A similar
effect has been observed in the reduction of LTP in animals following withdrawal of
chronic morphine application during which tolerance is likely to have developed, which
can be restored with reperfusion of the drug (Bao et al, 2007).
The distribution of MOR expression in CA1 is mainly in the pyramidal layer. MOR
expression is also observed on SO and SR, while the lowest levels are in the SL-M
(Drake & Milner, 2002; McQuiston, 2008). MOR expression can be further localized to
GABAergic interneurons (McQuiston, 2007), with differential expression and therefore
morphine effects on different CA1 interneuron subsets. Morphine exposure increases
excitatory post synaptic potentials (EPSPs) strongly in CA1 SO, SP, and SR; but weakly
in SL-M, indicating the effects of MOR activation on local excitatory/inhibitory balance
differs among hippocampal layers depending on differences in presynaptic inputs from
MOR-expressing interneurons or from MOR-expressing afferents from other brain
regions (McQuiston, 2008; Sadegh & Fathollahi, 2014). The laminar effects depend on
the projections of varying interneuron subsets to other layers (McQuiston, 2007), where
changes in GABA release act to increase excitation through diminished action at both
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the GABAA and GABAB receptors (McQuiston & Saggau, 2003; McQuiston, 2007). A
substantial portion of CA1 network interactions come from inhibitory interneurons, of
which there is an ever-expanding classification of subtypes (Cenquizca & Swanson,
2006; Klausberger & Somogyi, 2008; Wheeler et al, 2015; Hamilton et al, 2017b). I have
found Tat exposure disrupts the hippocampal interneuron network which we believe is
in part responsible for the behavioral and physiological deficits observed in our data and
in previous publications (Fitting et al, 2013; Marks et al, 2016). Considering that
morphine acts in part through the disinhibition of GABAergic inputs (Liao et al, 2005),
and that Tat damages the interneuron network, it is reasonable to conclude that
combining morphine with Tat will more strongly disrupt the normal functioning of the
hippocampus, making the present findings more surprising.
Of the 21+ types of interneurons found within the hippocampal area CA1
(Cenquizca & Swanson, 2006; Klausberger & Somogyi, 2008; Wheeler et al, 2015), we
have found selective vulnerability in two discrete subtypes and vulnerability within two
other interneuron families that we have not yet fully defined. Induction of Tat expression
in our mouse model resulted in losses of nNOS+/NPY− interneurons in the stratum
pyramidale (IS3s) and in the SR (neurogliaform cells) (Acsady et al, 1996a; Acsady et
al, 1996b; Chamberland et al, 2010; Tricoire et al, 2010; Armstrong et al, 2012; Tricoire
& Vitalis, 2012; Tyan et al, 2014; Marks et al, 2016). We also observed reductions in the
total population of PV+ interneurons within the pyramidal layer, and SST+ interneurons
within the SO. While our data did not show conclusively which subsets are affected,
they suggest that the major contributor to these losses are the bistratified cells and OLMs, respectively (Buhl et al, 1996; Muller & Remy, 2014). The initial definition of Tat
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effects in the hippocampus can now be used alongside what we know about the
endogenous opioid system in the hippocampus to help inform our understanding of their
potential interactions. MOR, DOR, and KOR are expressed with some, but not
complete, overlap in subsets of GABAergic interneurons (Drake & Milner, 1999; Halasy
et al, 2000; Pelkey et al, 2017), and are usually found presynaptically, with lower levels
expressed postsynaptically on dendrites (Lambert et al, 1991; Drake & Milner, 1999;
Pelkey et al, 2017). Pyramidal cells also express low levels of DOR (Stumm et al,
2004). While the hippocampus as a whole responds to morphine, there is differential
sensitivity, with CA3 being more affected at low doses of morphine, and CA1 effects
emerging with higher receptor occupancy (Jones et al, 1994). MOR immunoreactivity is
found in PV+ and SST+ cells, including the OL-M cells and IS3s (Acsady et al, 1996a;
Acsady et al, 1996b; Drake & Milner, 2002; Stumm et al, 2004), as well as Ivy cells and
neurogliaform cells (Lafourcade & Alger, 2008; McQuiston, 2008; Krook-Magnuson et
al, 2011). DOR expression occurs primarily in NPY+ and SST+ projections to the
pyramidal layer, generally on cells originating in SO (Commons & Milner, 1996; Stumm
et al, 2004). With KOR tending to overlap with DOR expression (Svoboda et al, 1999).
The connectivity between interneurons and the localization of the opioid receptors on
processes is critical to the way they modulate CA1 synaptic events. MOR and
DOR/KOR systems appear to fill separate but complimentary roles, with MOR activity
modulating feed-forward inhibition, and DOR/KOR modulating feedback inhibition
(Pelkey et al, 2017). DOR activity appears to hyperpolarize both bistratified cells and
OLMs, which can unbalance the normal gating of inputs to favor activation of pyramidal
cells by the EC (Svoboda et al, 1999). MOR activity, by contrast, tends to regulate the
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activity of terminals synapsing onto pyramidal cells rather than hyperpolarizing
interneurons and reducing firing in that way, although this process still occurs in Ivy cells
(Glickfeld et al, 2008; Krook-Magnuson et al, 2011).
IS3s and OL-Ms play a stong role in spatial memory, which is affected in HAND
(Antinori et al, 2007). Tat has been shown to worsen spatial learning and memory in the
Morris water maze and Barnes maze tasks, and to limit memory in contextual fearconditioning and novel object recognition tasks, as has Gp120 (Sanchez-Alavez et al,
2000; Carey et al, 2012; Fitting et al, 2013; Kesby et al, 2016; Marks et al, 2016). The
diversity of interneurons and their interconnections underlie the processing power of the
hippocampus, which is revealed in the complexity of integrated interneuronal input into
CA1 pyramidal neurons (Buhl et al, 1994; Acsady et al, 1996a; Acsady et al, 1996b; Sik
et al, 1997; Ali et al, 1998; Drake & Milner, 2002; Klausberger et al, 2004; Cenquizca &
Swanson, 2006; Klausberger & Somogyi, 2008; Tricoire et al, 2010; Leão et al, 2012;
Tricoire & Vitalis, 2012; Lovett-Barron et al, 2014; Muller & Remy, 2014; Sun et al,
2014; Marks et al, 2016). It is the modulation of the complex interneuron-pyramidal cell
interface that appears to be specifically affected by Tat, resulting in the observed
behavioral deficits (Drake & Milner, 2002; Cenquizca & Swanson, 2006; Klausberger &
Somogyi, 2008; Fitting et al, 2013; Lovett-Barron et al, 2014; Tyan et al, 2014; Marks et
al, 2016). For example, the vulnerable interneuron subsets we identified reportedly play
a strong role in mnemonic and spatial memory processes (Sik et al, 1997; Cenquizca &
Swanson, 2006; Leão et al, 2012; Lovett-Barron et al, 2014) and form a unique
microcircuit (Tricoire & Vitalis, 2012; Muller & Remy, 2014; Tyan et al, 2014; Marks et
al, 2016) within the larger CA1 subfield. We believe this microcircuit is critical in the
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etiology of HIV-related mnemonic disorders (Buhl et al, 1994; Acsady et al, 1996a;
Acsady et al, 1996b; Sik et al, 1997; Ali et al, 1998; Drake & Milner, 2002; Klausberger
et al, 2004; Cenquizca & Swanson, 2006; Klausberger & Somogyi, 2008; Tricoire et al,
2010; Carey et al, 2012; Leão et al, 2012; Tricoire & Vitalis, 2012; Lovett-Barron et al,
2014; Muller & Remy, 2014; Sun et al, 2014; Kesby et al, 2016; Marks et al, 2016). The
IS3s play a crucial role in setting the rhythm and tone in a key inhibitory circuit that
regulates output from CA1 pyramidal cells, acting as a feedback control mechanism
through control of other interneurons (Chamberland & Topolnik, 2012; Tyan et al, 2014).
This feedback occurs by regulating the disinhibition of OL-M cells, which inhibit
pyramidal

cells and

have

significant

cross

interaction

with

bistratified

cells

(Chamberland et al, 2010; Chamberland & Topolnik, 2012; Tyan et al, 2014). The
optogenetic activation of IS3s decreases OL-M cell firing and stimulating IS3s can
produce activity in OL-Ms mimicking theta oscillations (Tyan et al, 2014). OL-Ms will
have significant crosstalk with bistratified cells, which can also be inhibited by IS3s
(Leão et al, 2012; Muller & Remy, 2014). This interaction defines a gating mechanism,
in which dendrites receiving inputs from CA3 (in the SR) or entorhinal cortex (in the SLM) will be preferentially inhibited, while negating the effects of opposing inputs (Leão et
al, 2012; Lovett-Barron et al, 2014; Muller & Remy, 2014).
Tat and opiate-induced functional imbalances in the interneuron network
profoundly affect the output of pyramidal cells independently, but the question remains
to what extent they will interact. The data seems to support the notion that despite Tat
and morphine having the tendency to alter hippocampal function, the interactions
between them from a functional perspective are limited (Figs 3.4-3.8). That does not
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necessarily mean, however, that they do not interact at a deeper level which might
mask a simple identification of the effect. Tat has previously been shown to lower the
expression of the mu opiate receptor in the hippocampus, while not effecting the
expression of DOR or KOR (Fitting et al, 2010a), and MOR signaling activity in the
striatum and amygdala also appear to be altered by Tat (Hahn et al, 2016). This shift in
the balance of receptors/receptor activation could underlie a genuine interaction
between Tat and morphine that would not manifest as an explicit worsening of function.
It has been demonstrated that mild neuroprotective effects of morphine and other MOR
antagonists can occur at low doses, or rather, with low level activation of MOR, likely
due to the relative levels of MOR, DOR, and KOR activation (Zhao et al, 2006; AmmonTreiber et al, 2007; Fitting et al, 2010a; Kawalec et al, 2011). At the same time, it is
known that the activation of DOR and KOR can have different effects on cellular
processes and that the effects mediated by DOR and KOR often run counter to the
effects of MOR (Loacker et al, 2007; Saboory et al, 2007; Lutz & Kieffer, 2013).
Additionally, MOR and DOR/KOR systems appear to operate in separate but
complimentary systems in the hippocampal GABAergic network (Valentino et al, 1982;
Plager & Vogt, 1988; Drake & Milner, 2002; Loacker et al, 2007; McQuiston, 2008;
Krook-Magnuson et al, 2011; Williams & Milner, 2011; Pelkey et al, 2017), and most
importantly, many MOR agonists can also act at DOR and KOR with lower efficacy, but
a non-zero effect (Beckman, 2014). It is a possibility that the reduced levels of MOR
expression caused by Tat, coupled with the moderate neuroprotective effects
achievable by activating the right combinations of opioid receptors, begins to explain
why independent Tat and morphine/morphine withdrawal effects are evident, but
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interactive effects are not. it might be that a genuine interaction is occurring, but the
effect is actually neuroprotective, and could explain why it appears that morphine
treatment ameliorates or obviates the observed effects of Tat in Barnes maze
performance and resting membrane potential. This question could be tested by
administering MOR, DOR, and KOR antagonists to mice, and repeating the
physiological studies performed in the presence of these same antagonists. Ideally, a
dose response curve could be generated for each of these antagonist categories for
physiological functionality and Tat interactions, with the degree of antagonism of DOR
and KOR systems likely to reveal interactive functional pathology due to Tat and
morphine interactions.
Despite all of these observations in support of alterations in the GABAergic
interneuron network by both HIV-1 Tat and by morphine, It is not possible to attribute
this to an actual loss of inhibitory innervation. Previous studies of the effects of Tat in
the hippocampus showed that the amount of Syt2, the presynaptic organizer of
GABAergic synapses was decreased in CA1. The Syt2 loss was specifically in the SR,
while the overall amount of gephyrin in CA1 was increased (Fitting et al, 2013). Our
data shows that the density of gephyrin puncta within the regions of the pyramidal cell
with typically high levels of inhibitory contacts do not change with Tat or morphine
treatments (Fig 3.12). Nevertheless, this observation does not necessarily contradict the
previous finding. One potential explanation is that the increase in gephyrin, believed to
be compensatory for the loss of Syt2 expression, was sufficient to maintain inhibitory
presynaptic contacts on the aspinous portions of pyramidal cell dendrites. Another
potential explanation would be that the increase in gephyrin and loss of Syt2 is limited to
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specific types of inhibitory presynaptic contacts, either local (ISI type 1, 2, or 3)
interneurons or from extrahippocampal regions (septohippocampal projections). In
either case, it would not necessarily be the lack of synaptic contacts onto pyramidal
cells, but alterations in the network activity, that would be responsible for the observed
physiological effects.
Beyond questions about the contribution of damage to the inhibitory
interneuronal network to the disturbances in functional output, mention also must be
made about the observed structural and functional changes to the excitatory systems
within CA1. In the present studies, there were differential effects of Tat and morphine on
the spine density and spine types present across the dendrites occupying SO, SR, and
SL-M. Moreover, interactions between Tat and morphine were evident in SO and SL-M,
where decreases as well as increases in different spine types were observed. Increases
in spine density or a particular spine type can be just as disruptive to the overall balance
of a complex circuit as a reduction. The excitatory presynaptic inputs onto pyramidal cell
dendrites differ within each layer and region of the hippocampus. The degree to which
spine density or spine type changes may reflect some alteration in the excitatory input
being given or received by these areas. The largest contributors to excitatory input in
CA1 pyramidal cells are the Shaffer collateral inputs onto SR and the temporoammonic
inputs from entorhinal cortex that form presynaptic contacts throughout SL-M (Amaral &
Lavenex, 2007; Agster & Burwell, 2013). Both the Shaffer collaterals and
temporoammonic pathway possess collateral fibers that split from the main fiber tract
and synapse onto the dendrites in SO, where their excitatory activity is directly
modulated by cholinergic inputs from the septal nuclei (Seress et al, 2002; Buño et al,
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2006; Zheng et al, 2011). In addition to cholinergic inputs from the septal nuclei,
afferents from the diagonal band of Broca also modulate the activity of Interneurons in
SO (Gulyás et al, 1991; Amaral & Lavenex, 2007; McQuiston, 2014; Bell et al, 2015).
Although there is some evidence of direct excitation by septohippocampal inputs, the
observation may simply be a reflection of the net disinhibition driven by GABAergic
action of the septohippocampal inputs, resulting in increased pyramidal cell activity (Oka
& Yoshida, 1985; Toth et al, 1993). Interestingly, some of the excitatory inputs from EC
to SO appear to come from nNOS positive pyramidal cells (Seress et al, 2002), along
with observations of the contributions of NO to excitotoxicity and morphine tolerance,
might be a good target for further study (Lue et al, 1999; Eugenin et al, 2007; King et al,
2010; Sanchez-Blazquez et al, 2010; Garzon et al, 2011; Marks et al, 2016). In addition
to the intrahippocampal excitatory inputs, there are several extrahippocampal regions
which send excitatory inputs onto CA1 pyramidal cells. Afferents from the basomedial
nuclei of the amygdala synapse onto dendrites throughout CA1 along the temporal
hippocampus, and receive some input from CA1 (Pikkarainen et al, 1999; Amaral &
Lavenex, 2007; Kim & Cho, 2017). More specifically, SL-M receives inputs from the
accessory basal nucleus, while both SO and SR receive inputs from the caudomedial
region of the parvicellular division (Pikkarainen et al, 1999). The Perirhinal cortex
synapses onto the dendrites in SL-M, and receives inputs from CA1 resulting in
synchronous activation under certain oscillation patterns (Supcun et al, 2012; Agster &
Burwell, 2013; Vinck et al, 2015). The perirhinal cortex also interacts directly with the
amygdala (Supcun et al, 2012). Finally, excitatory inputs from the nucleus reuniens
(NR) synapse onto dendrites within SL-M, as well as SL-M interneurons (Dolleman-Van

129

der Weel et al, 1997; Amaral & Lavenex, 2007). The NR is part of a circuit involved in
spatial memory consolidation in which (1) pyramidal cells in CA1 project to the PFC, (2)
pyramidal neurons in the PFC project to the NR, and (3) the NR then projects back to
CA1 (Cassel et al, 2013; Griffin, 2015).
Alterations to any of these inputs to CA1 could profoundly change the net effect
of hippocampal processing (Lee & Park, 2013; Newmark et al, 2013; Wu et al, 2014a;
Benetti et al, 2015), and are likely to be directly affected by Tat and/or morphine (Table
1.1 lists the large number of brain regions affected by Tat and morphine). However,
even in the absence of direct neuropathology causing decreased excitatory input, the
inputs to CA1 from each of these regions are likely disrupted by local disturbances in
synaptodendritic structure and function depending on the combination of Tat and
morphine. A general observation can be made that morphine is known to modulate
spine shape. The endogenous opioid system plays a role in maintaining the integrity of
dendritic spines; however, the application of morphine can overwhelm the normal
function of the endogenous system, and result in a loss of spine stability (Liao et al,
2005). More specific observations can be made, however, when considering the
complexity of local microcircuits and inter-regional connections. First, it is notable that
across all three regions, the least amount of change was seen in SR, where there was
no observation of a shift in spine density following exposure to Tat or morphine, and
comparatively fewer shifts in the type of spines present. The fact that the spines in SR
remain comparatively stable despite the Tat and opiate insults is intriguing. There are
some shifts in the types of spines seen in the region; yet, there is no evidence of
interactive effects of Tat and morphine. A main effect of Tat to increase thin/filopodia
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type spines, and a main effect of morphine to decrease mushroom-type spines are both
observed in SR. The Tat-induced increases in the proportion of thin/filopodia type
spines is unexpected, as LTP is known to be reduced in Tat+ animals (Li et al, 2004;
Fitting et al, 2013). Nonetheless, increases the filopodia are though represent newly
formed connections and coincide with learning and plasticity (Rochefort & Konnerth,
2012; Bailey et al, 2015). In the SL-M, there is an interesting occurrence where a
statistically significant Tat effect upon further examination appears to be more due to
differential effects of morphine to reduce spine density on pyramidal cells in Tat−, but
not Tat+, mice (Fig 3.11C). This is of particular interest considering that the amygdala is
known to send projections onto this layer, and that Tat has been seen to differentially
modulate MOR activity in the amygdala, with Tat decreasing MOR signaling
(Pikkarainen et al, 1999; Hahn et al, 2016). In this case, it makes sense that if Tat
reduces MOR signaling, morphine itself will have less inhibitory activity on outputs from
the amygdala to SL-M in Tat+ than Tat− animals, coinciding well with the observations
of spine density in SL-M. While the amygdalar component is of note, it is also important
to recall the existence of inputs from EC onto SL-M dendrites, and that the amygdala
and perirhinal cortex have been shown to interact with each other and contribute to
spatial memory processing with the perirhinal cortex and EC projections overlapping in
the SL-M (Supcun et al, 2012; Agster & Burwell, 2013; Lee & Park, 2013). Beyond
changes in the density of spines in SL-M, morphine treatment was observed to reduce
the amount of thin spines in the layer, suggesting a shift away from stable connections
toward formation of new synapses, a notion supported by the fact that Tat and morphine
interacted to reduce the amount of mushroom spines in SL-M (Fig 3.11D) (Rochefort &
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Konnerth, 2012; Bailey et al, 2015). In the SO, there was another differing pattern of
spine morphology perturbation, with morphine reducing spine density regardless of Tat,
and shifts in the amount of mushroom and stubby spines, but not thin spines. Like the
SL-M, the SO also receives amygdalar inputs; however, the specific nuclei that project
to these regions are different. More likely to be a contributing factor to SO morphology
would be the modulation of septohippocampal inputs and their effects on the
glutamatergic inputs from EC and CA3 (Seress et al, 2002; Amaral & Lavenex, 2007).
Morphine has been shown to reduce the spontaneous firing of GABAergic neurons in
the septum and diagonal band, which would then have an effect on the modulation of
activity in the hippocampus and spatial memory formation (Alreja et al, 2000). This may
explain in part the morphine-induced reductions in spine density. The change in
morphologic types of dendritic spines is more difficult to draw conclusions from, as the
shifts were between mushroom- and stubby- shaped spine types; both associated with
stable synapses (Rochefort & Konnerth, 2012; Bailey et al, 2015). Variations in spine
neck diameter may still have effects on the amount of calcium able to flow through the
spine, allowing for subtle changes in input processing to occur with changes in the
representation of stable spine types (Noguchi et al, 2005). Overall, while interesting to
consider, the complexity of these local and regional networks makes pinpointing the
exact cause of the changes in spinous morphology impossible given the current
dataset, with further conclusions necessitating a more focused circuit based approach
with a focus on extrahippocampal afferent projections.
Increased dendritic damage was seen across all three major dendritic
compartments in response to Tat expression and to morphine, with SO and SL-M being
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more affected than SR, mirroring the ways in which these regions changed or did not
change spine density and spine types. The observation of damage (Figs 3.9B,E,
3.10B,E-F, 3.11 B,E) stands in contrast to the notable lack of damage observed in
pyramidal cells by Fitting et al (2013). It is possible that differences in the technique
used to process the images made damage appear more evident in the present study.
Alternatively, it is possible that the cellular trauma induced by the act of patching onto
the cells themselves caused a strong enough perturbation to make damage appear in
neurons that were already unhealthy or disrupted as a result of exposure to Tat and
morphine, whereas the healthy control neurons were not damaged by the patching
process.
Future directions
In light of the discovery of selectively vulnerable interneuron populations within
the CA1, further studies on the physiological effects on these cells might be appropriate
(Marks et al, 2016). When it is considered that previous studies in the hippocampus
showed no increase in the number of apoptotic cells within the CA1 subfield following
Tat exposure (Fitting et al, 2013), and that chromatolytic damage observed in the
hippocampus with HIV infection is not necessarily lethal, and can in fact be reversible
(Kim et al, 2008; Torres & Noel, 2014), it is reasonable to conclude that the missing
interneurons observed in these studies may not be dead, but merely damaged;
performing at sub optimal levels, and expressing various markers below the biochemical
detection threshold of fluorescent immunohistochemical techniques. If this is the case,
pharmacological rescue of these cells may be possible, in addition to more focused
studies on their pathology. In the studies presented here, however, some interneurons
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of the identified vulnerable subgroups remain in the tissue, which also begs the
questions of why they are not affected as much as other cells of the same class, and
what role the subtle variations in populations play in their resilience. Since the
publication of the interneuron studies presented here, a broader understanding of the
hippocampal interneuron complement was unveiled in the hippocampome project
(Wheeler et al, 2015; Rees et al, 2016). The hippocampome is a compendium of cell
types within the hippocampus based on gene expression patterns, with estimates of cell
type categories which go far beyond the previously touted 21+ types of interneurons
within the CA1. Recent improvements and additions to the hippocampome project have
been aimed at clarifying disparate naming conventions of interneuron populations,
identifying more subtypes of hippocampal principal cells, and exploring the network
connectivity of the hippocampus (Rees et al, 2016; Hamilton et al, 2017a; Hamilton et
al, 2017b; Rees et al, 2017). The idea that there are subtypes within existing
interneuron groups is not new. Variations within the expression of proteins and of
localization within the CA1 subfield have been noted within the bistratified cells, O-LMs,
and neurogliaform cells (Tricoire et al, 2010; Chittajallu et al, 2013; Muller & Remy,
2014; Pelkey et al, 2017), and in fact, many of the classifications that existed prior to the
hippocampome project were based on one or two subtle differences, as in the case of
IS3s (Acsady et al, 1996a; Acsady et al, 1996b; Tricoire et al, 2010). It is not
unreasonable to expect that functional differences which were previously undetected,
less defined, or unexplored within the cell types Identified as being vulnerable to Tat
may play a causal role in that phenomenon. Our observation of putative losses of O-LM
cells and bistratified cells might be better explained with this in mind. O-LMs have been
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demonstrated to have 2 distinct subtypes, with one expressing 5HT3RA, and the other
lacking. In addition, these subsets of O-LMs may either express parvalbumin at low
levels, or not at all (Chittajallu et al, 2013). While the earlier discussed results did
demonstrate a loss sof somatostatin positive cells in the SO, and while there was no
significant reduction in cells that co-express somatostatin and parvalbumin in this
region, there was a trend toward significance was observed when the population of
somatostatin positive cells that lacked parvalbumin expression were examined. This
suggests that the total loss of somatostatin positive interneurons, while containing
individual neurons from both subpopulations, is mostly comprised of parvalbumin
negative O-LMs. A similar observation can be made regarding the loss of parvalbumin
positive interneurons in the pyramidal layer which I have suggested are putative
bistratified cells. The broad class of bistratified cells may or may not express
somatostatin, and can even have some subtle variations in their relative depth within the
CA1 subfield, and so may encompass several similar neuron varieties (Chittajallu et al,
2013; Marks et al, 2016; Pelkey et al, 2017).
A project to assess the firing properties of IS3 cells in the CA1 was begun, but
terminated for technical reasons. Tat mice were bred with a live of tdTomato VIP
reporter mice to enable targeted patch clamping of VIP positive cells, with the intention
of identifying VIP+ IS3 cells within the pyramidal layer for physiological and
morphological analysis. Several cells were successfully patched and subsequently
identified as putative IS3s by confirming morphological and basic physiological
properties (Tyan et al, 2014). This project had to be terminated due to a problem with
the TdTomato construct association with the VIP promoter, which caused TdTomato to
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be expressed constitutively in the mice (Fig 4.1), rendering it impossible to identify any
one cell under excitation. Necropsy revealed that the only materials/tissues that did not
glow under excitation were the fur, bones, and blood. This project is a logical next step
in continuing the exploration of the effects of Tat and morphine on the functionality of
the CA1, and is in fact commonly asked for by individuals who learn of the study on the
effects of Tat on the interneuron network. A few additional components that should be
added to the study for comprehensiveness include the expansion of the scope to
include multiple subtypes of interneurons beyond the IS3s, and the inclusion of MOR,
DOR, and KOR agonists/antagonists to determine the role of opioids in the functionality
of these interneurons following Tat exposure. Additionally, a paired recording system in
which recordings are made from pyramidal cells and identified interneurons
simultaneously under these conditions would further clarify the interactions between Tat
and the presence of opioids in the CA1 system.
Further mechanistic studies of the physiology of the pyramidal cells themselves
would be beneficial in which pyramidal cells are systematically isolated from the
surrounding circuits by sequential application of specific antagonists This study was
attempted with inhibition of AMPA and NMDA with AP5 and CNQX respectively,
CGP55845 was added to the AP5 and CNQX containing solutions to inhibit GABAB
receptors, and finally Bicuculline was added to the other antagonists to inhibit GABAA
receptors, with a final goal of isolating the pyramidal cells from glutamatergic and
GABAergic neurotransmission. While this study was attempted, technical errors resulted
in the failure of the experiment. Moving forward, some alterations to the design would
be useful in clarifying the outcomes further. First, in the original experiment, application
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of the GABAB antagonist CGP 55845 always occurred before application of bicuculline
to antagonize GABAA. It would be better to alternate which GABA antagonist is applied
first in case there is any additive effect of GABA receptor types. This would be important
moving forward, and both GABAA and GABAB receptors are involved in the functionality
of CA1 regional circuitry (McQuiston, 2007; Pelkey et al, 2017). Additionally, this study
would benefit greatly from the acquisition of mini EPSPs/IPSPs and paired pulse
facilitation experiments in conjunction with the isolation of pyramidal cells from the
surrounding circuitry and various morphine exposure/withdrawal paradigms. In order to
better investigate the link between circuit function and behavior, it would also be useful
to observe the effects of Tat and morphine/morphine withdrawal on LTP in the
hippocampus (Bao et al, 2007; Fitting et al, 2013; Portugal et al, 2014).
Behaviorally, additional studies into the effects of Tat and morphine on spatial
memory acquisition would be worth pursuing. In the present studies (Figs 3.1, 3.2),
Morphine administration is achieved by the implantation of an indwelling pellet resulting
in continuous morphine release over several days. This presents a few confounding
factors, including the potential for peripheral inflammation resulting from the pelleting
surgery itself affecting behavioral outputs, even with proper post-surgical care (Chen et
al, 2008; Vizcaychipi et al, 2014). Additionally, continuous morphine application does
not adequately mirror the usage pattern of opioid abusers, who will go through a series
of highs and lows in their pursuit and use of opioid drugs (Eitan et al, 2017). The results
of this experiment may be easier to interpret, and more translational if a paradigm of
repeated morphine injections were used rather than the implantation of a morphine
pellet. While this is not without its own problems, including confounds from the
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repetitious injections and the increased amount of handling that would be necessary,
contrasting these data with the continuous administration might yield valuable insight. It
may also be useful to isolate MOR, DOR, and KOR effects by including their respective
antagonists through the duration of treatment to see if the effects of the differential
contribution hypothesis I have laid out here are indeed observable in behavioral
outcomes (Ammon-Treiber et al, 2007; Fitting et al, 2014; Fitting et al, 2015b; Hahn et
al, 2016).
A pilot study was performed to examine the degree of hippocampal inflammation
associated with HIV-1 Tat and morphine. The effects of Tat and morphine on cytokine
levels were examined in hippocampi isolated from randomly selected mice following
behavioral analysis discussed in chapter 3, with 3 to 4 animals in each of four groups
(Table 4.1) utilizing the Bioplex cytokine assay (Bioplex, Catalog #M60009RDPD). A
main effect of Tat was observed for levels of GM-CSF [F(1,9) = 6.525, p < 0.05], with
Tat+ mice having lower levels of this cytokine than Tat− mice. Similarly, there was a
trend for Tat+ animals to display reduced levels of CCL2 that Tat− animals [Main effect;
F(1,10) = 4.718, p = 0.055]. Of the 23 cytokines assayed, no other cytokines were
significantly affected by Tat and/or morphine. G-CSF, was unable to be analyzed due
several samples being excluded for errors in data aquisiton (table 4.2). The observation
that Tat+ animals had a decreased expression of GM-CSF was surprising, as the
expression of this cytokine tends to increase with inflammatory insult rather than
decrease (Choi et al, 2014). GM-CSF is usually considered a pro-inflammatory cytokine
because it acts as a growth factor for macrophages, it is involved in the differentiation of
immune cells, and it’s levels increase with inflammation (Bhattacharya et al, 2015). The
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reasons why GM-CSF is not elevated in the hippocampus of Tat+ mice is uncertain,
although it may due to timing or perhaps result from the development of innate immune
tolerance in response to unrelenting Tat exposure (Gonek et al, 2017). Alternatively,
some elevation in baseline levels of cytokines might occur in our control mice during
surgical implantation of the placebo pellets. It has previously been shown that peripheral
inflammation can trigger the inflammation in the CNS (DiSabato et al, 2016) .
A study in progress is further examining the interactive effects of HIV-1 Tat and
the effects of morphine withdrawal on cytokine levels. Tat transgenic animals are being
exposed to doxycycline for 5 days, prior to receiving either a placebo or 25-mg
morphine pellet implant, which remains in place concurrently with doxycycline
administration for an additional 5 days. On the last day, animals are given a
subcutaneous injection of either saline, or 10 mg/kg naloxone 1 hour before harvesting
the tissue to induce precipitated withdrawal in morphine-treated mice, yielding a
balanced study design with 8 groups; placebo/saline, morphine/saline,
placebo/naloxone, and morphine/naloxone in both Tat- and + mice. It is difficult to
predict the outcome of this study due to several potentially opposing observations in our
mouse model. HIV-1 Tat may directly effect the function of the endogenous opioid
system. Notably, in the hippocampus, MOR transcript levels are reduced, but not DOR
and KOR (Fitting et al, 2010a), which may result in alterations in morphine
responsiveness in the region (Fitting et al, 2010a; Razavi et al, 2014). Tat+ mice have
been shown to develop greater tolerance to morphine, and less severe withdrawal
behaviors. These effects coincide with the temporal expression of Tat (Fitting et al,
2012; Fitting et al, 2016). While the withdrawal behaviors in Tat+ mice may be
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diminished, the severity of functional effects within specific brain tissues are likely to be
more heterogenous (Fitting et al, 2010a; Fitting et al, 2010b; Gelman et al, 2012; Nath,
2015). MOR expression is observed in astrocytes, and there are astrocyte specific
splice variants (Dever et al, 2012), and similar to the broader CNS expression of MOR,
HIV can cause a shift in the expression levels of different splice variants, likely causing
alterations in the normal balance of functions modulated by those receptors by the
endogenous opioid system (Fitting et al, 2010a; Dever et al, 2012). Fitting et al (2010b)
showed that HIV Tat increased in the production of cytokines and chemokines in culture
from multiple regions of the brain, while neither gp120 or morphine affected cytokine
release; however, the hippocampus was not included in that study. Interestingly, there
was no interaction between Tat and morphine on the production of cytokines and
chemokines. Alternatively, the pilot data shows that most cytokines did not change
when assayed from the entire hippocampus from Tat+ mice, nor was there any
observed effect of morphine. The only cytokine that did change (GM-CSF) was
decreased. Although there is no extant hippocampal screen to compare this data
against, the near global effect of Tat on cultured astrocytes from varying CNS regions
makes this possibility very unlikely (Fitting et al, 2010b). This could indicate that the
sample size in the pilot data was not sufficient, but more likely suggest that the pattern
of cytokines released from an intact, adult hippocampal system treated over time with
Tat and morphine differs from pattern of cytokines seen in an artificial in vitro system in
which neonatal astrocytes are cultured in isolation and treated acutely with Tat and
morphine (Fitting et al, 2010b). Since the mice used for the withdrawal component of
this project had been exposed to morphine for several days, it is not expected that any

140

morphine effect will be seen in light of the pilot data as the 5 day exposure period is
long enough for tolerance to develop. Nevertheless, there is a chance that the
inflammatory cytokine response to spontaneous withdrawal, which is less abrupt than
precipitated withdrawal caused by giving an opioid receptor antagonist such as
naloxone, may qualitatively differ from the cytokine response after 5 days of chronic
morphine exposure.
An added layer of complexity to all the above-mentioned future directions would
come with adjustments to the timing of experiments and treatment periods. The studies
presented and proposed in this document all have a relatively acute Tat exposure
paradigm, with experiments occurring after 10-12 days of DOX administration, and any
morphine exposure happening within the last 5 days of that 10-12 day window. With the
consideration of the temporal component of neuroinflammatory processes (Schwartz &
Baruch, 2014), and the effects of HIV in aging populations (Ances et al, 2012), Many
more questions relevant to discrete populations of both HIV+ individuals and opioid
users can be addressed, and questions regarding the timing of the development of
observable behavioral effects vs underlying circuit pathology can be addressed in
greater detail (Norman et al, 2007; Vander Jagt et al, 2008; Schier et al, 2017).
Concluding remarks
The effects of HIV infection and more specifically the Tat protein in the
hippocampus are less well studied than other regions of the CNS like the striatum or the
cortex, and relatively few studies have focused on the effects of HIV infection on the
neural circuitry and resultant functional activity of the hippocampus or any other region
of the brain. The studies performed here are among the first observations of the effects
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of HIV infection on the physiological activity of the hippocampus, and the first studies of
their kind exploring interactions of Tat and morphine on the physiological outputs of the
hippocampus. The results of these studies have revealed selective vulnerability of
interneuron subsets to HIV-1 Tat, shown electrophysiological deficits related to HIV-1
Tat, and perhaps most importantly, suggest that HIV-1 Tat and morphine do not
synergistically interact to worsen pathology in the hippocampus despite the prevailing
wisdom that morphine exposure exacerbates the progression of HIV induced
neuropathology throughout the brain. These new data open the door to circuitry-based
inquiry in the context of both neuroAIDS and opiate abuse, form a starting point for
many new questions to be studied, and ultimately stand as a novel insight into the
etiology of HAND development that will hopefully be useful in informing the treatment of
these disorders in patients.
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Figure 4. 1: TdTomato x VIP expressing mice

Images depicting transgenic mice expressing TdTomato under the control of the
VIP promoter (A, D, E), or constitutively (B-E) under excitation under blue light using the
Nightsea fluorescence visualization system (Nightsea, Bedford, MA).
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Cytokine
IL-1a
IL-1b
IL-2
IL-3
IL-4
IL-5
IL-6
IL-9
IL-10
IL-12 p40
IL-12 p70
IL-13
IL-17
Eotaxin
GM-CSF
IFN-γ
KC
MCP-1
MIP-1α
MIP-1β
RANTES
TNF-α

Tat- Placebo
n=3
5.17 ± 0.16
25.97 ± 0.2
51.01 ± 3.1
3.56 ± 0.3
1.84 ± 0.32
2.5 ± 0.41
4.2 ± 0.27
27.99 ± 2.5
10.33 ± 0.83
11.25 ± 0.88
228.14 ± 3.59
90.21 ± 7.76
61.22 ± 6.22
130.13 ±18.23
27.12 ± 1.58
120.23 ± 13
3.56 ± 0.3
46.05 ± 3.81
2.12 ± 0.27
30.56 ± 3.48
12.91 ± 1.28
404.12 ± 61.59

Tat+ Placebo
n = 3-4
5.93 ± 0.46
32.58 ± 2.65
67.91 ± 7.21
3.3 ± 0.48
1.26 ± 0.04
2.58 ± 0.33
4.63 ± 0.22
24.52 ± 1.47
8.87 ± 0.11
11.45 ± 1.74
211.56 ± 41.4
142.34 ± 20.23
55.34 ± 4.65
128.53 ± 4.99
15.91 ± 4.96*
135 ± 45.54
3.2 ± 0.48
35.01 ± 4.91b
1.75 ± 0.41
37.1 ± 0.95
12.81 ± 0.33
495.42 ± 104.82

Tat- Morphine
n = 3-4
6.74 ± 1.07
31.57 ± 3.12
70.78 ± 9.65
3.923 ± 0.46
1.76 ± 0.16
4.06 ± 0.73
4.1 ± 0.79
28.83 ± 4.26
12.15 ± 1.56
11.93 ± 1.36
228.26 ± 14.43
138.27 ± 31.25
69.92 ± 5.13
136.16 ± 12.14
26.46 ± 1.77
141.88 ± 16.16
3.92 ± 0.46
45.73 ± 2.36
2.26 ± 0.26
30 ± 2.73
14.81 ± 1.64
386.32 ± 96.27

Tat+ Morphine
n = 3-4
6.08 ± 0.87
30.69 ± 3.08
65.41 ± 7.85
2.662 ± 0.78
5.34 ± 4.23
2.85 ± 0.28
4.29 ± 0.67
21.81 ± 4.67
9.54 ± 1.58
11.85 ± 2.24
240.92 ± 19.09
138.16 ± 24.43
50.78 ± 10.84
121.38 ± 13.12
22.377 ± 3.11*
132.64 ± 27.46
2.66 ± 0.78
39.44 ± 5.4b
1.56 ± 0.58
29.97 ± 4.13
11.74 ± 1.37
553.38 ± 8.93

Table 4. 1: Effects of Tat and morphine on hippocampal cytokine levels
Table 4.1 lists the levels of multiple cytokines assayed using the Bioplex
analysis. * indicates a significant main effect of Tat (p < 0.05). bindicates a trend toward
a main effect of Tat (p = 0.055). Values are expressed as mean µg/ml ± SEM.
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Sample
Tat
ID#

Drug

Desired Final
Concentration
Concentration
(µg/mL)
(ug/mL)

Volume
Sample
(µL)

Volume IP
Buffer
(µL)

Final
protein
content

1
2
3
4

-

Placebo
Placebo
Placebo
Morphine

4099.92
5476.04
4658.41
2000.93

500
500
500
500

15.244
11.41
13.417
31.23

47.26
51.09
49.08
31.26

62.5
62.5
62.5
62.5

5

-

Morphine

3982.01

500

15.7

46.8

62.5

6
7
8
9

+
+

Morphine
Morphine
Placebo
Placebo

5028.84
5375.62
365.66
2858.09

500
500
200
500

12.428
11.627
68.37
21.87

50.07
50.87
-5.87
40.632

62.5
62.5
50.8
62.5

10

+

Placebo

4568.35

500

13.68

48.82

62.5

11
12
13
14

+
+
+
+

Placebo
Morphine
Morphine
Morphine

3163.41
3320.84
4798.52
4040.32

500
500
500
500

19.76
18.82
13.025
15.47

42.74
43.67
49.48
47.03

62.5
62.5
62.5
62.5

15

+

Morphine

3088.98

500

20.23

42.27

62.5

Table 4. 2: Protein extracted from hippocampal samples
Records of the amount of protein extracted from hippocampal tissue
samples as recorded by the BCA analysis. Dilution factors to achieve the desired
protein concentration, the amount of additional buffer needed, and the final protein
concentration for each sample are listed. Sample 8 (Tat+ / placebo) was excluded from
all analyses due to low protein yield.
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